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Abstract 
 
 
17-Hydroxysteroid dehydrogenase 1 (17-HSD1) catalyzes the conversion of the weakly 
active estrone (E1) to the highly active estradiol (E2). Recently, 17β-HSD1 came into the focus 
of interest as a novel therapeutic target for the treatment of estrogen dependent diseases like 
breast cancer (BC) and endometriosis. Two new classes of non-steroidal 17-HSD1 inhibitors 
were designed and synthesized as potential therapeutics. The search started from the 
pharmacophore screening of in house library (molecules with MW < 350). The virtual hits 
were experimentally validated, and, finally, a new core structure ([5-(2-hydroxyethyl)-4-
methyl-1,3-thiazol-2-yl](3-hydroxyphenyl)methanone) with a moderate inhibitory activity for 
17-HSD1 was identified. Rigidification of the flexible hydroxy ethyl chain led to a 
benzothiazole derivative which already showed high inhibitory potency towards the target 
enzyme. Further structural modifications - OH substitution pattern, addition and variation of 
small substituents on different position of the phenyl moiety – via the synthesis of 70 new 
compounds led the discovery of two new classes of potent -HSD1 inhibitors with IC50 
values in the low nanomolar range. In order not to counteract the therapeutic efficacy of 17β-
HSD1 inhibitors it is important that the compounds are selective towards 17β-HSD2 since this 
enzyme catalyses the reverse reaction (oxidation of E2 to E1) and furthermore to avoid 
intrinsic estrogenic and systemic effects, the inhibitors should not show affinity to the estrogen 
receptors  and β. Besides an excellent selectivity over 17-HSD2 and the estrogen receptors 
(ERs)  and , the most promising compounds of this study showed good cell permeability 
(T47-D), fair metabolic stability in human liver microsomes and moderate hepatic CYP 
inhibition. High inhibitory potency and selectivity was also found towards marmoset monkey 
17-HSD1 and 17-HSD2 indicating that these compounds are suitable for in vivo evaluation 
in this animal endometriosis model. In conclusion, the present thesis provides an extensive 
structure-activity study regarding 17-HSD1 inhibition which might be useful for the 
developement of a clinically applicable therapeutic for the treatment of estrogen-dependent 
diseases. 
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Zusammenfassung 
 
 
17β-Hydroxysteroid Dehydrogenase 1 (17β-HSD1) katalysiert die Biosynthese vom schwach 
wirksamen Estron (E1) zum hoch potenten Estradiol (E2). In den letzten Jahren ist 17β-HSD1 
als neuartiges therapeutisches Target zur Behandlung von Estrogen-abhängigen Krankheiten, 
wie Burstkrebs und Endometriose in den Fokus gekommen. 
In dieser Arbeit wurden zwei neue Klassen nicht-steroidaler 17β-HSD1 Hemmstoffe designet, 
synthetisiert und biochemisch evaluiert. Zum Einstieg wurde basierend auf ko-krystallisierte 
steroidale Inhibitoren ein Pharmakophor-Modell erstellt. Dieses wurde dann zum Screening 
einer in In-house Substanzbibliothek (MW < 350) genutzt. Die besten virtuellen Hits wurden 
experimentell validiert und ([5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-2-yl](3-
hydroxyphenyl)methanone) wurde als neue Core-Struktur mit moderater Hemmwirkung 
identifiziert. 
Rigidisierung der flexiblen Hydroxyethyl-Seitenkette führte zur Synthese eines 
Benzylimidazol-Derivates, welches eine beachtliche Steigerung der Aktivität zeigte. Weitere 
strukturelle Variationen, wie z.B. Veränderung der OH-Position, Einfügen bzw. Ersetzen neuer 
Substituenten an unterschiedlichen Positionen des Phenyl-Ringes, führten zur Synthese von 
mehr als siebzig Verbindungen, die in zwei Klassen potenter HSD1-Hemmstoffe unterteilt 
werden können. IC50-Werte im niedrigen nanomolaren Bereich wurden erzielt. 
Um der therapeutischen Effizienz dieser 17β-HSD1 Inhibitoren nicht entgegenzuwirken ist es 
wichtig, dass diese Verbindungen selektiv gegen 17β-HSD2 sind, da dieses Enzym die 
Rückreaktion (Umwandlung von E2 wird in E1) katalysiert. Des weiteren sollen potentielle 
17β-HSD1 Hemmstoffe auch keine Affinität zu den Estrogen-Rezeptoren α und β aufweisen, 
um systemische Wirkungen zu vermeiden. Abgesehen von einer exzellenten Selektivität gegen 
17β-HSD2 sowie beider Estrogenrezeptoren zeigten die vielversprechendsten der 
synthetisierten Substanzen auch eine gute Permeabilität in T47-D Zellen, eine akzeptable 
metabolische Stabilität in humanen Lebermikrosomen und nur eine moderate Hemmung 
einiger hepatischer CYP Enzyme. Beide neuen Substanzklassen wiesen eine hohe Hemmung 
von 17β-HSD1 sowie Selektivität gegen 17β-HSD2 von Callithrix jacchus auf, was sie für eine 
in vivo Testung an diesem Endometriose-Model in Frage kommen läßt. 
Zusammenfassend ist festzustellen, daß in dieser Doktorarbeit eine ausführliche Struktur-
Wirkungs-Studie von 17β-HSD1 Inhibitoren beschrieben ist, die eine wichtige Rolle für die 
weitere Entwicklung von Therapeutika zur Behandlung von Estrogen-abhängigen 
Erkrankungen spielen kann. 
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1. Introduction 
 
1.1 Estrogenic hormones 
 
Estrogens are important steroidal hormones which bear different physiological functions. 
The main beneficial effects include their role in programming the breast and uterus for sexual 
reproduction [1]: in the ovary, E2 stimulates the proliferation of granulosa cells and the growth 
of follicles [2-3], in the uterus, E2 in combination with progesterone regulates the cyclic 
growth of the endometrium [4] and is also crucial for the maintenance of pregnancy and fetal 
development [5-6]. Moreover, estrogens control cholesterol production in ways that limit the 
build-up of plaque in the coronary arteries [7], and preserve bone strength by helping to 
maintain the proper balance between bone build-up and breakdown [8-9]. Moreover, a large 
number of studies have pointed out the influence of estrogens on the cardiovascular system 
[10], central nervous system [11-12] and immune system [13].  
In addition to its important beneficial effects, however, estrogens can also cause serious 
problems arising from its ability to promote the cell proliferation in breast and uterus. 
 
1.1.1  Estradiol and Estrogen Receptors (ERs) signaling pathways 
 
The most important estrogenic hormones in the human body are E1 and E2. The most 
physiologically active estrogen is E2 which has an affinity to ERs higher than E1 and 
differently from the short-acting estrogens like E1 causes nuclear binding of the ER complex 
for a long period of time [14]. The biological effects of E2 are mediated through at least three 
(A and C-D in Figure 1) of the four ER signaling pathways [15]. 
 
 
 
Figure 1: The four main mechanisms of E2 and Estrogen Receptor signaling: A) Classical 
ligand-dependent; B) Ligand-independent; C) ERE-independent; D) Cell-surface (nongenomic) 
signaling (figure revised from [16]). 
 
The four main mechanisms of E2 and ER signaling are the following: 
 
A) Classical ligand-dependent mechanism: The binding of E2 induces ER to 
conformational change, homodimerization and high affinity binding to specific DNA 
response elements (EREs), which are located within the regulatory regions of target 
genes. Depending on the cell and the presence of co-activators [17] this mechanism 
exerts either a positive or negative effect on expression of the down-stream target gene. 
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B) Ligand-independent mechanism: In the absence of E2 polypeptide growth factors [18] 
such as epidermal growth factor (EGF) and insulin-like growth factor-1 (IGF-1) are 
able to activate ER (via phosphorilation cascate) and increase the expression of ER 
target genes. 
 
C) ERE independent mechanism: The complex E2-ER may activate alternative responsive 
elements such as AP-1 through association with other DNA-bound transcription factors 
(Fos/Jun) [19], which tether the activated ER to DNA, resulting in an up-regulation of 
gene expression. 
 
D) Cell-surface (non genomic) signaling: The observed rapid biological effects of E2 in the 
bone, breast, vasculature and nervous system suggests that estrogens may also elicit 
nongenomic effects, possibly through cell surface ER form (i.e. GPER1 [20-21]) that 
are linked to intracellular signal transduction proteins (e.i. MAPK or PI3-kinase/Akt 
pathways). 
 
Two estrogen receptors, ER and ER, have been described as nuclear transcription factors 
that are activated by estrogens. Upon E2 binding the two receptors form homodimers or 
heterodimers and play different roles in estrogen signalling: whereas ER has been usually 
described as proliferative mediator [22], ER was found modulating the action of ER in 
reproductive tissue (like uterus [23]) and having features of tumor soppressor in prostate cancer 
[24]. However, recently ERβ was found to be the principal receptor involved in the progression 
of human endometriosis [25]. Tissue localization studies have revealed distinct expression 
patterns for the two ERs: whereas ER is the predominant subtype expressed in the breast, 
uterus, cervix, vagina, and several additional target organs, ER exhibits a more limited 
expression pattern and is primarily detected in the ovary, prostate, testis, spleen, endometrium, 
lung, hypothalamus, and thymus [16]. In recent years, a third estrogen receptor has emerged, 
GPR30 or G protein-coupled estrogen receptor 1 (GPER1). This is a membrane-bound protein 
and mediates estrogenic responses in cardiovascular and metabolic regulation. Both GPER1 
knock-out models and pharmacological agents have revealed that GPER1 activation may have 
several beneficial effects in the cardiovascular system including vasorelaxation, inhibition of 
smooth muscle cell proliferation, and protection of the myocardium against 
ischemia/reperfusion injury, and in the metabolic system including stimulation of insulin 
release and protection against pancreatic β-cell apoptosis [20]. 
 
1.1.2  Production of estrogen in women 
 
In man and higher primates (i.e. monkeys) a large part (before menopause) or entirely (after 
menopause) of sex steroids are synthesized locally in peripheral target tissues from the inactive 
adrenal precursors: dehydroepiandrosterone (DHEA) and its sulfate derivative (DHEA-S) [26] 
(Figure 2). 
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Figure 2: Schematic representation of the role of ovarian and adrenal sources of sex steroids in 
women. (figure revised from [27]). 
 
In human at the age of 6-8 years the production of DHEA and DHEA-S by the adrenals 
increases and plasma levels of DHEA-S in adult women are usually 1000 to 10000 times 
higher than those of estrogens produced by the ovaries. This indicates that in human the highly 
active estrogenic hormone E2 is mainly synthesized in in the peripheral cells where it exerts its 
action (intracrine concept).  
The membrana granulosa of dominant follicles of ovaries is the main source of circulating 
estrogens in premenopausal women [28-29]. After menopause, androgens of both adrenal 
(DHEA-S) and ovarian (androstenedione) origin are converted in E2 in peripheral tissues [30-
33]. The great majority of estrogen form in circulation, in both premenopausal and 
postmenopausal women, is estrone sulfate (E1-S) which is hydrolyzed to E1 by estrone 
sulfatase in various human tissues [34-35]. E1 is reduced to E2 by 17-hydroxysteroid 
dehydrogenase type 1 (17-HSD1), which is also widely distributed in various peripheral 
tissues [36-38]. Nowadays, the peripheral estrogen production is considered to play very 
important roles in the pathogenesis and development of hormone dependent diseases (like 
breast carcinoma) (Figure 3). 
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Figure 3: Illustration of estrogen production in breast cells. (figure revised from [39]). 
 
Dehydroepiandrosterone (DHEA) sulfatase, Estrone sulfatase, Aromatase, 3-
hydroxysteroid dehydrogenase (3-HSD), 17-hydroxysteroid dehydrogenase type 1 (17-
HSD1) and 17-hydroxysteroid dehydrogenase type 2 (17-HSD2) modulate the 
transactivaction of estrogen receptors in the target cell [40-41]. This implicate that via the 
intracrine mechanism where the active steroid is directly synthesized in the target cell without 
being released in the blood system these steroidogenic enzymes act as molecular switches 
allowing for pre-receptor modulation of E2 action [42]. 
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1.2  Estrogen-dependent diseases (EDDs) 
 
E2 is involved in the initiation and progression of estrogen dependent diseases (EDDs) like 
breast cancer, ovarian tumor [43], endometriosis, endometrial hyperplasia [44], and uterine 
leiomyoma [45]. The E2 action is mediated via activation of ERs [46-50]. 
 
1.2.1  Breast cancer 
 
Breast cancer is a malignant neoplasia that forms in tissues of the breast, usually the ducts 
and lobules. Different types of breast cancer exist and they are classified depending on stage, 
aggressiveness, and genetic makeup. In 2008, 460,000 females died from breast cancer which 
is the most frequent cancer type among women; the risk factors to contract this disease are still 
poorly understood but it is well known that they increase with age. 
More than 70% of patients affected by breast cancer have an estrogen-receptor positive 
(ER+) tumor indicating that estradiol stimulates the cancer growth [51]. In these cases in 
addition to the standard cancer therapies like surgery, chemotherapy and radiotherapy, different 
endocrine therapies are well established in the clinics [52-55]: SERMs (Selective Estrogen 
Receptor Modulators) and antiestrogen constrain the estrogen action at the receptor level, 
aromatase inhibitors (AIs) suppress the estrogen formation by inhibiting the last step of E1 
biosynthesis and Gonadotropin Releasing Hormone (GnRH) analogues completely cut the 
ovarian steroid formation via direct blockage of the GnRH receptors in the pituitary gland or 
via stimulating the negative feedback GnRH response. (Figure 4). 
 
 
 
Figure 4: Schematic representation of the site of action of the existing endocrine therapies 
(figure revised from [27]). 
 
All these hormone therapies result in a systemical reduction of estrogenic effects 
throughout the body leading to severe side-effects. For example, SERMs are also known to 
induce carcinoma in endometrium while aromatase inhibitors induce osteoporosis. 
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Furthermore, AIs are restricted to postmenopausal women since in premenopausal women they 
cause an increase of gonadotropin secretion by hypothalamus and pituitary axis counteracting 
the effect of the AIs itself via indirect stimulation of the ovaries to increase androgen 
production. On the contrary, GnRH analogues are only restricted to premenopausal women in 
the adjuvant treatment of breast cancer. 
 
1.2.2 Endometriosis 
 
Endometriosis is a condition in which the cells that line inside of the uterus grow outside of 
this organ in other areas, such as the ovaries, fallopian tubes and abdominal cavity. Up to 10% 
of all women may have endometriosis (most of all without symptoms). It causes adhesions and 
scarring, pain, dysmenorrhea (nausea, vomiting and diarrhea), fatigue, heavy bleeding and it 
may be found in 24 % to 50 % of women who experience infertility (American Society For 
Reproductive Medicine). Usually is diagnosed during pelvic exam, like laparoscopy, MRI 
scans, CT scans, gynecological examinations or surgical treatment [56]. 
The etiology of this disease is still poorly understood. The most widely accepted theory is 
that the disorder originates from retrograde menstruation of endometrial tissue through the 
fallopian tubes into the peritoneal cavity [57-58]. In endometriosis cell proliferation and 
inflammation are the symptoms responsible for chronic pelvic pain and infertility. Based on 
these symptomatic evidences a positive-feedback cycle for E2 and prostaglandin formation in 
endometriotic tissues has been postulated (Figure 4 [59]). 
 
 
Figure 5: Schematic representation of the positive-feedback cycle for estrogen and 
prostaglandin formation (figure revised from [59]). 
 
E2 enhances the cell proliferation and invasion of endometriotic tissue (growth) while both 
prostaglandins and cytokines mediate pain (inflammation) and infertility. E2 is produced 
locally in the endometriotic tissue in both ovulatory and postmenopausal women: the precursor 
androstenedione (A) coming from ovaries or adrenals is first converted to E1 by aromatase and 
subsequently reduced to E2 by 17β-HSD1 in the peripheral tissues and endometriotic implants. 
Endometriotic tissue is also capable to synthesize A from cholesterol via the activity of steroid 
acute regulatory (StAR) proteins and other steroidogenic enzymes. E2 induces cyclooxygenase 
(COX-2) which synthesize prostaglandins (PGE2) in endometriosis. Interleukines (IL-1β), 
vascular endothelial growth factor (VEGF), and PGE2 itself are also potent inducers of COX-2. 
PGE2 in turn is the most potent known stimulator of StAR and aromatase in endometriotic 
stromal cells. This establishes a positive-feedback loop in favor of continuous estrogen and 
prostaglandin formation in endometriosis. 
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Beside the surgery (endometriotic tissue removal) and the usage of palliative therapies 
focused on sympthomes (non-steroidal anti-inflammatory drugs), clinical hormone therapies 
are designed to suppress the estrogen biosynthesis: Oral contraceptive (which inhibits the 
menstruation), GnRH-analogues and recently AIs are used to restrain the growth of 
endometriotic tissue [53]. Due to the alteration of the hormone balance, it leads also to several 
side effects such as weight gain, acne, depression, osteoporosis [60]. 
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1.3  17-HSDs 
 
1.3.1  General features 
 
17-HSDs are NADPH/NAD+-dependent oxidoreductive enzymes, characterized by 
cofactor folding pattern known as Rossmann fold, which stereospecifically interconvert 
ketones and the corresponding secondary alcohols. They belong to the short chain 
dehydrogenase/reductase (SDR) family [61]. The only exception is 17-HSD5 (AKR1C3) 
which is an aldo-ketoreductase (AKR) [62]. Up to date twelve 17-HSDs of the fourteen 
mammalian subtypes identified [63-65] have been found in human tissues [63]. The tissue 
distribution, the sub-cellular localization, the substrate specifity (i.e. steroids, lipids or 
retinoids), and the catalytic preference (oxidation or reduction) are different for these enzymes.  
Nine subtypes of 17-HSDs are involved in diseases, mainly steroid dependent diseases like 
EDD, while for the other five the physiological function is not clear yet (Table 1) [66]. 
For the sake of clarity the nomenclature of 17-HSD enzymes that is followed here is 
based on the chronological order of descovery [67]. Recently, a new gene-based nomenclature 
for SDRs has been proposed by the international SDR-initiative [68]. 
 
Table 1: Human 17-hydroxysteroid dehydrogenases (table revised [66]). 
 
Type	 Gene	 SDR	or	AKR	nomenclature Function	 Disease‐association	
1	 HSD17B1	 SDR28C1	 Steroid	(estrogen)	synthesis	 Breast	&	prostate	cancer,	endometriosis	
2	 HSD17B2	 SDR9C2	 Steroid	(estrogen,	androgen,	progestin)	inactivation	 Osteoporosis	
3	 HSD17B3	 SDR12C2	 Steroid	(androgen)	synthesis	
Pseudohermaphroditism	in	
males	associated	with	obesity	
4	 HSD17B4	 SDR8C1	
Fatty	acid	‐oxidation,	
steroid	(estrogen,	androgen)	
inactivation	
D‐specific	Bifunctional	
Protein‐deficiency,	prostate	
cancer	
5	 AKR1C3	 AKR1C3	 Steroid	(androgen,	estrogen,	prostaglandin)	synthesis	 Breast	&	prostate	cancer	
6	 HSD17B6	 SDR9C6	
retinoid	metabolism,	3‐
3epimerase,	steroid	
(androgen)	inactivation?	
	
7	 HSD17B7	 SDR37C1	 Cholesterol	biosynthesis,	steroid	(estrogen)	synthesis	 Breast	cancer	
8	 HSD17B8	 SDR30C1	
Fatty	acid	elongation,	
steroid	inactivation,	
estrogens,	androgens	
Polycystic	kidney	disease	
9	 HSD17B9	 SDR9C5‐2	 Retinoid	metabolism
10	 HSD17B10	 SDR5C1	
Isoleucine,	fatty	acid,	bile	
acid	metabolism,	steroid	
(estrogen,	androgen)	
inactivation	
X‐linked	mental	retardation	
MHBD	deficiency	
Alzheimer’s	disease	
11	 HSD17B11	 SDR16C2	 Steroid	(estrogen,	androgen)	inactivation,	lipids?	 	
12	 HSD17B12	 SDR12C1	 Fatty	acid	elongation,	steroid	(estrogen)	synthesis	 	
13	 HSD17B13	 SDR16C3	 Not	demonstrated 	
14	 HSD17B14	 SDR47C1	
Steroid	(estrogen,	
androgen?)	inactivation,	
fatty	acid	metabolism
Breast	cancer,	prognostic	
marker	
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1.3.2  Cell metabolism and unidirectional steroid flux in living cells 
 
In intact cells 17-HSDs catalyze unidirectional reactions: either a hydride transfer from 
reduced cofactor (NADPH) to a ketosubstrate or a hydride transfer from a hydroxysubstrate to 
oxidized cofactor (NAD+), which occur with a proton shift for charge equalization. The 
different 17β-HSDs bind either NADP(H) or NAD(H), which act as soluble electron carriers 
[69]. Structural and mutagenesis studies showed that in the Rossmann fold [70] of 17β-HSD1 
and 17β-HSD3, a positively charged amino acid forms a ionic bond with the 2’-phosphate 
group of NADP(H) (Arg37 in 17β-HSD1, [71]; Arg80 in 17β-HSD3, [72]). These enzymes 
preferably bind the phosphorylated cofactors rather than the non-phosphorilated one. On the 
contrary in 17β-HSD2 and 17β-HSD4 a negatively charged amino acid residue (Glu116 in 17β-
HSD2, [73]; Asp41 in 17β-HSD4, [74]) is considered to be the reason for NAD(H) specificity 
(Figure 6). 
 
 
 
Figure 6: Important 17β-HSDs residues for cofactor recognition. (A) Reductive 17β-HSD1: 
interaction of Arg37with NADPH (PDB file: 1A27); (B) Oxidative 17β-HSD4: interaction of 
Glu41with NAD+ (PDB file: 1ZBQ); with NADPH, NAD+, Arg37 and Asp41 rendered as 
sticks and labelled. Figure rendered with MOE (www.chemcomp.com) (figure revised from 
[66]). 
 
In living cells, the catalysis is unidirectional due to the fact that concentrations of cofactors 
(NADP(H) and NAD(H)) are much higher (micromolar range) than the ones of substrates (i.e. 
ketosteroids and hydroxysteroids) which are in the nanomolar range. Furthermore, NADP(H) is 
abundant in its reduced form (NADPH/NADP+ > 500), whereas NAD(H) is mainly present in 
its oxidized form (NAD+/NADH > 700) and these ratios are homeostatically maintained by 
glucose metabolism and O2 supply (Figure 7). 
 
 
 
Figure 7: Interplay between intermediary metabolism and 17-HSDs reactions (figure revised 
from [69]). 
INTRODUCTION  10 
 
1.4  17-HSD1 
 
1.4.1 Potential drug target 
 
17-HSD type 1 catalyzes the final step of the estrogen biosynthesis: the activation of the 
weak estrogen, E1, to its potent homologue E2 which has a crucial role in supporting the 
growth of hormone-dependent breast cancer and endometriosis in women (Figure 8). 
 
 
 
Figure 8: Conversion of E1 into E2 catalyzed by 17-HSD1 and the reverse reaction (from E2 
to E1) catalyzed by 17-HSD2. 
 
In estrogen-dependent diseases an increased E2/E1 ratio as well as high levels of 17-
HSD1 expression at mRNA and protein level, make the selective inhibition of 17-HSD1 an 
attractive therapeutic target for their treatment. Different studies have shown that the ratio 17-
HSD1/17-HSD2 is increased in the tumors of patients with ER+ breast cancer [75-77]. 
Furthermore, several studies indicate that patients with high 17-HSD1 expression have 
significantly shortened disease free and overall survival [78-79]. 
A change in the expression pattern of the steroidogenic enzymes is responsible for a high 
concentration of E2 in endometriotic tissues as well [80]. Recent studies showed that there is 
down regulation of 17-HSD2 at mRNA level in endometriotic lesions, while both aromatase 
and 17-HSD1 are up regulated, in comparison to normal tissues [81-82]. 
Therapies aiming the inhibition of 17-HSD1, consequently, would give an innovative 
approach to the treatment of this disorder. 17-HSD1 inhibitors must be selective towards 17-
HSD2, since inhibition of this enzyme may have opposing action (increase the E2/E1 ratio) and 
towards ER to avoid systemical estrogenic response. 
 
1.4.2 Sequence and structural analysis of human 17-HSD1 
 
17-HSD1, as already mentioned above, belongs to short-chain dehydrogenase/reductase 
(SDR) family. It is active as a soluble cytosolic homodimer, it has characteristical cofactor 
(NADPH) folding pattern known as Rossmann fold and catalyzes stereospecifically the transfer 
of a hydride (pro-S from nicotinamide C4 of cofactor) to estrone [83]. 17-HSD1 has 
characteristic amino acid motifs which are conserved in all SDR enzymes (Figure 9). 
INTRODUCTION  11 
 
 
 
Figure 9: SDR characteristic amino acid motifs of 17-HSD1: Tertiary structure of 17-HSD1 
rendered as cartoon, with a zoom into SDR conserved regions T-G-xxx-G-x-G, N-A-G, Y-xxx-
K as well as S142 and N114 are highlighted. Figure rendered with MOE 
(http://www.chemcomp.com/). 
 
The SDR conserved motifs are T-G-xxx-G-x-G in the cofactor binding cleft, N-A-G and Y-
xxx-K in the active center where Y (Tyr155) and K (Lys159) together with Asn114 and Ser142 
are fundamental for catalysis (catalytic tetrad) [84-85]. The N-A-G motif is responsible for 
stabilization of protein 3D-structure. Differently from other SDR enzymes, 17-HSD1 displays 
high substrate selectivity mainly due to the ordered C-terminal region which forms a specific 
binding cavity. Furthermore, important amino acids of the substrate binding pocket are Leu149 
which responsible for C18/C19-steroid discrimination [86-87] and Gly145 which plays a key 
role in steroid/retinoid discrimination [88]. The cofactor binding cleft is constituted by the 
Rossmann fold that consists of a seven-stranded, parallel -sheet core structure surrounded by 
six parallel -helics. Differently from the substrate binding cleft (i.e. the C-terminal part), the 
Rossmann fold together with the T-G-xxx-G-x-G motif is the most rigid and conserved part of 
17-HSD1. 
No 17-HSD1 crystal structure complexed with E1 (substrate) exists. The published crystal 
structures are available in the protein data bank (PDB) as: apoform, holoform, binary complex 
with E2, androgens or steroidal inhibitors and ternary complex with cofactor, E2 or inhibitors. 
If present E2 (product) is stabilized by hydrogen bonds between its O3 and His221/Glu282, as 
well as between its O17 and Tyr155/Ser142 [89]. Furthermore, a highly flexible FG’-loop 
(not always resolved) has been identified between cofactor and substrate. The data reveal the 
importance of this loop for ligand binding. Two small apolar subpockets could be identified in 
proximity of substrate binding cleft, the first next to the catalytic tetrade (next to Tyr155) while 
the second next to C-terminal region (next to Glu282) (Figure 10). 
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Figure 10: 17-HSD1 complexed with E2B inhibitor: interactions between steroidal inhibitor 
and S142, Y155, H221 and E282 are highlighted. FG’-loop is depicted in yellow between 
substrate and cofactor (NADPH). Figure rendered with MOE (http://www.chemcomp.com/). 
 
1.4.3 Catalytic mechanism of 17-HSD1 
 
In the postulated catalytic mechanism of 17-HSD1, the pro-S hydride on C4 of pyridine 
moiety of NADPH is transferred to the -face of the estrone at the C17 carbon. It has not been 
clarified yet wether the hydride transfer occurs simultaneously (concerted mechanism) or 
stepwise. Structure analysis, mutagenesis studies and sequence alignment evidenced the amino 
acid residues important for the catalysis: Asn114, Ser142, Tyr155 and Lys159 (catalytic tetrad) 
and a water molecule play a critical role in the enzymatic process stybilizing the substrate and 
forming a H-bond network which is responsible for the proton transfer (Figure 11) [90-93].  
 
 
 
Figure 11: scheme of the possible catalytic mechanism for 17-HSD1. Hydrogen bonds are 
represented in dashed lines. 
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1.5  Inhibitors of 17-HSD1 
 
17-HSD1 inhibitors should not inhibit 17-HSD2 and, of course, should not be 
estrogenic. Inhibitory activity towards aromatase or E1-sulfatase might be considered not 
deleterious for the terapeutical goal (Figure 3). Beside biological inhibitory activity towards the 
target enzyme and selectivity, 17-HSD1 inhibitors should show properties related to 
“druggability” (i.e., ADME/toxicity) defined by Lipinski [94]. During the last fifteen years 
several patents and publications concerning 17-HSD1 inhibitors have been reported [66 and 
95-100]. Although clear structure-activity relationships have been shown, no clinical candidate 
has been reported yet. 
Steroidal 17-HSD1 inhibitors as well as non-steroidal ones are described to bind to the 
steroid binding cleft and/or the pocket where usually the cofactor is situated. An exception is 
given by phytoestrogens which interact with the dimer interface of 17-HSD1 as suggested by 
competitive NMR-experiments and docking studies [101]. Recently, new non-steroidal potent 
coumarin derivatives as inhibitors of 17β-HSD type 1 were published [102-103]. 
The steroidal compounds are based on E1 and E2 cores and the best biological results were 
exhibited by derivatives with substitution at the C2, C15 and C16 positions [104-112] (Table 
2). 
 
Table 2: Best steroidal 17-HSD1 inhibitors described. 
 
 
 
Beside their high inhibitory potency toward the target enzyme drawbacks were reported for 
steroidal inhibitors: i.e. the hybrid inhibitor (S1 in Table 2) designed to bind to both the steroid 
binding cleft and the cofactor binding site has been described as not able to penetrate the cell 
membrane. Compound S2 showed to increase cancer T-47D cell proliferation (estrogenicity). 
Concerning the non-steroidal inhibitors different classes have been published in the last 
four years [113-126]. These compounds show advantages compared to steroidal structures such 
as synthetic accessibility, drug-likeness, selectivity and non-estrogenicity. 
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Table 3: Best non-steroidal 17-HSD1 inhibitors described. 
 
 
 
The biphenyl mimetics of E1, like NS1 in Table 3, showed very weak inhibitory activity in 
cell-based assay. Thiophenepyrimidinones (i.e. NS2) showed high 17-HSD1 inhibitory 
activity (73 % at 0.1 M)  in a cell-free recombinant human assay at low E1 concentration (30 
nM) but only 74 % at 1M in human MCF-7 breast cancer cells transfected with cDNA 
encoding for human 17-HSD1 and using a low substrate concentration (2 nM). The best non-
steroidal 17-HSD1 inhibitors were described so far by the Hartmann group. Three classes 
have been developed via pharmacophore model: a) (Hydroxyphenyl)naphthols (i.e. NS4), b) 
Bis(hydroxyphenyl)substituted arenes (i.e. NS5) and c) Bicyclic substituted 
hydroxyphenylmethanones (i.e. NS6). The best results were obtained by structures like NS6, 
which showed very good 17-HSD1 inhibitory activity (in non-cellular as well as cellular 
assays) and selectivity towards 17-HSD2 and ER.  
 
1.6  Animal models for in vivo evaluation of 17-HSD1 inhibitors. 
 
In lower mammals unlike man and higher primates (i.e. monkeys), the ovaries and not the 
peripheral target tissues are the primary sources of estrogens. In fact in rat and mouse the 
secretion of sex steroids takes place exclusively in the gonads. When animal models are 
developed to study hormone dependent diseases, this difference is usually overtaken by the 
usage of animal´s ovariectomy followed by h17-HSD1 source implatation or of xenograft 
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imunodeficient animals. With aim of testing 17-HSD1 inhibitors in vivo as well as gaining 
insight into physiopathological role of this enzyme in the development of EDDs, several 
animal models were recently established. 17-HSD1 of different species differs regarding 
sequence-identity in a range from 51 % (zebrafish) to 99 % (chimpanzee) and similarity from 
70 % to 100 %, respectively. 17-HSD1 of mouse and rat has 74 % and 75 % sequence 
identity, respectively, and both share 83 % similarity comparing with human one. Due to this 
moderate homology/identity and due to the fact that 17-HSD1 tissue distribution considerably 
varies between lower species and human, xenograft models using nude mice were developed to 
overcome these problems (Table 4 [44 and 127-133]). A marmoset (Callithrix jacchus) model 
was used to reproduce endometriosis [134]. 17-HSD1 of marmoset has 80 % sequence 
identity and 83 % homology with human one. Although several potent human 17-HSD1 
inhibitors showing strong activity towards the marmoset enzyme could be identified, in vivo 
application has not been reported yet. The phylogenetic similarity between marmoset and 
human makes this model interesting and more significant than rodent models [66]. 
 
Table 4: Summary of the different 17-HSD1 animal models described. 
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2.  Outline of this thesis 
 
2.1  Scientific goal 
 
In both premenopausal and postmenopausal women, the inhibition of peripheral E2 
production is nowadays regarded as a better therapeutical strategy compared to the existing 
endocrine therapies in the treatment of EDDs. Most of all fewer side effects are supposed since 
the systemic estrogen should not be affected. 
17-HSD1 and 17-HSD2, expressed in different amounts in estrogen target cells (usually 
expressing also ERα and/or ), play a pivotal role in regulating the growth of hormone-
dependent breast cancer and endometriosis in women. Due to the fact that 17-HSD1 catalyzes 
the last step of the synthesis of the most potent estrogen (E2) and has been often found 
overexpressed compared to 17-HSD2 in diseased tissues of patients affected by EDDs, this 
enzyme is considered to be the key-target to stop pheripheral estradiol production. 
Several animal models published in the last years proved the in vivo efficacy of 17-HSD1 
inhibitors to reduce estrogen stimulated growth in diseases like breast cancer, endometriosis 
and endometrial hyperplasia. Although up to date no 17-HSD1 inhibitor has entered clinical 
trials, the inhibition of 17-HSD1 is considered a promising new therapeutical approach for the 
treatment of estrogen-dependent pathologies. 
Thereby the main goal of the present thesis was to develop new potent and selective non-
steroidal inhibitors of 17-HSD1 structurally different from the previously described ones as 
suitable tools for in vivo application in order to afford new chemical entities able to improve 
the hormone-dependent diseases treatment. 
To achieve this purpose, novel 17-HSD1 inhibitors have been designed and synthesized 
via a combination of computer-aided methodology (hit identification by pharmacophore 
screening) and subsequent structural optimization. In addition to their ability to inhibit 17-
HSD1 in a cell free assay (placental preparate), the selectivity of the compounds here described 
towards 17-HSD2 (cell free inhibition assay) and ERs (binding affinity test) was evaluated. 
Furthermore, the most potent and selective 17-HSD1 inhibitors were screened according to 
their ability to inhibit E2 formation in intact T47-D tumour cells (intracellular potency) to have 
insights regarding cellular membrane permeation and to exclude possible intracellular 
metabolism. Finally, the inhibitory activity of the most interesting compounds was determined 
towards 17-HSD1 and 17-HSD2 enzymes of Callithrix jacchus (placental cell preparation) 
to select the most suitable inhibitors for in vivo evaluation in marmoset monkey model. 
 
 
2.2  Working strategy 
 
Derivation of pharmacophore model and hit identification (chapter 3.I):  
Although up to now more than twenty crystallographic structures of human 17-HSD1 are 
available in the Protein Data Bank (PDB) as apoform, binary or ternary complex (with 
steroidal ligand and/or cosubstrate), X-ray based information about protein-ligand interactions 
of the enzyme with nonsteroidal inhibitors is not available. For this reason, in our search for 
new non-steroidal hits structurally different from those previously described, in the first project 
of the present work it was considered unsuitable an outwardly simple virtual screening strategy 
based on docking studies performed on a randomly selected 17-HSD1 crystal structure 
available in the literature. Alternatively, a ligand-based approach was followed and a new 
pharmacophore model for 17-HSD1 was built, as in silico screening tool, based on 
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cocrystallized ligands with some additional protein structure information. This pharmacophore 
model was used to screen a small in house library (approximately forty thiazole derivatives 
with MW in the range of 150-350). The virtual hits were experimentally validated regarding 
their inhibitory activity towards 17-HSD1, and, finally, [5-(2-hydroxyethyl)-4-methyl-1,3-
thiazol-2-yl](3-hydroxyphenyl)methanone covering six features in the pharmacophore and 
showing weak activity in 17-HSD1 cell free inhibition assay was selected as new core 
structure for further optimization. (Figure 12). 
 
 
 
Figure 12: pharmacophore aided hit descovery 
 
Hit optimization (chapter 3.I):  
The hit optimization started from the rigidification (decrease of freedom conformational 
degrees) of the flexible hydroxy ethyl chain of the hit, leading to a benzothiazole derivative 
linked via a carbonyl bridge in the 2 position to 3-hydroxy-phenyl ring (Figure 13). 
 
 
 
Figure 13: hit optimization overview 
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Furthermore the carbonyl bridge between the two aromatic rings bearing a sp2 trigonal 
geometry which allows for electronic delocalization (conjugation) and the oxygen atom which 
may accept two H-bonds was exchanged with different linkers bearing a sp3 tetrahedral bridge 
and/or H-bond donating groups to investigate the influence of these features on the 17HSD1 
inhibitory activity. The carbonyl bridge was also replaced by longer functional groups, such as 
amide, retro amide, sulphonamide, urea, and thiourea and benzyl amide to inquire whether a 
linker, bearing a non-constrained angled geometry, could allow the phenyl ring to exploit 
different regions of the binding cleft (Figure 13). 
 
Further optimization in the class of benzothiazole derivatives (chapter 3.II):  
 In the second project of the present work (1,3-benzothiazol-2-yl)-(3-hydroxy-
phenyl)methanone and 3-hydroxy-N-(6-hydroxy-benzothiazol-2-yl)benzamide as the best 17-
HSD1 inhibitors from the first study were optimized. The influence of electronic, lipophilic, 
steric and H-bonding properties on biological activity have been investigated by introducing 
different substituents on the phenyl moiety, exchanging the hydroxy group on the 
benzothiazole moiety with hydrogen, methoxy and benzyloxy as well as N-methylating the 
amide function (Figure 13). 
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3. Results 
 
3.I Hydroxybenzothiazoles as New Nonsteroidal Inhibitors 
of 17-Hydroxysteroid Dehydrogenase Type 1 (17-HSD1). 
 
Major part of this chapter will be published in PloSOne. 
 
 
Abstract: Beside its physiological role, 17-estradiol (E2), the most potent estrogen is also 
known to be involved in the development of estrogen-dependent diseases (EDD) like breast 
cancer and endometriosis. Existing endocrine therapies for these indications – treatments with 
aromatase inhibitors, GnRH-analogues or anti-estrogens - result in a radical and unspecific 
reduction of estrogenic effects throughout the body leading to severe side-effects like 
osteoporosis or induction of endometrial carcinoma. 
17-HSD1 catalyses the reduction of the weak estrogen estrone (E1) to the highly potent E2 
and is often overexpressed in breast cancer tissue. An inhibition of 17-HSD1 could selectively 
reduce the E2-level in specific tissues thus allowing for a novel, targeted approach in the 
treatment of EDD resulting in fewer side-effects compared to the established treatments. 
In continuation of our search for new nonsteroidal 17-HSD1 inhibitors a pharmacophore 
screening of a compound library was conducted which led to the identification of the 
moderately active hit (5). Rigidification and further modifications resulted in the discovery of 
novel inhibitors with benzothiazole-scaffold. Their putative binding modes were investigated 
by correlating their biological data with features of the pharmacophore model. The most active 
compounds 6 and 21 show IC50-values in the nanomolar range and reasonable selectivity 
against 17-HSD2 and the estrogen receptors, respectively. They can thus be regarded as first 
benzothiazole-type lead compounds for the development of potential therapeutics. 
 
Introduction 
 
Estrogens are important steroidal hormones which bear different physiological functions. The 
main beneficial effects include their role in programming the breast and uterus for sexual 
reproduction [1], controlling cholesterol production in ways that limit the build-up of plaque in 
the coronary arteries [2], and preserving bone strength by helping to maintain the proper 
balance between bone build-up and breakdown [3-4]. Among female sex hormones, 17-
estradiol (E2) is the most potent estrogen carrying out its action either via transactivation of 
estrogen receptors (ERs) [5] or by stimulating nongenomic effects via the MAPK signaling 
pathway [6]. In addition to its important beneficial effects, however, E2 can also cause serious 
problems arising from its ability to promote the cell proliferation in breast and uterus. Although 
this is one of normal function of estrogen in the body, it can also increase the risk of estrogen 
dependent diseases (EDD), like breast cancer, endometriosis and endometrial hyperplasia [7-
10]. Suppression of estrogenic effects is consequently a major therapeutic approach. This is 
proved by routine clinic use of different endocrine therapies, for instance with GnRH 
analogues, SERMs (Selective estrogen receptor modulators), antiestrogens, and aromatase 
inhibitors [11-13] for the prevention, as well as the adjuvant treatment of breast cancer. 
However, all these therapeutics systemically lower estrogen hormone action, therefore causing 
significant side effects such as osteoporosis, thrombosis, stroke and endometrial cancer [14-
16]. Thus, a new approach which aims at affecting predominantly the intracellular E2 
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production in the diseased tissues (intracrine approach), would consequently be a very 
beneficial improvement for the treatment of EDD. Such a therapeutic strategy has already been 
shown to be effective in androgen dependent diseases like benign prostate hyperplasia by using 
5- reductase inhibitors [17-21]. 
The type 1 enzyme of the 17β-hydroxysteroid dehydrogenase (17β-HSD) family, which is 
responsible for the intracellular NADPH-dependent conversion of the weak E1 into the highly 
potent estrogen E2, was found overexpressed at mRNA level in breast cancer cells [22-24] and 
endometriosis [25]. Inhibition of this enzyme is therefore regarded as a novel intracrine 
strategy in EDD treatment with the prospect of avoiding the systemic side effects of the 
existing endocrine therapies. Although to date, no candidate has entered clinical trials, the 
ability of 17β-HSD1 inhibitors to reduce the E1 induced tumor growth has been shown using 
different animal models, indicating that the 17β-HSD1 enzyme is a suitable target for the 
treatment of breast cancer [26-28]. The same effect was also demonstrated by Day et al. [28], 
Laplante et al. [29] and Kruchten et al. [30] using in vitro proliferation assays.  
In order not to counteract the therapeutic efficacy of 17β-HSD1 inhibitors it is important that 
the compounds are selective against 17β-HSD2. This enzyme catalyses the reverse reaction 
(oxidation of E2 to E1), thus playing a protective role against enhanced E2 formation in the 
diseased estrogen dependent tissues. Interestingly, potent and selective 17-HSD2 inhibitors 
were recently reported for the treatment of osteoporosis [31-32]. Additionally, to avoid 
intrinsic estrogenic and systemic effects, the inhibitors should not show affinity to the estrogen 
receptors  and β. 
Several classes of 17-HSD1 inhibitors have been described in the last years [33-40], most of 
them having a steroidal structure. During the past decade, our group reported on four different 
classes of nonsteroidal 17β-HSD1 inhibitors [41-51]. Compounds 1-4 (Figure 1) exhibit IC50 
values toward 17β-HSD1 in the nanomolar range and high selectivity against 17β-HSD2 and 
the ERs in our biological screening system [52]. 
 
 
 
Figure 1. Non-steroidal 17-HSD1 inhibitors published by our group. 
 
In our search for new nonsteroidal leads that are structurally different from those previously 
described, an in silico screening of our in-house compound library was performed using a 
pharmacophore model derived from crystallographic data. A virtual hit was identified with a 
moderate inhibitory activity for 17-HSD1, structural optimization led to the discovery of 
benzothiazoles as novel, potent inhibitors of the target enzyme with good in vitro biological 
activitiy. Further computational studies were performed to better understand the favourable 
interactions achieved by these inhibitors in the active site. 
 
1) Pharmacophore and hit identification. Although up to now more than twenty 
crystallographic structures of human 17-HSD1 are available in the Protein Data Bank (PDB) 
as apoform, binary or ternary complex (with steroidal ligand and/or cosubstrate), X-ray based 
information about protein-ligand interactions of the enzyme with nonsteroidal inhibitors is not 
available. Further, the steroidal binding pocket in these crystal structures evidenced differences 
in terms of size and geometry due to a pronounced flexibility of some parts of its surrounding 
[53]. This fact might affect an outwardly simple virtual screening strategy such as random 
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selection of one crystal structure to perform docking studies and was considered unsuitable to 
the search of new hits. To overcome this, we chose to follow a different strategy: a new 
pharmacophore model for 17-HSD1 was built, as in silico screening tool, based on 
cocrystallized ligands and with some additional protein structure information, and a ligand-
based approach was followed. 
This pharmacophore model was used to screen a small in house library (approximately forty 
thiazole derivatives with MW in the range of 150-350), virtual hits were experimentally 
validated, and, finally, a new core structure (compound 5 - [5-(2-hydroxyethyl)-4-methyl-1,3-
thiazol-2-yl](3-hydroxyphenyl)methanone) was selected. This was used as a new scaffold for 
further optimization. 
 
2) Hit optimization. 
a) rigidification. Due to the fact that rigidification (decrease of freedom conformational 
degrees) can often increase potency, compound 6 was designed freezing the flexible hydroxy 
ethyl chain of compound 5 leading to a benzothiazole derivative linked via a carbonyl bridge in 
the 2 position to 3-hydroxy-phenyl ring (6) (see Figure 2). 
 
 
 
Figure 2. Rigidification strategy. 
 
b) Bridge: length, geometry and H-bonding properties.  
The carbonyl bridge between the two aromatic rings in compound 6 bearing a sp2 trigonal 
geometry allows for electronic delocalization (conjugation) and the oxygen atom may accept 
two H-bonds. To investigate the influence of these features on the 17HSD1 inhibitory 
activity, compounds 7-11 (Table 1), bearing a sp3 tetrahedral bridge, were synthesized. 
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Table 1. 17-HSD1 inhibitory activity for compounds, 5 and 6-25. 
 
 
 
Compound X R1 R2 HSD1a 
    % inhib. (1µM) IC50b (nM) 
5    34 nd 
6 CO m-OH OH 91 44 
7 CHOH m-OH OH 28 nd 
8 CHOCH3 m-OH OH 13 nd 
9 CHSCH3 p-OH OH ni nd 
10 CH2 p-OH OCH3 ni nd 
11 CH2 p-OH OH 24 nd 
12 CO m-OH H 75 365 
6i CO m-OCH3 OCH3 ni. nd 
13 CO p-OCH3 OH 27 nd 
14 CO p-OH OH 85 243 
15 NHCO o-OH OCH3 ni nd 
16 NHCO o-OH OH ni nd 
17 NHCO m-OH OCH3 31 nd 
18 NHCO m-OH OH 40 nd 
19 CONH p-OCH3 OH ni. nd 
20 CONH p-OH OH 39 nd 
21 CONH m-OH OH 83 243 
22 SO2NH m-OH OH ni nd 
23 NHCONH m-OH OH ni. nd 
24 NHCSNH m-OH OH 62 nd 
25 CH2CONH m-OH OH ni nd 
 
a Human placenta, cytosolic fraction, substrate [3H]E1 + E1 [500 nM], cofactor NADH [500 μM]. b Mean values 
of three determinations, standard deviation less than 10 %. c nd: not determined. d ni: no inhibition. 
 
The carbonyl bridge was also replaced by longer functional groups, such as amide (i.e. 18), 
retro amide (i.e. 21), sulphonamide (22), urea (23), thiourea (24) and benzyl amide (25) to 
inquire whether a linker, bearing a non-constrained angled geometry, could allow the phenyl 
ring to exploit different regions of the binding cleft. 
 
Results 
 
1) Pharmacophore generation.  
Five diverse 17-HSD1 crystal structures (PDB-ID: 1equ, 1i5r, 3hb5, 1a27, 1dht) [53-57] were 
superimposed (backbone root mean square deviation (RMSD) of 0.7 Å) and the cocrystallized 
steroidal ligands EQI, HYC, E2B, E2, and DHT, respectively, (Figure 3) were used to build the 
pharmacophore model using the Molecular Operating Environment (MOE; 
www.chemcomp.com) software. 
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Figure 3: 17-HSD1 co-crystallized steroidal ligands. Five 17-HSD1 cocrystalized 
steroidal ligands (EQI, HYC, E2B, E2, DHT) available as PDB (respectively: 1equ, 1i5r, 3hb5, 
1a27 and 1dht) used to build the pharmacophore model. 
 
The five crystal structures were chosen to cover most of the chemical space occupied by their 
17HSD1 ligands, and both the presence of the cosubstrate (NADP+/NADPH) as well as a 
good resolution was considered important for their selection. This because our pharmacophore 
model should integrate both ligand- and protein-derived information, gained from the analysis 
of different crystal structures.  
Indeed, superimposition of the mentioned 3D complexes (ligands and proteins) enabled us to 
define the pharmacophore features of both the ligands and of the constant regions of the 
protein, involved in ligand-protein interaction. While the selection of the ligand-derived 
features was focused on the slightly different chemical properties of substrates and inhibitors, 
the protein-derived features were chosen considering “rigid” active site residues (all atom 
RMSD for all crystal structures < 0.5 Å) as well as amino acids important for the enzymatic 
activity. Additionally, the flexible βFαG'-loop (residues 187-196) [53] lining the active site was 
excluded, and additional Don/Acc features were retained from the cofactor (NADP+). 
Thus, on the ligand side the pharmacophore model (Figure 4) consists of five 
hydrophobic/aromatic features HY1-HY5 (four from steroid scaffold and one from E2B/HYC, 
respectively), one aromatic ring projection P5 (associated to HY5; used to direct the ligand 
placement in the pharmacophore screen), three H-bond acceptor-and-donor AD1-AD3 (two 
from the steroid scaffold and one from E2B) and one H-bond donor D4 (corresponding to the 
NH2 of the amide in E2B). 
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Figure 4. Pharmacophore model. The pharmacophoric features derived from the ligands are 
rendered as dotted spheres and are color-coded: dark orange for aromatic ring and aromatic 
ring projection (HY1 and HY5), green for hydrophobic regions (HY2-HY4) and magenta for 
acceptor and donor atom features (AD1-AD3 and D4). The identified aromatic ring projection 
HY6 as well as the donor projection feature D7 is not exploited by inhibitors with steroidal 
molecular scaffold. The protein-derived acceptor or donor features (A1a, D1b, AD2a, AD2b, 
A3a, D4a, D4b, AD5a, AD5b, D6a and A6b) and the aromatic ring projection P5 are depicted 
as yellow, meshed spheres. 
 
Nine acceptor (A) or donor (D) feature projections were derived from the protein and used to 
direct the ligand orientation in the pharmacophore screening (projections indicate putative 
protein binding partners; the number indicate the ligand feature, while the small letters a and b 
the inverse H-bonding properties of residues involved in a common network, e.g. A1a is a 
donor and D1b is an acceptor, and both interact with AD1): A1a - His221, D1b - Glu282, 
AD2a - Ser142, AD2b - Tyr155, A3a - Leu96, D4a - Asn152, D4b - Leu95, AD5a - Ser222, 
AD5b - Tyr218. In addition, four features were also retained from the cofactor NADP(H): A6b 
and D6a from the amide moiety and HY6 as aromatic ring projections from the nicotinamide 
ring (potential interaction site of the ligand with Tyr155 and cofactor), as well as D7 as a 
acceptor projection (phosphate group of the cofactor). More geometric properties of the 
pharmacophore are attached as supporting information in TableS1. 
This pharmacophore model, comprising 23 features, was now used to screen our small 
molecule in house library and the virtual hits were tested experimentally. A partial match 
strategy was adopted for the screening, in which the molecules are left free to be placed into 
the pharmacophore and only virtual hits are retained that cover at least six features.  
Compound 5, which resulted to be the most potent hit, covers the following six features: HY2-
HY5, AD2 and D4 (Figure 5). 
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Figure 5. Rigidification. Compound 5 (A) and compound 6 (B) mapped to the pharmacophore 
model. 
 
Interestingly, in a subsequent screening, also compound 6, the newly synthesized, rigidified 
homologue of 5, was found to match six features. Overlaying it with equilin, one of the 
steroidal ligands used to build the pharmacophore model, shows that the phenyl ring of the 
benzothiazole moiety can mimic the steroidal B ring (see figure S1 in supporting information). 
 
2) Chemistry. 
The synthesis of the thiazolyl derivative 5 was performed as shown in Figure 6 starting from 
the commercially available 2-(4-methyl-1,3-thiazol-5-yl)ethanol and 3-hydroxybenzaldehyde. 
 
 
 
 
Figure 6. Synthesis of compound 5. Reagents and conditions: (a) TBDMSiCl, imidazole, DMF, rt, 20 h; 
(b) Method A: 1) nBuLi, anhydrous THF, - 70 °C, 1 h; 2) anhydrous THF, - 15 °C, 90 min; (c) Method C: SIBX, 
anhydrous THF, 0 °C to 60 °C, 20 h; (d) TBAF, THF, rt, 2 h. 
 
To avoid side reactions due to the presence of the free hydroxy groups, we decided to protect 
both groups using tert-butyldimethylsilyl chloride and imidazole in DMF at room temperature, 
overnight [59], to afford 5iiia and 5iiib, respectively. Then nucleophilic addition (method A) 
[60] of in situ 2-lithiated 5iiia to 5iiib in THF at -15°C for 90 minutes yielded the secondary 
alcohol 5ii. The latter was oxidized to the carbonyl derivative 5i using stabilized 2-
iodoxybenzoic acid (SIBX) as oxidative reagent in THF at 60°C (method C) [61] prior to the 
deprotection of both silyl protecting groups under mild basic conditions (TBAF in THF at 
room temperature for 2 hours) [62] to afford compound 5. 
The benzothiazolyl derivatives 6-11 and 13-18 were synthesized as shown in Figure 7. 
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Figure 7. Synthesis of compounds 6-11 and 13-18. Reagents and conditions: (a) 1) NaNO2, H3PO4 
(85 %), - 10 °C, 20 min, 2) H3PO2, H3PO4 (85 %), - 10 °C to rt, 20 h; (b) Method A: 1) nBuLi, anhydrous THF, - 
70 °C to - 20 °C, 1 h, 2) for 6ii and 9ii: methoxy benzaldehyde, for 15i and 17i: methoxy benzoisocyanate, 
anhydrous THF, - 15 °C, 90 min; (c) for 6i and 13i, Method C: SIBX, anhydrous THF, 0 °C to 60 °C, 20 h; for 10 
and 11i: TMSiCl, NaI, CH3CN, reflux, 20 h; (d) Method D: for 6-9 and 15-18: BF3S(CH3)2, anhydrous CH2Cl2, rt, 
20 h; for compounds 11 and 13-14, Method E: pyridinium hydrochloride, 220 °C, 4 h. 
 
The commercially available 6-methoxy-benzothiazol-2-yl amine was reduced to 6iii in the first 
step via a previously described diazotation followed by reductive elimination of nitrogen [63]: 
6-methoxy-benzothiazol-2-yl amine was first dissolved in 85 % phosphoric acid, heated up 
until complete solubilisation and then cooled to -10°C, prior the slowly addition of aqueous 
solution of NaNO2 to yield the diazonium salt. The resulting instable intermediate was 
subsequently transformed in 6iii adding the former solution to a 0°C pre-chilled 50 % aqueous 
phosphonic acid solution and let the temperature rise to room temperature overnight. Then 
nucleophilic addition (method A) of in situ 2-lithiated 6iii to 3-methoxybenzaldehyde or 4-
methoxybenzaldehyde, respectively, in THF at -15°C for 90 minutes, allowed us to afford the 
secondary alcohols 6ii and 9ii, respectively. The same method was used for the synthesis of 
12ii, starting from the commercially available benzothiazole and 3-methoxabenzothiazole, and 
the preparation of amides 15i and 17i, starting from 6iii and 2-methoxybenzoisocyanate or 3-
methoxybenzoisocyanate, respectively. The secondary alcohols 6ii, 9ii and 12ii were oxidized 
(method C) to the carbonyl derivatives, 6i, 12i and 13i. The ether cleavage on the methoxy 
groups of 9ii with BF3S(CH3)2 in anhydrous CH2Cl2 at room temperature for 20 hours (method 
D) [42] took place with concomitant formation of the thioether derivative 9. The reduction of 
9ii using trimethyl silyl chloride and NaI in acetonitrile [64] led to the formation of the desired 
compound 11i and an additional product (10), where one of the methoxy group was retained. 
The reaction of 6i with BF3S(CH3)2 (method D) led to the formation of the desired compound 6 
and two additional reduced products (7 and 8). The ether cleavage of the methoxy groups of 
11i and 13i was carried out by using pyridinium hydrochloride at 220°C for 4 hours (method 
E) [42] to afford compounds 11, 13 and 14. The ether cleavage on the methoxy groups of 15i 
and 17i with BF3S(CH3)2 (method D) allowed us to obtain compounds 15-18. 
The benzamides (19-21), benzenesulfonamide (22), urea (23), thiourea (24) and acetamide (25) 
derivatives were afforded in a common 2-steps synthetic pattern (Figure 8). 
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Figure 8. Synthesis of compounds 19-25. Reagents and conditions: (a) Method B: pyridine, 100°C, 20 
h, for 19i to 21i: methoxy benzoylchloride, for 22i: methoxy phenylsulfochloride, for compound 23i: methoxy 
benzoisocyanate, for 24i: methoxy benzoisothiocyanate, for compound 25i: methoxy benzylchloride; (b) for 19-
21,  Method D: BF3S(CH3)2, anhydrous CH2Cl2, rt, 20 h; for 22-25, Method F: BBr3, CH2Cl2, -78 °C to rt, 20 h. 
 
Compounds 19i and 21i-25i were synthesised via amide coupling (method B) [65] starting 
from the commercial available 6-methoxy-benzothiazol-2-ylamine and 4-methoxy-benzoyl 
chloride, 3-methoxy-benzoyl chloride, 3-methoxy-sulphonyl chloride, 3-methoxy-
benzoisocyanate, 3-methoxy-benzoisothiocyanate and 3-methoxy-phenyl acetyl chloride, 
respectively. The ether cleavage of the methoxy groups was carried out with pyridinium 
hydrochloride (method E) or BBr3 (method F) [44] yielding compounds 19-21 and 22-25, 
respectively. 
 
3) Biological results. 
a) Activity: Inhibition of human 17β-HSD1. In the cell free assay, the placental cytosolic 
enzyme was used. Tritiated E1 (final concentration: 500 nM) was incubated with 17β-HSD1, 
cofactor (500 µM), and inhibitor as previously described [52]. After HPLC separation of 
substrate and product, the amount of labeled E2 formed was quantified. The hybrid inhibitor 
(EM-1745) evaluated using recombinant protein in a cell free assay as described by Poirier et 
al. [55] was used as external reference and gave similar values as described (IC50 = 52 nM). 
Compounds showing less than 10 % inhibition at 1μM were considered to be inactive. IC50 
values were determined for compounds showing more than 70 % inhibition at 1 µM. The 
inhibition values of the test compounds are shown in Table 1. Compound 2 (Figure 1), 
identified in our previous study [44] was used as internal reference (IC50 = 8 nM). 
The rigidified benzothiazole derivative 6 was far more potent towards the target enzyme (91 % 
at 1 μM) than 5 (34 % at 1 μM) and thus turned out to be a very promising scaffold (IC50 = 44 
nM), taking into account also its low molecular weight (271 g/mol). 
The inhibitory potency of the compounds is strongly dependent on length and type of the 
bridge connecting the aromatic moieties. The replacement of the flat sp2 bridge (methanone in 
compound 6) by a tetrahedral sp3 one like alcohol (7), methoxy (8), methylsulfanyl (9) and 
methylene (11) turned out to be deleterious for the inhibitory activity at the target enzyme. 
Compounds 7-9 showed activities of 28 %, 13 % and 7 %, respectively at 1 M concentration. 
The loss of potency obtained from those compounds as well as from compounds 10 and 11 
seems to be influenced by the bridge geometry and not by the H-bonding properties, since an 
alcohol (acceptor and donor), a methoxy methyl (acceptor only) and a methylene (neither 
acceptor nor donor) were all less potent than the carbonyl group.  
As the keto bridge (6) appeared to be the most appropriate moiety, it was taken as starting 
point to perform further modifications on the influence of the H-bonding groups. Compound 
12, without hydroxy group in the 6 position of the benzothiazole moiety, was designed to 
evaluate the importance of this functional group (6i) and showed 8 fold lower inhibitory 
activity than 6 (see Table 1). Furthermore, to investigate whether either methoxy group or 
hydroxy group in para on the phenyl moiety of compound 6 could exploit the pharmacophoric 
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feature AD3 (see Figure 4 and 5) compounds 13 and 14 were synthesized. The lower inhibitory 
activity of the para methoxy derivative 13 (27 % at 1 μM) compared to the hydroxy compound 
14 (85 % at 1 μM) proves the importance of an H-bonding donator in this position; there is 
however a decrease of activity when the hydroxy group is shifted from meta to para.  
Derivatives with two bridging atoms between the hydroxy phenyl and the hydroxyl 
benzothiazole moieties, like amide 18, retroamide 21 and sulphonamide 22, were also 
synthesized. Unlike the one unit bridge class, in the amide series, both the H-bonding 
properties as well as the sp2 geometry turned out to be discriminating factors for 17-HSD1 
inhibitory activity. The introduction of an amide bridge in the place of the carbonyl function 
(compound 18: 40 % at 1 μM vs compound 6: 91 % at 1 μM) results in a significantly 
decreased inhibitory potency as well as in the case of sulphonamide derivative 22 (no 
inhibition at 1 μM). Interestingly, replacement with retro amide (21) gives only a slight 
decrease of inhibitory activity (21: IC50 = 243 nM vs 6: IC50 = 44 nM). 
Independently on the nature of the bridge (amide or retroamide), changing the hydroxyl 
substitution pattern (16 and 20) is detrimental for activity as well as protection as methoxy 
group (15, 17 and 19).  
The extension of the bridge to three units resulted in the inactive urea 23 and benzylamide 25. 
Interestingly the thiourea 24 showed a moderate inhibitory activity. 
 
b) Selectivity: Inhibition of 17-HSD2 and affinities to the estrogen receptors  and . In 
order to gain insight into the selectivity of the most active compounds, inhibition of 17β-HSD2 
and the relative binding affinities to the estrogen receptors  and  were determined. Since 
17β-HSD2 catalyzes the inactivation of E2 into E1, inhibitory activity toward this enzyme 
must be avoided. The 17-HSD2 inhibition was determined for compounds showing 17-
HSD1 inhibitory activity of 70 % at 1 μM using an established assay [52] similar to the 17β-
HSD1 test and a selectivity factor (SF = IC50(HSD2)/IC50(HSD1)) was determined. Placental 
microsomal 17-HSD2 was incubated with tritiated E2 (final concentration: 500 nM) in the 
presence of NAD+ (1500 µM) and inhibitor. Separation and quantification of labeled substrate 
(E2) and product (E1) was performed by HPLC using radiodetection. IC50 values and 
selectivity factors are presented in Table 2. 
 
Table 2. Influence of the bridge and hydroxy group on the inhibition of the human  
17-HSD1 and 17-HSD2. 
 
 
Compound X R1 R2 HSD1a [IC50 (nM)c] HSD2b [IC50 (nM)c] SFd 
6 CO m-OH OH 44 1035 24 
12 CO m-OH H 365 1356 4 
14 CO p-OH OH 243 2471 10 
18 NHCO m-OH OH 1307 3813 3 
21 CONH m-OH OH 243 9264 38 
 
a Human placenta, cytosolic fraction, substrate [3H]E1 + E1 [500 nM], cofactor NADH [500 μM]. b Human 
placenta, microsomal fraction, substrate [3H]E2 + E2 [500 nM], cofactor NAD+ [1500 μM]. c Mean values of three 
determinations, standard deviation less than 10 %. d Selectivity factor = IC50 (HSD2)/IC50(HSD1). 
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Among the series bearing the carbonyl function as bridge, compound 6 showed the best 
selectivity factor (24 fold more active on HSD1 than HSD2). The absence of hydroxyl on the 
benzothiazole (12) or moving the meta hydroxyl of 6 to para hydroxyl of 14 leads to a drop in 
selectivity. Furthermore, compound 21, bearing the retro amide function as bridge, shows 
higher selectivity factor (SF = 38) than compound 18 (amide bridge, SF = 3) as well as 
compound 6 (carbonyl bridge, SF = 24). 
A further prerequisite for 17β-HSD1 inhibitors to be used as potential drugs is that they do not 
show affinity for ER and ER, since binding to these receptors, either agonistically or 
antagonistically, could counteract the therapeutic concept of mainly local action. The binding 
affinities of the most interesting compounds of this study (6 and 21) were determined using 
recombinant human protein (0.25 pmol of ER or ER, respectively) in a known competition 
assay [52] applying [3H]E2 (10 nM) and hydroxyapatite (data are shown in Table 3). 
 
Table 3. Binding affinities for the human estrogen receptors  and  of lead compounds. 
 
 RBAa (%) 
Compound ERb ERb 
6 1.000 < RBA < 10.000 0.100 < RBA < 1.000 
21 0.010 < RBA < 0.100 RBA < 0.001 
 
a RBA (relative binding affinity). E2: 100 %, mean values of three determinations, standard deviations less than 
10 %. b Human recombinant protein, incubation with 10 nM [3H]E2 and inhibitor for 1 h. 
 
A compound exhibiting less than 0.1 % relative binding affinity towards ERs was considered 
not to bind to the ERs under in vivo conditions (using T47-D [30] cell line obtained from 
ECACC, Salisbury). This assumption is based on the comparison of the compound’s binding 
affinity with the one of E1. E1 itself indeed is a ligand of the ERs with a relative binding 
affinity of about 10% [66-67]. Due to its RBA value of less than 0.1%, a selective inhibitor 
will be displaced by E1 from the ER binding site and is therefore unlikely to exert an ER 
mediated effect in vivo. 
Compound 6 turned out to considerably bind to both estrogen receptors, whereas compound 21 
shows very marginal affinity towards them (RBA lower than 0.1 % for ER and lower than 
0.001 % in the case of ER).  
 
c) Further Biological Evaluation. Additionally, the intracellular potency of the most selective 
compound (21) on E2 formation was evaluated as previously described [52] using the T47-D 
cell line that expresses 17β-HSD1 and - to a much lesser extent -17β-HSD2 [68]. The 
compound inhibited the formation of E2 after incubation with labelled E1 showing an IC50 
value of 245 nM. This result indicates that the compound is able to permeate the cell 
membrane, and to inhibit the transformation of E1 into E2 intracellularly. 
 
4) Binding mode analysis and SAR 
In order to rationalize the influence of the different bridges in this new set of 17-HSD1 
inhibitors, and to clarify the position of the phenyl moiety, all synthesized compounds reported 
herein were screened with our pharmacophore model. 
The carbonyl compound 6 matched six pharmacophore features (HY2-HY5, AD2 and D4), but 
it does not exploit the feature HY1, which corresponds to the steroidal A-ring moiety (see 
Figure 9A). 
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Figure 9. Pharmacophoric features exploited by the two lead compounds. Six for 
compound 6 (showed in A) and five for compound 21 (showed in B). 
 
The retroamide 21 was found in a different orientation in the pharmacophore with respect to 6, 
without occupying the feature HY6. It might adopt two preferred isomeric forms (cis and trans) 
which cannot be separated at room temperature because they interconvert readily. The 
energetically favorable [69] linear (trans) isomer exploits five pharmacophoric features (HY1-
HY4 and AD1). In addition the hydroxy group on the benzothiazole in proximity of aromatic 
features HY5 and HY6, as depicted in Figure 9B, while the cis isomer could not match the 
required six features. Binding of 21 in the trans-form may thus be assumed. Interestingly, the 
retro amide bridge exploits the pharmacophoric feature HY2, in the case of compound 6 
exploited by the benzothiazole phenyl ring, suggesting these two compounds to bind 
differently. Thus, both compound 6 and 21 were considered as two new lead structures. 
To better understand the favourable interactions achieved by compounds 6 and 21 in the five 
different crystal structures used to build up the pharmacophore, a thorough analysis of the 
respective surrounding residues was performed. Herefore also the flexible amino acid residues, 
formerly excluded in the pharmacophore generation process, were considered. The 
cocrystallized steroidal ligands were replaced by either 6 or 21 (via the pharmacophore) and 
the resultant complexes were optimized with the ligX module of MOE. This module optimize 
the protein-ligand complex by first adjusting the protonation state of the residues, tethering the 
active site heavy atoms and, finally, energy minimizing the complex. The results highlighting 
the interactions between our 17-HSD1 inhibitors and the five crystal structures are shown in 
Table 4. 
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Table 4. Interactions found in the complexes between the lead compounds (6 and 21) and 
the five 17-HSD1 crystal structures used to build up the pharmacophore. 
 
Compound interactions amino acid residues 1equ 1i5r 3hb5 1a27 1dht 
6 H Ser142 (donor)  3.31 3.38 3.70 3.26 
  Asn152 (acceptor) 2.53a 2.45 2.56  2.97 
  Asn152 (donor)    2.49 2.55 
  Tyr155 (donor) 3.90  3.80 3.71  
  His221 (d donor) 3.13 3.33    
  Tyr 155 6.71 3.98 3.82 4.06 4.16 
  Arg258 4.89     
21 H Tyr155 (acceptor) 2.91 3.13 3.03 2.75 3.03 
  Tyr218 (donor)  3.82    
  His221 (donor) 2.47 2.45  2.65 2.51 
  Glu282 (acceptor) 2.43  2.52  2.43 
  Arg258 4.34     
 
a Distance (Å) between the heteroatoms for H-bonds (H) and between centroids or centroid and cation for -
interactions (). 
 
For compound 6 five hydrogen bond interactions could be observed: between its meta hydroxy 
group of the phenyl ring and Asn152 (dO-O = 2.45-2.97 Å and dO-N = 2.49-2.55 Å), between the 
carbonyl oxygen of the bridge and both Ser142 and Tyr155 (dO-O = 3.26-3.70 Å and dO-O = 
3.71-3.90 Å), and between the hydroxy group of the benzothiazol and His221 (dO-N = 3.13-3.33 
Å). In addition, a cation- interaction between the phenyl ring of benzothiazole and Arg258 
(dN-centroid = 4.89 Å) as well as a - interaction between the phenyl ring and Tyr155 (dcentroid-
centroid = 3.98-6.71 Å) were found.  
For compound 21 also five hydrogen bond interactions were identified: between the meta 
hydroxy group of the phenyl ring and both His221 and Glu282 (dO-N = 2.45-2.65 Å and dO-O = 
2.43-2.52 Å, respectively), between the carbonyl oxygen of the amide bridge and Tyr218 (dO-O 
3.82 Å), and between the hydroxy group of the benzothiazole and Tyr155 (dO-O = 2.75-3.13 Å). 
Again, a cation- interaction between the phenyl ring and Arg258 was found (dN-centroid = 4.34 
Å).  
It is noteworthy that only the interactions with Tyr155 (- stacking for 6 and hydrogen bond 
for 21) could be observed for all five crystal structure-inhibitor complexes optimized with 
ligX, whereas all the other were present depending on which crystal structure was used. This 
further substantiated the importance of Tyr155 for the stabilization of a ligand. 
The differences in inhibitory activity between 6 (IC50 43 nM) and 21 (IC50 243 nM) could not 
be thoroughly explained by considering only the hydrogen bonds, since only in 3hb5 and 1a27 
more interactions were found for 6 compared to 21. On contrary, the - stacking interaction 
of 6 with Tyr155, missing for 21, as well as the cation- (charge transfer) interaction between 
Arg258 and the phenyl ring of benzothiazole seem to be particularly important for the 17-
HSD1 inhibition. Compound 21 was found to be involved only in -stacking with Arg258, and 
no H-bond interactions with Ser142 were found in any of the complexes (exemplificative 
shown for 1equ, Figure 10 and 11). 
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Figure 10. Pharmacophore derived complex between 17-HSD1 (X-ray 1equ) and 
compound 6 (dark orange). NADP+ (green), interacting residues (blue), potential interacting 
residues (black) and ribbon rendered tertiary structure of the active site are shown. 
 
 
 
Figure 11. Pharmacophore derived complex between 17-HSD1 (X-ray 1equ) and 
compound 21 (magenta). NADP+ (green), interacting residues (blue), potential interacting 
residues (black) and ribbon rendered tertiary structure of the active site are shown. 
 
In addition, the interactions between the hydroxy group in HY1 of compound 6 and His221, as 
found in different crystal structures (1equ and 1i5r), is in agreement with the postulated 
binding mode.  
Summarizing, the two lead compounds 6 and 21 bind very differently: they are flipped 
horizontally by 180° and with the planes of their benzothiazole moieties form an angle of 90°. 
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Discussion 
 
The inhibitor design concept of the present study triggered the synthesis of compound 6 and 21 
as promising new lead structures by optimizing a novel, in silico identified, core scaffold (5). 
The classical medicinal chemistry approach of rigidification was successfully applied to 
compound 5 and led to the discovery of the highly potent benzothiazole 6. The introduction of 
the aromatic benzothiazole freezes the position of hydroxyl moiety in an ideal position to 
establish an H-bond with H221. In addition, this aromatic benzothiazole can undergo a cation-
 interaction with Arg258, explaining the high gain in potency of 6 compared to 5. 
In the optimization process the carbonyl bridge of 6 was varied using several linkers with 
different lengths, geometries and H-bonding properties. From the biological results as well as 
from the performed in silico studies it became apparent, that the 17-HSD1 inhibitory activity 
is highly influenced by the nature of the linker: the comparison of inactive tetrahedral alcohol 
(7), methoxy (8), thiomethyl (9), methylene (10), and sulphonamide (22) with the active, 
planar carbonyl (6) and amide derivatives (18 and 21) led us to conclude that a flat geometry of 
the linker is required for the activity. The fact that the retroamide 21 is five times more active 
than the amide 18 can be explained by a steric clash observed between the carbonyl of amide 
bridge and Leu149. Furthermore, the carbonyl group of 21 was found to establish a H-bond 
interaction with Tyr218 which is not possible for 18. 
Comparing the binding modes of 6 and 21, it becomes clear that the hydroxyl-phenyl moieties 
of the two compounds do not interact with the same area of the enzyme. In case of compound 
6, HY5 and D4 are plausible features covered by the hydroxyphenyl moiety. The meta 
hydroxy-phenyl moiety of 21, on the other hand, exploits HY1 and AD1. The difference in 
activity between 6 and 21 is in agreement with the number of features covered by each 
compound (6 versus 5). 
It is striking that the newly discovered class of benzothiazole derivatives shows structural 
characteristics which are similar to those of other classes of 17β-HSD1 inhibitors: two phenolic 
hydroxy-groups separated by a rather unpolar scaffold structure [39, 44, 51]. The necessity for 
the lipophilicity of the scaffold is reflected by the gain in potency observed with the thiourea 
(24: 62 % inhibition at 1 M) compared to the less lipophilic urea (23: no inhibition at 1 M). 
Analysis of the amino acid residues which surround compound 6 in its pharmacophore binding 
pose indicates that two hydrogen bonds with Asn152 and one - interaction with Tyr155 are 
established. Recently published docking studies in the case of bicyclic substituted 
hydroxyphenylmethanones suggest similar interactions [51]. Interestingly, there is a decrease 
of activity in both compound classes when the hydroxy group is shifted from the meta- to the 
para position. This similarity in SAR supports the hypothesis that the hydroxyphenyl moieties 
of both compound classes bind in the same area of the enzyme. 
In order to evaluate the protein-ligand interaction, the ligands of the different X-ray structures 
studied were replaced by compound 6 and 21 according to their pharmacophoric binding 
modes and the interactions between the inhibitors 6 and 21 and each of the crystal structures 
were considered. The maximum number of interactions was observed with the crystal structure 
1equ, originally containing the inhibitor equiline. This because Arg258 of 1equ is turned into 
the active site. Notably, the importance of this amino acid residue was already postulated by 
Alho-Richmond S et al. [70], who proposed to target it in the inhibitor design process. 
The selectivity against 17β-HSD2 should be achieved to mainly avoid systemic effects since 
the expression of this enzyme is downregulated in EDD tissues but it is present in several 
organs (i.e. liver, small intestine, bones). However, it is difficult to estimate how high the SF 
should be to minimize potential side effects due to the lack of respective in vivo data. For our 
drug development program, an SF of approximately 20 is considered sufficient to justify 
further biological evaluation. In this study the retroamide 21 is the most 17HSD2 selective 
compound identified. It is striking that the amide 18 shows a complete loss in selectivity 
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against 17HSD2. As no 3D-structure of this enzyme is known, it is not possible to figure out 
the structural differences between the two enzymes at protein level. These results indicate that 
the orientation of the amide group is an important feature to gain activity for 17HSD1 and 
selectivity against 17HSD2. 
 
Conclusions 
 
In the present study two new classes of 17-HSD1 inhibitors were identified. As no X-ray 
structure of 17HSD1 complexed with non-steroidal compound exists the followed 
pharmacophoric approach resulted in being a powerful tool since it combines the knowledge of 
crystal structure-steroidal ligand complexes with structure analysis of active nonsteroidal 
inhibitors. In this study, 6 is the most active compound in term of 17-HSD1 inhibition (IC50 = 
44 nM), showing fair selectivity  against 17-HSD2 (SF = 24) but pronounced affinity to ERs 
(RBA < 10 for Er and RBA < 1 for ER).  
Compound 21 on the other hand showed medium inhibitory activity at the target enzyme (IC50 
= 243 nM) as well as fair selectivity (SF = 38) against 17-HSD2 and ERs (RBA < 0.1 for Er 
and RBA < 0.001 for ER). Furthermore, 21 inhibits the formation of E2 intracellularly with 
an IC50 value in the nanomolar range (245 nM). Thus shows that it is able to enter the cell, and 
to be active at the target enzyme. Further optimizations of these first benzothiazole-type lead 
compounds are underway in order to develop potential candidates for in vivo application. 
 
Supporing information 
 
Experimental section 
 
Chemical Methods. Chemical names follow IUPAC nomenclature. Starting materials were purchased 
from Acros, Aldrich, Alfa Aesar, Maybridge, Merck or Fluka and were used without purification.  
Column chromatography (CC) was performed on silica gel (70-200 m) coated with silica, preparative 
thin layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and 
reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in  (parts per million: ppm), by reference to the hydrogenated residues of 
deuteriated solvent as internal standard CDCl3:  = 7.24 ppm (1H-NMR) and  = 77 ppm (13C-NMR), 
CD3OD:  = 3.32 ppm (1H-NMR) and  = 49.05 ppm (13C-NMR), CD3COCD3:  = 2.05 ppm (1H-
NMR) and  = 29.9 ppm (13C-NMR) and CD3SOCD3:  = 2.50 ppm (1H-NMR) and  = 39.43 ppm 
(13C-NMR). Signals are described as s, d, t, dd, ddd, m, dt, q for singlet, doublet, triplet, doublet of 
doublets, doublet of doublets of doublets, multiplet, doublet of triplets and quadruplet respectively. All 
coupling constants (J) are given in hertz (Hz). 
Mass spectra (ESI) were recorded on a TSQ Quantum (Thermo Finnigan) instrument. 
Tested compounds are > 95 % chemical purity as measured by HPLC. The methods for HPLC analysis 
and a table of data for all tested compounds are provided in the supporting information. 
The following compounds were prepared according to previously described procedures: 3-(tert-butyl-
dimethyl-silanyloxy)-benzaldehyde (5iiib) [1], 6-methoxy-1,3-benzothiazole (6iii) [2], (6-hydroxy-1,3-
benzothiazol-2-yl)(3-hydroxyphenyl)methanone (6) [3], (6-methoxy-1,3-benzothiazol-2-yl)(4-
methoxyphenyl)methanone (13i) [3], 1,3-benzothiazol-2-yl(3-hydroxyphenyl)methanone (12) [4], (6-
hydroxy-1,3-benzothiazol-2-yl)(4-methoxyphenyl)methanone (13) [3], (6-hydroxy-1,3-benzothiazol-2-
yl)(4-hydroxyphenyl)methanone (14) [3], 4-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide 
(19i) [5], 3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (21i) [5]. 
 
Method A, general procedure for nucleophilic addition: To a solution of thiazole derivative 
unsubstituted in position 2 (1 eq) in anhydrous THF a 2.5 M solution of n-BuLi (1 eq) in hexane was 
added dropwise at -78 °C (dry ice/acetone bath) under anhydrous conditions. The reaction mixture was 
stirred for 1 h at –78 °C to form the formyl anion in situ. Then a solution of electrophile (0.8 eq) in 
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anhydrous THF was added dropwise at –78 °C and additionally stirred for 30 min. The temperature was 
then risen to –20 °C (NaCl/ice/dry ice/acetone bath) and the stirring was continued for 90 min. 
Saturated NH4Cl solution was added to quench the reaction, and the aqueous layer was extracted three 
times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium 
sulfate, filtered and concentrated to dryness. The product was purified by CC or recrystallisation. 
 
Method B, general procedure for nucleophilic substitution: To a solution of 2-amino-6-
methoxybenzothiazole (1 eq) in dry pyridine the respective benzoyl chloride, isocyanate or 
isothiocianate (1 eq.) was added dropwise at room temperature. The reaction mixture was refluxed for 4 
h. Water was added to quench the reaction, and the aqueous layer was extracted with ethyl acetate. The 
combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated 
to dryness. The product was purified by CC or recrystallisation. 
 
Method C, general procedure for oxidation: A mixture of aliphatic alcohol (1 eq) and 2-
iodoxybenzoic acid (2 eq) in anhydrous THF was stirred at 0 °C for 10 min. Then, the reaction mixture 
was heated to 60 °C for 18 h. After cooling to room temperature, saturated sodium thiosulfate solution 
was added to quench the reaction and the aqueous layer was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to 
dryness. The product was purified by CC or recrystallisation. 
 
Method D, general procedure for ether cleavage: To a solution of methoxybenzene derivative (1 eq) 
in dry dichloromethane at room temperature, boron trifluoride methyl sulfide complex in 
dichloromethane (1 M, 75 eq per methoxy function) was added dropwise. The reaction mixture was 
stirred for 20 h at room temperature under nitrogen atmosphere. Water was added to quench the 
reaction, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over magnesium sulfate, filtered and concentrated to dryness. The product was 
purified by CC, preparative TLC, preparative HPLC or recrystallisation, respectively. 
 
Method E, general procedure for ether cleavage: A mixture of methoxybenzene derivative (1 eq) and 
pyridinium hydrochloride (50 eq per methoxy function) was heated to 220 °C for 18 h. After cooling to 
room temperature, water, 1 M HCl and ethyl acetate were added. The aqueous layer was separated and 
extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium 
sulfate, filtered and concentrated to dryness. The product was purified by CC followed by preparative 
TLC or preparative HPLC, respectively. 
 
Method F, general procedure for ether cleavage: To a solution of methoxybenzene derivative (1 eq) 
in anhydrous dichloromethane at -78 °C (dry ice/acetone bath), boron tribromide in dichloromethane (1 
M, 5 eq per methoxy function) was added dropwise. The reaction mixture was stirred for 20 h at room 
temperature under nitrogen atmosphere. Water was added to quench the reaction, and the aqueous layer 
was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over 
sodium sulfate, filtered and concentrated to dryness. The product was purified by CC followed by 
preparative TLC or preparative HPLC, respectively. 
 
General procedure for purification using preparative HPLC. All declared final compounds were 
purified via an Agilent Technologies Series 1200-preparative HPLC using a linear gradient run 
(solvents: acetonitrile, water) from 20 % acetonitrile to 100 % in 36 min. 
 
5-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-4-methyl-thiazole (5iiia). To a solution of 5-(2-
hydroxyethyl)-4-methyl-thiazole (8.0 g, 55.86 mmol) and tert-butyldimethylsilyl chloride (12.63 g, 
83.79 mmol) in DMF, imidazole (6.46 g, 94.97 mmol) was added in portion for 1 hour at 0 °C. The 
reaction mixture was stirred for 6 h at room temperature. Water was added to quench the reaction and 
the aqueous solution was then extracted three times with ethyl acetate. The combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered and concentrated to dryness. The 
product was used in the next synthetic step without purification; yield: quant. (14.38 g); 1H NMR 
(CDCl3): 0.06 (s, 6H), 0.80 (s, 9H), 2.32 (s, 3H), 2.88 (t, J = 6.0 Hz, 2H), 3.70 (t, J = 6.0 Hz, 2H), 8.47 
(s, 1H); 13C NMR (CDCl3): -2.3, 15.3, 24.9, 32.0, 34.6, 62.2, 127.3, 149.2, 150.0; 
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{5-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-4-methyl-thiazol-2-yl}-[3-(tert-butyl-dimethyl-
silaniloxy)-phenyl]-methanol (5i). The title compound was prepared by reaction of 5-[2-(tert-butyl-
dimethyl-silanyloxy)-ethyl]-4-methyl-thiazole (5iiia) (5 g, 19.42 mmol), n-BuLi (2,5 M in hexane; 7.8 
mL, 19.42 mmol) and 3-(tert-butyl-dimethyl-silanyloxy)-benzaldehyde (5iiib) (3.53 g, 14.94 mmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 80:20); yield: 64 % (4.06 
g); 1H NMR (CDCl3): -0.03 (s, 6H), 0.18 (s, 6H), 0.84 (s, 9H), 0.97 (s, 9H), 2.30 (s, 3H), 2.86 (t, J = 6.5 
Hz, 2H), 3.70 (t, J = 6.5 Hz, 2H), 5.89 (s, 1H), 6.77 (dd, J = 8.2 Hz, J = 2.5 Hz, 1H), 6.96 (s, 1H), 7.03-
7.05 (m, 1H), 7.20 (t, J = 7.9 Hz, 1H); 13C NMR (CDCl3): -5.5, -4.4, 18.2, 18.2, 21.0, 25.7, 25.8, 30.0, 
63.2, 73.2, 118.2, 119.4, 119.8, 129.3, 129.5, 143.2, 147.6, 155.8, 171.1; 
 
{5-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-4-methyl-thiazol-2-yl}-[3-(tert-butyl-dimethyl-
silaniloxy)-phenyl]-methanone (5i). The title compound was prepared by reaction of {5-[2-(tert-butyl-
dimethyl-silanyloxy)-ethyl]-4-methyl-thiazol-2-yl}-[3-(tert-butyl-dimethyl-silaniloxy)-phenyl]-
methanol (5ii) (0.5 g, 1.01 mmol) and SIBX (0.57 g, 2.02 mmol) according to method C. The product 
was purified by CC (hexane/ethyl acetate 95:5); yield: 94 % (0.47 g); 1H NMR (CD3OD) 2.33 (s, 3H), 
2.91 (t, J = 6.0 Hz, 2H), 3.68 (t, J = 6.0 Hz, 2H), 6.94 (d, J = 7.9 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.59 
(s, 1H), 7.72 (d, J = 7.9 Hz, 1H); 13C NMR (CD3DO): 15.1, 30.3, 62.0, 117.3, 121.1, 122.8, 129.6, 
136.7, 138.2, 152.0, 152.1, 157.1, 163.3; 
 
[5-(2-hydroxyethyl)-4-methyl-thiazol-2-yl]-(3-hydroxy-phenyl)-methanone (5). To a solution of {5-
[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-4-methyl-thiazol-2-yl}-[3-(tert-butyl-dimethyl-silaniloxy)-
phenyl]-methanone (5i) (0.47 g, 0.96 mmol) in THF at 0 °C (dry ice) tetra-n-butylammonium fluoride 
(0.62 g, 2.38 mmol) in THF  was added dropwise. The reaction mixture was stirred for 2 h at room 
temperature under nitrogen atmosphere. Water was added to quench the reaction, and the aqueous layer 
was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over 
magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC (hexane/ethyl 
acetate 50:50); yield: 80 % (0.20 g); 1H NMR (CD3OD): 2.33 (s, 3H), 2.91 (t, J = 6.4 Hz, 2H), 3.68 (t, J 
= 6.4 Hz, 2H), 6.94 (d, J = 7.9 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.59 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H); 
13C NMR (CD3DO): 15.1, 30.3, 62.0, 117.3, 121.1, 122.8, 129.6, 136.7, 138.2, 152.0, 152.1, 157.1, 
163.3; MS (ESI): 264.0 (M+H)+; 
 
(6-methoxy-1,3-benzothiazol-2-yl)(3-methoxyphenyl)methanol (6ii). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazole (6iii) (0.5 g, 3.03 mmol), n-BuLi (2,5 M in 
hexane; 1.2 mL, 3.03 mmol) and 3-methoxy-benzaldehyde (0.27 mL, 2.32 mmol) according to method 
A. The product was purified first by CC (chloroform/ethyl acetate 70:30); yield: quant. (0.61 g); 1H 
NMR (CD3OD): 3.72 (s, 3H), 3.79 (s, 3H), 5.95 (s, 1H), 6.83 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H) 7.02-7.05 
(m, 3H), 7.25 (t, J = 8.2 Hz, 1H), 7. 6 (d, J = 2.5 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H); 13C NMR (CD3DO): 
55.0, 55.6, 72.5, 104.8, 112.1, 112.9, 115.2, 118.7, 123.0, 129.4, 135.8, 143.9, 147.2, 147.3, 156.9, 
159.2; 
 
(6-methoxy-1,3-benzothiazol-2-yl)(4-methoxyphenyl)methanol (9ii). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazole (6iii) (0.5 g, 3.03 mmol), n-BuLi (2,5 M in 
hexane; 1.2 mL, 3.03 mmol) and 4-methoxy-benzaldehyde (0.3 mL, 2.32 mmol) according to method 
A. The product was purified by CC (chloroform/ethyl acetate 70:30); yield: quant. (0.61 g); 1H NMR 
(CDCl3): 3.79 (s, 3H), 3.85 (s, 3H), 6.06 (s, 1H), 6.88-6.90 (m, 2H), 7.04 (dd, J = 9.1 Hz, J = 2.5 Hz, 
1H), 7.26 (d, J = 2.5 Hz, 1H), 7.42 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 9.1 Hz, 1H); 13C NMR (CDCl3): 
55.3, 55.8, 73.9, 104.3, 114.2, 115.5, 116.5, 117.0, 123.4, 128.1, 133.2, 136.6, 146.9, 157.6, 159.8,  
172.6; 
 
1,3-benzothiazol-2-yl(3-methoxyphenyl)methanol (12ii). The title compound was prepared by 
reaction of benzothiazole (0.20 mL, 1.85 mmol), n-BuLi (2,5 M in hexane; 0.74 mL, 1.85 mmol) and 3-
methoxy-benzaldehyde (0.2 mL, 1.42 mmol) according to method A. The product was purified by CC 
(hexane/ethyl acetate 80:20); yield: 91 % (0.35 g); 1H NMR CDCl3: 3.92 (s, 3H), 6.26 (s, 1H), 6.97-
7.03 (m, 1H), 7.24-7.26 (m, 2H), 7.42 (t, J = 8.2 Hz, 1H), 7.48-7.51 (m, 1H), 7.57-7.60 (m, 1H), 7.96 (d, 
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J = 8.5 Hz, 1H), 8.10 (d, J = 8.2 Hz, 1H); 13C NMR (CDCl3): 55.2, 74.1, 112.0, 114.3, 119.0, 121.7, 
123.0, 125.1, 126.1, 129.8, 135.2, 142.4, 152.4, 159.9, 175.1; 
 
6-methoxy-benzothiazole-2-carboxylic acid (2-methoxy-phenyl)-amide (15i). The title compound 
was prepared by reaction of 6-methoxy-1,3-benzothiazole (6iii) (0.20 g, 1.21 mmol), n-BuLi (2,5 M in 
hexane; 0.5 mL, 1.21 mmol) and 1-isocyanato-2-methoxy-benzene (0.1 mL, 0.93 mmol) according to 
method A. The product was purified by CC (hexane/ethyl acetate 80:20); yield: quant. (0.25 g); 1H 
NMR (CD3OD): 3.92 (s, 3H), 4.0 (s, 3H), 6.95 (dd, J = 8.2 Hz, J = 1.3 Hz, 1H), 7.03 (dd, J = 8.2 Hz, J 
= 1.2 Hz, 1H), 7.10 (dq, J = 8.2 Hz, J = 1.6 Hz, J = 0.6 Hz, 1H), 7.17 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 
7.40 (d, J = 2.5 Hz, 1H), 8.03 (d, J = 9.1 Hz, 1H), 8.51 (dd, J = 7.9 Hz, J = 1.6 Hz, 1H), 9.76 (s, 1H); 
13C NMR (CD3OD): 55.9, 56.0, 104.3, 110.5, 117.1, 120.1, 120.3, 121.3, 124.5, 125.2, 127.3, 139.3, 
147.7, 148.9, 159.3, 162.0; 
 
6-methoxy-benzothiazole-2-carboxylic acid (3-methoxy-phenyl)-amide (17i). The title compound 
was prepared by reaction of 6-methoxy-1,3-benzothiazole (6iii) (0.25 g, 1.51 mmol), n-BuLi (2,5 M in 
hexane; 0.6 mL, 1.51 mmol) and 1-isocyanato-3-methoxy-benzene (0.2 mL, 1.16 mmol) according to 
method A. The product was purified by CC (hexane/ethyl acetate 80:20); yield: quant. (0.25 g); the 
compound was used for the next step without characterization. 
 
 (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxyphenyl)methanone (6i). The title compound was 
prepared by reaction of (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxyphenyl)methanol (6ii) (0.35 g, 
1.16 mmol) and SIBX (0.65 g, 2.32 mmol) according to method C. The product was purified by CC 
(hexane/ethyl acetate 95:5); yield: quant. (0.35 g); 1H NMR (CD3OD): 3.91 (s, 3H), 3.93 (s, 3H), 7.17-
7.22 (m, 2H), 7.41 (d, J = 2.5 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H), 8.03-8.04 (m, 1H), 8.10 (d, J = 9.1 Hz, 
1H), 8.19-8.22 (m, 1H); 13C NMR (CD3DO): 55.5, 55.9, 103.4, 115.2, 117.6, 120.3, 124.1, 126.5, 
129.5, 136.4, 139.1, 148.5, 159.6, 159.8,  164.6, 184.9; MS (ESI): 299.9 (M+H)+; 
 
2-[(4-hydroxyphenyl)(methylsulfanyl)methyl]-1,3-benzothiazol-6-ol (9). The title compound was 
prepared by reaction of (6-methoxy-1,3-benzothiazol-2-yl)(4-methoxyphenyl)methanol (9ii) (0.30 g, 
1.00 mmol) and boron trifluoride methyl sulfide complex in dichloromethane (1 M, 15.8 mL, 150.00 
mmol) according to method D. The product was purified by CC (hexane/ethyl acetate 50:50); yield: 86 
% (0.26 g); 1H NMR (CD3OD): 2.10 (s, 3H), 5.36 (s, 1H), 6.77-6.79 (m, 2H), 6.97 (dd, J = 8.8 Hz, J = 
2.5 Hz, 1H), 7.27 (d, J = 1.9 Hz, 1H), 7.31-7.33 (m, 2H), 7.72 (d, J = 8.5 Hz, 1H); 13C NMR (CD3OD): 
14.4, 56.7, 107.5, 114.9, 115.5, 116.8, 123.0, 131.1, 131.3, 131.5, 136.6, 145.4, 155.1, 156.9, 168.7; MS 
(ESI): 302.6 (M+H)+; 
 
6-methoxy-2-(4-hydroxybenzyl)benzothiazole (10). A solution of NaI (0.89 g, 5.97 mmol) and 
Trimethylsilyl chloride (0.8 mL, 5.97 mmol) in acetonitrile was stirred at room temperature for 15 min. 
The reaction mixture was cooled to 0 °C, and before a solution of (6-methoxy-1,3-benzothiazol-2-yl)(4-
methoxyphenyl)methanol (9ii) (0.20 g, 0.66 mmol) in acetonitrile was added drop-wise during 15 min. 
The reaction mixture was then refluxed overnight. To quench the reaction a solution of NaHCO3 was 
slowly added at room temperature, followed by a solution of Na2S2O3·5H2O. The aqueous solution was 
then extracted three times with ethyl acetate. The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC 
(hexane/ethyl acetate 80:20); yield: 28 % (0.05 g); 1H NMR (CDCl3): 3.84 (s, 3H), 4.31 (s, 2H), 6.76-
6.79 (m, 2H), 7.04 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 7.16-7.19 (m, 2H), 7.24 (d, J = 2.5 Hz, 1H), 7.86 
(d, J = 9.1 Hz, 1H); 13C NMR (CDCl3): 39.3, 55.8, 104.3, 114.3, 115.3, 115.9, 122.8, 128.7, 130.2, 
130.3, 136.5, 147.0, 155.5, 157.5, 170.2; MS (ESI): 272.5 (M+H)+; 
 
6-methoxy-2-(4-methoxybenzyl)benzothiazole (11i). A solution of NaI (0.89 g, 5.97 mmol) and 
Trimethylsilyl chloride (0.8 mL, 5.97 mmol) in acetonitrile was stirred at room temperature for 15 min. 
The reaction mixture was cooled at 0 °C, and a solution of (6-methoxy-1,3-benzothiazol-2-yl)(4-
methoxyphenyl)methanol (9ii) (0.20 g, 0.66 mmol) in acetonitrile was added drop-wise during 15 min. 
The reaction mixture was then refluxed overnight. To quench the reaction a solution of NaHCO3 was 
slowly added at room temperature, followed by a solution of Na2S2O3·5H2O. The aqueous solution was 
then extracted three times with ethyl acetate. The combined organic layers were washed with brine, 
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dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC 
(hexane/ethyl acetate 80:20); yield: 56 % (0.11 g); 1H NMR (CDCl3): 3.79 (s, 3H), 3.83 (s, 3H), 4.33 (s, 
2H), 6.86-6.89 (m, 2H), 7.04 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 7.23 (d, J = 2.5 Hz, 1H), 7.26-7.29 (m, 
2H), 7.86 (d, J = 9.1 Hz, 1H); 13C NMR (CDCl3): 39.6, 55.2, 55.7, 104.2, 114.2, 115.0, 123.1, 125.7, 
129.4, 130.2, 136.8, 147.6, 157.4, 158.8, 163.8,  169.3; 
 
1,3-benzothiazol-2-yl(3-methoxyphenyl)methanone (12i). The title compound was prepared by 
reaction of 1,3-benzothiazol-2-yl(3-methoxyphenyl)methanol (12ii) (0.35 g, 1.29 mmol) and SIBX 
(0.72 g, 2.58 mmol) according to method C. The product was purified by CC (hexane/ethyl acetate 
90:10); yield: 61 % (0.215 g); 1H NMR CDCl3: 3.92 (s, 3H), 7.23 (dd, J = 8.2 Hz, J = 2.8 Hz, 1H), 7.48 
(t, J = 8.2 Hz, 1H), 7.54-7.61 (m, 2H), 8.02-8.06 (m, 2H), 8.24 (t, J = 8.2 Hz, 2H); 13C NMR (CDCl3): 
55.5, 115.3, 120.6, 122.2, 124.2, 125.8, 126.9, 127.6, 129.5, 136.2, 137.0, 153.9, 159.6, 167.1, 185.1; 
 
2-[(3-hydroxyphenyl)(hydroxy)methyl]-1,3-benzothiazol-6-ol. (7). The title compound was prepared 
by reaction of (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxyphenyl)methanone (6i) (0.17 g, 0.57 
mmol) and boron trifluoride methyl sulfide complex in dichloromethane (1 M, 9.0 mL, 85.55 mmol) 
according to method D. The product was purified by preparative HPLC; yield: 16 % (0.02 g). 1H NMR 
(CD3OD): 5.84 (s, 1H), 6.61 (dd, J = 2.5 Hz, J = 0.9 Hz, 1H), 6.84-6.87 (m, 3H), 7.06 (t, J = 7.9 Hz, 
1H), 7.17 (d, J = 2.5 Hz, 1H), 7.59 (d, J = 8.8 Hz, 1H); 13C NMR (CD3OD): 66.8, 75.0, 107.6, 114.6, 
116.1, 116.8, 119.0, 123.8, 130.6, 144.6, 147.6, 156.9, 158.7, 175.6; MS (ESI): 274.0 (M+H)+; 
 
2-[(3-hydroxyphenyl)(methoxy)methyl]-1,3-benzothiazol-6-ol. (8). The title compound was prepared 
by reaction of (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxyphenyl)methanone (6i) (0.17 g, 0.57 
mmol) and boron trifluoride methyl sulfide complex in dichloromethane (1 M, 9.0 mL, 85.55 mmol) 
according to method D. The product was purified by preparative HPLC; yield: 16 % (0.02 g). 1H NMR 
(CD3OD): 3.35 (s, 3H), 5.42 (s, 1H), 6.63-6.65 (m, 1H), 6.80-6.87 (m, 3H), 7.08 (t, J = 7.8 Hz, 1H), 
7.17 (d, J = 2.2 Hz, 1H), 7.61 (d, J = 8.8 Hz, 1H); 13C NMR (CD3OD): 57.8, 84.3, 107.6, 114.9, 116.5, 
116.9, 119.4, 124.0, 130.8, 137.6, 141.9, 147.5, 157.1, 158.9, 172.5; MS (ESI): 288.0 (M+H)+; 
 
6-hydroxy-2-(4-hydroxybenzyl)benzothiazole (11). The title compound was prepared by reaction of 
6-methoxy-2-(4-methoxybenzyl)benzothiazole (11i) (0.11 g, 0.37 mmol) and pyridinium hydrochloride 
(4.29 g, 37.10 mmol) according to method E. The product was purified by recrystallisation 
(hexane/ethyl acetate); yield: 47 % (0.05 g); 1H NMR (CD3OD): 4.27 (s, 2H), 6.76-6.80 (m, 2H), 6.96 
(dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 7.16-7.18 (m, 2H), 7.21 (d, J = 2.5 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H); 
13C NMR (CD3OD): 39.9, 107.6, 116.6, 116.7, 118.5, 118.8, 123.4, 129.5, 131.2, 137.6, 137.9, 157.3, 
163.7, 171.6; MS (ESI): 258.5 (M+H)+; 
 
6-methoxy-benzothiazole-2-carboxylic acid (2-hydroxy-phenyl)-amide (15). The title compound 
was prepared by reaction of 6-methoxy-benzothiazole-2-carboxylic acid (2-methoxy-phenyl)-amide 
(15i) (0.10 g, 0.32 mmol) and boron trifluoride methyl sulfide complex in dichloromethane (1 M, 5.0 
mL, 47.72 mmol) according to method D. The product was purified by recrystallisation (ethyl acetate); 
yield: 21 % (0.02 g). 1H NMR (CD3COCD3): 3.94 (s, 3H), 6.90-6.95 (m, 1H), 7.02-7.03 (m, 2H), 7.24 
(dd, J = 9.1 Hz, J = 2.7 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 8.05 (d, J = 9.1 Hz, 1H), 8.36 (d, J = 8.2, 
1H), 9.38 (s, 1H), 9.87 (s, 1H); 13C NMR (CD3COCD3): 56.8, 105.7, 116.5, 118.9, 121.4, 121.4, 126.2, 
126.4, 127.5, 140.4, 148.0, 148.7, 158.8, 160.8, 162.9; MS (ESI): 301.1 (M+H)+; 
 
6-hydroxy-benzothiazole-2-carboxylic acid (2-hydroxy-phenyl)-amide (16). The title compound was 
prepared by reaction of 6-methoxy-benzothiazole-2-carboxylic acid (2-methoxy-phenyl)-amide (15i) 
(0.1 g, 0.32 mmol) and boron trifluoride methyl sulfide complex in dichloromethane (1 M, 5.0 mL, 
47.72 mmol) according to method D. The product was purified by recrystallisation (ethyl acetate); 
yield: 11 % (0.01 g). 1H NMR (CD3COCD3): 6.90-6.95 (m, 1H), 7.02-7.03 (m, 2H), 7.20 (dd, J = 8.8 
Hz, J = 2.2 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H), 8.30 (m, 1H); 13C NMR 
(CD3COCD3): 107.7, 115.9, 118.3, 120.8, 120.9, 125.6, 126.1, 126.9, 139.9, 147.3, 147.7, 158.1, 158.3, 
161.6; MS (ESI): 287.0 (M+H)+; 
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6-methoxy-benzothiazole-2-carboxylic acid (3-hydroxy-phenyl)-amide (17). The title compound 
was prepared by reaction of 6-methoxy-benzothiazole-2-carboxylic acid (3-methoxy-phenyl)-amide 
(17i) (0.10 g, 0.32 mmol) and boron trifluoride methyl sulfide complex in dichloromethane (1 M, 5.0 
mL, 47.72 mmol) according to method D. The product was purified by recrystallisation (ethyl acetate); 
yield: 21 % (0.02 g). 1H NMR (CD3COCD3): 3.94 (s, 3H), 6.67 (dd, J = 2.1 Hz, J = 0.9, Hz, 1H), 7.2 
(m, 2H), 7.36 (m, 1H), 7.36 (t, J = 2.1 Hz, 1H), 7.59-7.61 (m, 1H), 7.99 (d, J = 8.8 Hz, 1H), 8.83 (s, 
1H), 9.86 (s, 1H); 13C NMR (CD3COCD3): 57.3, 106.2, 109.2, 113.2, 113.5, 119.3, 126.8, 131.5, 140.8, 
141.0, 149.3, 159.8, 159.8, 161.2, 163.6; MS (ESI): 301.0 (M+H)+; 
 
6-hydroxy-benzothiazole-2-carboxylic acid (3-hydroxy-phenyl)-amide (18). The title compound was 
prepared by reaction of 6-methoxy-benzothiazole-2-carboxylic acid (3-methoxy-phenyl)-amide (17i) 
(0.10 g, 0.32 mmol) and boron trifluoride methyl sulfide complex in dichloromethane (1 M, 5.0 mL, 
47.72 mmol) according to method D. The product was purified by recrystallisation (ethyl acetate); 
yield: 11 % (0.01 g). 1H NMR (CD3COCD3): 6.67 (dd, J = 2.1 Hz, J = 0.9, Hz, 1H), 7.19-7.21 (m, 2H), 
7.35-7.37 (m, 1H), 7.55 (d, J = 2.1 Hz, 1H), 7.59 (t, J = 2.1 Hz, 1H), 7.95 (d, J = 8.8 Hz, 1H), 8.83 (s, 
2H), 9.83 (s, 1H); 13C NMR (CD3COCD3): 108.7, 109.1, 113.2, 113.4, 119.2, 127.0, 131.5, 140.9, 
141.1, 148.7, 159.1, 159.8, 159.9, 162.9; MS (ESI): 287.0 (M+H)+; 
 
3-methoxy-N-(6-methoxy-benzothiazol-2-yl)-benzenesulfonamide (22i). The title compound was 
prepared by reaction of 6-methoxy-benzothiazol-2-ylamine (0.3 g, 1.66 mmol) and 3-methoxy-
benzenesulfonyl chloride (0.3 mL, 1.66 mmol) according to method B. The product was purified by 
recrystallisation (methanol); yield: 89 % (0.66 g); 1H NMR (CD3COCD3): 3.84 (s, 3H), 3.85 (s, 3H), 
7.00 (dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 7.13 (ddd, J = 7.9 Hz, J = 2.5 Hz, J = 0.9 Hz, 1H), 7.34 (d, J = 8.8 
Hz, 1H), 7.38 (d, J = 2.5 Hz, 1H), 7.41-7.43 (m, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.48 (dt, J = 7.9 Hz, J = 
1.3 Hz, 1H); 13C NMR (CD3COCD3): 56,0; 56,2; 107,5; 112,3; 114,4; 115,6; 118,6; 119,1; 130,7; 
130,8; 133,2; 134,3; 136,1; 145,1; 157,8; 
 
1-(6-methoxy-benzothiazol-2-yl)-3-(3-methoxy-phenyl)-urea (23i). The title compound was prepared 
by reaction of 6-methoxy-benzothiazol-2-ylamine (0.33 g, 1.85 mmol) and 1-isocyanato-3-methoxy-
benzene (0.2 mL, 1.85 mmol) according to method B. The product was purified by recrystallisation 
(methanol); yield: quant. (0.61 g); 1H NMR (CD3COCD3): 3.78 (s, 3H), 3.82 (s, 3H), 6.64 (dd, J = 8.2 
Hz, J = 2.2 Hz, 1H), 6.99 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 7.03-7.05 (m, 1H), 7.21-7.25 (m, 2H), 7.50 
(d, J = 2.5 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H); 13C NMR (CD3COCD3): 56,2; 56,8; 105,9; 106,1; 109,5; 
112,3; 115,6; 121,5; 121,5; 131,0; 134,0; 134,0; 141,2; 157,2; 161,3; 206,2; 
 
1-(6-methoxy-benzothiazol-2-yl)-3-(3-methoxy-phenyl)-thiourea (24i). The title compound was 
prepared by reaction of 6-methoxy-benzothiazol-2-ylamine (0.30 g, 1.66 mmol) and 1-isothiocyanato-3-
methoxy-benzene (0.23 mL, 1.66 mmol) according to method B. The product was purified by CC 
(chloroform/methanol 95:05); yield: 30 % (0.17 g); MS (ESI): 346 (M+H)+; 
 
N-(6-methoxy-benzothiazol-2-yl)-2-(3-methoxy-phenyl)-acetamide (25i). The title compound was 
prepared by reaction of 6-methoxy-benzothiazol-2-ylamine (0.3 g, 1.66 mmol) and (3-methoxy-
phenyl)-acetyl chloride (0.26 mL, 1.66 mmol) according to method B. The product was purified by CC 
(chloroform/methanol 95:05); yield: 82 % (0.45 g); MS (ESI): 329 (M+H)+; 
 
4-methoxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (19). The title compound was prepared 
by reaction of 4-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (19i) (0.5 g, 1.59 mmol) and 
boron trifluoride methyl sulfide complex in dichloromethane (1 M, 25.1 mL, 239.00 mmol) according 
to method D. The product was purified by preparative HPLC; yield: 23 % (0.11 g). 1H NMR (CD3OD): 
3.94 (s, 3H), 7.12-7.16 (m, 3H), 7.40 (d, J = 2.5 Hz, 1H), 7.78 (d, J = 9.1 Hz, 1H), 8.30-8.32 (m, 2H); 
13C NMR (CD3OD): 56.4, 109.2, 115.5, 118.4, 118.5, 118.6, 119.8, 124.4, 130.2, 134.2, 133.4, 158.0, 
166.4, 168.2, 173.3; MS (ESI): 300.1 (M+H)+; 
 
4-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (20). The title compound was prepared by 
reaction of 4-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (19i) (0.5 g, 1.59 mmol) and 
boron trifluoride methyl sulfide complex in dichloromethane (1 M, 25.1 mL, 239.00 mmol) according 
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to method D. The product was purified by preparative HPLC; yield: 13 % (0.06 g). 1H NMR (CD3OD): 
6.80-6.83 (m, 2H), 6.98 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 7.22 (d, J = 2.2 Hz, 1H), 7.64 (d, J = 9.1 Hz, 
1H), 8.10-8.12 (m, 2H); 13C NMR (CD3OD): 107.7, 115.9, 118.3, 120.8, 120.9, 125.6, 126.1, 126.9, 
139.9, 147.3, 147.7, 158.1, 158.3, 161.6; MS (ESI): 287.6 (M+H)+; 
 
3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (21). The title compound was prepared by 
reaction of 3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (21i) (0.5 g, 1.59 mmol) and 
boron trifluoride methyl sulfide complex in dichloromethane (1 M, 25.0 mL, 239.00 mmol) according 
to method D. The product was purified by recrystallisation (ethyl acetate); yield: quant. (0.46 g). 1H 
NMR (CD3OD): 6.83 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.95 (dd, J = 2.5 Hz, J = 0.9 Hz, 1H), 7.14 (d, J 
= 2.2 Hz, 1H), 7.26 (t, J = 8.2 Hz, 1H), 7.32 (t, J = 2.2 Hz, 1H), 7.37-7.39 (m, 1H), 7.48 (d, J = 8.8 Hz, 
1H); 13C NMR (CD3OD): 107.2, 112.3, 115.9, 116.5, 119.9, 121.0, 122.4, 127.5, 131.0, 134.7, 135.2, 
146.6, 155.9, 159.2; MS (ESI): 286.9 (M+H)+; 
 
3-hydroxy-N-(6-hydroxy-benzothiazol-2-yl)-benzenesulfonamide (22). The title compound was 
prepared by reaction of 3-methoxy-N-(6-methoxy-benzothiazol-2-yl)-benzenesulfonamide (22i) (0.52 g, 
1.48 mmol) and boron tribromide in dichloromethane (1 M, 14.8 mL, 14.80 mmol) according to method 
F. The product was purified by recrystallisation (H2O:methanol); yield: 88 % (0.42 g); 1H NMR 
(CD3SOCD3): 6.82 (dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 6.96 (dd, J = 8.2 Hz, J = 2.2 Hz, 1H), 7.12 (d, J = 
8.5 Hz, 1H), 7.18 (d, J = 2.5 Hz, 1H), 7.21-7.26 (m, 2H), 7.33 (t, J = 8.0 Hz, 1H), 9.63 (s, 1H), 10.00 (s, 
1H), 12.9 (s, 1H); 13C NMR (CD3SOCD3): 108,4; 112,2; 113,4; 115,2; 116,2; 119,1; 124,8; 125,8; 
130,0; 139,1; 143,2; 154,1; 157,5; MS (ESI): 323.1 (M+H)+; 
 
1-(6-hydroxy-benzothiazol-2-yl)-3-(3-hydroxy-phenyl)-urea (23). The title compound was prepared 
by reaction of 1-(6-methoxy-benzothiazol-2-yl)-3-(3-methoxy-phenyl)-urea (23i). (0.60 g, 1.82 mmol) 
and boron tribromide in dichloromethane (1 M, 18.2 mL, 18.20 mmol) according to method F. The 
product was purified by CC (chloroform/methanol 90:10); yield: 64 % (0.35 g); 1H NMR (CD3SOCD3): 
6.46 (dd, J = 1.5 Hz, J = 8.2 Hz, 1H), 6.84-6.87 (m, 2H), 7.08 (t, J = 7.9 Hz, 1H), 7.14 (t, J = 2.1 Hz, 
1H), 7.24 (d, J = 2.4 Hz, 1H), 7.46 (d, J = 8.8 Hz, 1H), 9.01 (s, 1H), 9.39 (s, 1H), 9.41 (s, 1H), 10.48 (s, 
1H); 13C NMR (CD3SOCD3): 105,8; 106,5; 109,3; 110,0; 114,8; 120,1; 120,2; 129,6; 132,6; 139,7; 
140,9; 153,9; 158,0; 206,5; MS (ESI): 302.1 (M+H)+; 
 
1-(6-hydroxy-benzothiazol-2-yl)-3-(3-hydroxy-phenyl)- thiourea (24). The title compound was 
prepared by reaction of 1-(6-methoxy-benzothiazol-2-yl)-3-(3-methoxy-phenyl)-thiourea (24i). (0.17 g, 
0.49 mmol) and boron tribromide in dichloromethane (1 M, 4.9 mL, 4.90 mmol) according to method F. 
The product was purified by CC (chloroform/methanol 90:10); yield: 26 % (0.04 mg); 1H NMR 
(CD3SOCD3): 6.53-6.56 (m, 1H), 6.87 (dd, J = 8.5 Hz, J = 2.3, 1H), 7.09-7.22 (m, 4H), 7.39-7.40 (m, 
1H), 8.30 (s, 1H), 9.41 (s, 1H), 9.48 (s, 1H), 9.58 (s, 1H); 13C NMR (CD3SOCD3): 115,2; 115,8; 116,1; 
116,23; 116,7; 116,8; 116,9; 117,0; 117,4; 117,6; 117,7; 125,2; 125,6; 157,3; MS (ESI): 318.1 (M+H)+; 
 
N-(6-Hydroxy-benzothiazol-2-yl)-2-(3-hydroxy-phenyl)-acetamide (25). The title compound was 
prepared by reaction of N-(6-methoxy-benzothiazol-2-yl)-2-(3-methoxy-phenyl)-acetamide (25i). (0.45 
g, 1.37 mmol) and boron tribromide in dichloromethane (1 M, 13.7 mL, 13.70 mmol) according to 
method F. The product was purified by preparative HPLC; yield: 36 % (0.15 g); 1H NMR (CD3SOCD3): 
3.69 (s, 2H), 6.66 (dd, J = 8.2 Hz, J = 2.2, J = 0.9, 1H), 6.74-6.77 (m, 2H), 6.88 (dd, J = 8.8 Hz, J = 2.5, 
1H), 7.11 (t, J = 7.7, 1H), 7.26 (d, J = 2.2, 1H), 7.54 (d, J = 8.8 Hz, 1H), 12.3 (s, 1H); 13C NMR 
(CD3SOCD3): 41,8; 106,4; 113,8; 115,2; 116,0; 119,8; 121,0; 129,3; 132,7; 136,0; 141,5; 154,1; 154,9; 
157,3; 169,7; MS (ESI): 301.1 (M+H)+; 
 
Biological Methods. [2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. 
Quickszint Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17-HSD1 and 17-HSD2 were obtained from human placenta according to previously described 
procedures. Fresh human placenta was homogenized and cytosolic fraction and microsomes were 
separated by centrifugation. For the partial purification of 17-HSD1, the cytosolic fraction was 
precipitated with ammonium sulfate. 17-HSD2 was obtained from the microsomal fraction. 
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Inhibition of 17-HSD1. Inhibitory activities were evaluated by an established method with minor 
modifications. Briefly, the enzyme preparation was incubated with NADH [500 µM] in the presence of 
potential inhibitors at 37 °C in a phosphate buffer (50 mM) supplemented with 20 % of glycerol and 
EDTA (1mM). Inhibitor stock solutions were prepared in DMSO. The final concentration of DMSO 
was adjusted to 1 % in all samples. The enzymatic reaction was started by addition of a mixture of 
unlabelled- and [2, 4, 6, 7-3H]-E1 (final concentration: 500 nM, 0.15 Ci). After 10 min, the incubation 
was stopped with HgCl2 and the mixture was extracted with diethylether. After evaporation, the steroids 
were dissolved in acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile 
phase in a C18 reverse phase chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, 
Düren) connected to a HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). 
Detection and quantification of the steroids were performed using a radioflow detector (Berthold 
Technologies, Bad Wildbad). The conversion rate was calculated after analysis of the resulting 
chromatograms according to the following equation: 100
1%2%
2%%  EE
Econversion . Each value 
was calculated from at least three independent experiments. 
 
Inhibition of 17-HSD2. The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 
procedure. The microsomal fraction was incubated with NAD+ [1500 µM], test compound and a 
mixture of unlabelled- and [2, 4, 6, 7-3H]-E2 (final concentration: 500 nM, 0.11 Ci) for 20 min at 37 
°C. Further treatment of the samples and HPLC separation were carried out as mentioned above. 
The conversion rate was calculated after analysis of the resulting chromatograms according to the 
following equation: 100
2%1%
1%%  EE
Econversion . 
 
ER affinity. The binding affinity of selected compounds to the ER and ER was determined 
according to Zimmermann et al. Briefly, 0.25 pmol of ER or ER, respectively, were incubated with 
[2, 4, 6, 7-3H]-E2 (10 nM) and test compound for 1 h at room temperature. The potential inhibitors were 
dissolved in DMSO (5 % final concentration). Evaluation of non-specific-binding was performed with 
diethylstilbestrol (10 µM). After incubation, ligand-receptor complexes were selectively bound to 
hydroxyapatite (5 g/ 60 mL TE-buffer). The complex formed was separated, washed and resuspended in 
ethanol. For radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was 
added and samples were measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, 
Turku). For determination of the relative binding affinity (RBA), inhibitor and E2 concentrations 
required to displace 50 % of the receptor bound labelled E2 were determined. RBA values were 
calculated according to the following equation: 100
)(
)2([%]
50
50 
compoundIC
EICRBA . The RBA value 
for E2 was arbitrarily set at 100 %. 
 
Inhibition of 17-HSD1 in T47-D cells. T47-D cells were obtained from ECACC, Salisbury. Stripped 
FCS and cell culture media were purchased from CCpro, Oberdorla. A stock culture of T47-D cells was 
grown in RPMI 1640 medium supplemented with 10 % FCS, L-glutamine (2 mM), penicillin (100 
IU/mL), streptomycin (100 µg/mL), insulin-zinc-salt (10 µg/mL) and sodium pyruvate (1 mM) at 37 °C 
under 5 % CO2 humidified atmosphere. 
The cells were seeded into a 24-well plate at 1x106 cells/well in DMEM medium with FCS, L-
glutamine and the antibiotics added in the same concentrations as mentioned above. After 24 h the 
medium was changed for fresh serum free DMEM, and a solution of test compound in DMSO was 
added. Final concentration of DMSO was adjusted to 1 % in all samples. After a pre-incubation of 30 
min at 37°C with 5 % CO2, the incubation was started by addition of a mixture of unlabelled- and [2, 4, 
6, 7-3H]- E1 (final concentration : 50 nM, 0.15 Ci). After 0.5 h incubation, the enzymatic reaction was 
stopped by removing of the supernatant medium. The steroids were extracted into diethylether. Further 
treatment of the samples was carried out as mentioned for the 17-HSD1 assay. 
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Table S1. Geometrical properties of the extended pharmacophore model. 
 
distances (Å) angles (°) radii of spheres (Å) 
A1a-D1b 4.0 A6b-HY6-D6a ~42 A1a 1.5 
A3a-D4b 2.8 AD1-HY1-HY2 ~129 A3a 1.1 
A6b-D6a 2.2 AD2-AD2a-AD2b ~67 A6b 1.4 
AD1-A1a 2.8 AD2-AD2b-AD2a ~59 AD1 1.2 
AD1-D1b 2.6 AD3-A3a-D4b ~82 AD2 1.5 
AD1-HY1 2.8 AD5b-HY2-AD5a ~54 AD2a 1.4 
AD2a-AD2b 2.6 D4-A3a-D4b ~54 AD2b 1.5 
AD2-AD2a 2.7 D4b-AD3-A3a ~50 AD3 1.2 
AD2-AD2b 2.9 D4-D4a-D4b ~41 AD5a 1.2 
AD3-D4 2.2 D4-D4b-A3a ~77 AD5b 1.5 
AD5a-AD5b 3.3 D4-D4b-D4a ~43 D1b 1.3 
AD5a-D4a 3.9 D6a-A6b-HY6 ~78 D4 1.3 
D4a-D4b 4.7 D7-AD3-D4 ~115 D4a 1.7 
D4-D4a 3.2 HY1-A1a-D1b ~75 D4b 1.3 
D4-D4b 3.0 HY1-AD1-HY2 ~27 D6a 1.4 
D7-A6b 2.8 HY1-D1b-A1a ~55 D7 1.2 
HY1-HY2 3.0 HY1-HY2-A1a ~52 HY1 1.7 
HY2-AD5a 4.7 HY1-HY3-HY2 ~41 HY2 1.7 
HY2-AD5b 5.8 HY2-AD5a-AD5b ~75 HY3 1.5 
HY2-D4a 3.9 HY2-AD5b-AD5a ~51 HY4 1.7 
HY2-HY3 2.7 HY2-HY3-HY4 ~115 HY5 1.5 
HY3-HY4 2.9 HY3-AD2-HY4 ~47 HY6 1.5 
HY4-AD2 2.6 HY3-HY2-HY4 ~34   
HY4-HY5 3.0 HY3-HY4-HY2 ~31   
HY4-HY6 4.1 HY4-AD2-HY5 ~40   
HY5-AD3 3.5 HY4-AD3-D4 ~60   
HY5-D4 3.7 HY4-D4-AD3 ~102   
HY5-P5 2.1 HY4-D7-AD2 ~23   
HY6-A6a 3.2 HY4-D7-AD3 ~56   
HY6-A6b 2.9 HY4-HY3-AD2 ~40   
HY6-D7 2.5 HY4-HY5-AD3 ~146   
P5-HY4 2.9 HY4-HY5-D4 ~110   
  HY4-HY5-P5 ~70   
  HY4-HY6-AD2 ~37   
  HY4-HY6-D7 ~167   
  HY4-HY6-HY5 ~45   
  HY4-P5-HY5 ~66   
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Figure S1. Compound 6 (dark orange) mapped to the pharmacophore model and overlaid with equiline 
(yellow). 
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3.II Novel Nonsteroidal Benzothiazole Type 17-
Hydroxysteroid Dehydrogenase 1 (17-HSD1) Inhibitors as 
new Candidates for in Vivo Evaluation. 
 
Major part of this chapter will be published in Journal of Medicinal Chemistry. 
 
 
Abstract: 17-HSD1 is a novel target for the treatment of estrogen-dependent diseases as it 
catalyzes intracellular estradiol formation. Starting from two recently described compounds, 
highly active 17-HSD1 inhibitors with strong selectivity regarding 17-HSD2 and the 
estrogen receptors α and β were developed. 4 and 15 are the most selective compounds toward 
17-HSD2 described so far. They showed strong inhibition of the marmoset target enzyme. 
Thus, they are ideal candidates to be tested in vivo in a marmoset model for endometriosis. 
 
Introduction 
 
For the treatment of steroid hormone-dependent diseases biosynthesis inhibitors blocking 
hormone formation in the corresponding endocrine gland provide an excellent strategy as has 
been demonstrated by the use of CYP19 (aromatase) inhibitors for the treatment of breast 
cancer (BC). 1 Three further cytochrome P450 (CYP) enzymes are presently in the focus of 
drug development: CYP17, 2 CYP11B2 3 and CYP11B1 4 for the treatment of prostate cancer, 
congestive heart failure and myocardial fibrosis and Cushing`s syndrome, respectively. As 
these therapeutic options result in systemic reductions of steroid hormone levels which often 
are associated with side effects, a softer option could be the inhibition of hormone activation in 
the diseased (target) cell. For the treatment of benign prostatic hyperplasia, this strategy has 
already been proven to be successful with inhibitors of 5-reductase, 5 which catalyzes the 
conversion of testosterone to the most potent androgen dihydrotestosterone. More recently 
17-hydroxysteroid dehydrogenase 1 (17-HSD1) came into the focus of interest as a novel 
therapeutic target for the treatment of estrogen dependent diseases like BC and endometriosis. 6 
17-HSD1 catalyzes the conversion of the weakly active estrone (E1) to the highly active 
estradiol (E2) and is overexpressed in some BC tissues. 6 Efficacy of 17-HSD1 inhibitors 
against human breast cancer cell lines has already been reported in vitro and in vivo (nude 
mouse), 7 whereas a proof of concept for endometriosis is still missing. Besides some 
approaches to develop steroidal inhibitors, 8 there have also been attempts by our and other 
groups to develop nonsteroidal inhibitors which should be advantageous with respect to side 
effects. 9 Recently we reported about two new 17-HSD1 inhibitors with different 
activity/selectivity profiles, the benzothiazol-2-yl-phenylmethanone A and the N-benzothiazol-
2-ylbenzamide B (Chart 1). 10 
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Chart 1: Structures` optimization 
 
Herein we report about the structure optimization of these two lead compounds with regard to 
17-HSD1 inhibitory activity as well as selectivity towards 17-HSD2 (the enzyme catalysing 
the reverse reaction) and the estrogen receptors (ERs) α and β. For selected compounds, 17-
HSD1 inhibitory potency in human T47-D breast cancer cells, inhibitory potency toward 17-
HSD1 and 17-HSD2 from Callithrix jacchus (animal model for endometriosis), 11 and 
inhibition of human hepatic CYP enzymes were determined. 
 
Results 
 
Chemistry: The synthesis of compounds 1-7 started from 6-methoxy-1,3-benzothiazol-2-yl 
amine or 1,3-benzothiazole. 1-2 and 4-5 were prepared in a four-step synthesis previously 
described 10 (a-d in Scheme 1). 
 
 
 
 
Scheme 1. Synthesis of Compounds 1-7.. Reagents and conditions: (a) 1) NaNO2, H3PO4 (85%), -10 °C, 
20 min, 2) H3PO2, H3PO4 (85%), -10 °C to rt, 20 h; (b) Method A: 1) nBuLi, anhydrous THF, -70 °C to -20 °C, 1 
h, 2) methoxy benzaldehyde, anhydrous THF, -15 °C, 90 min; (c) Method C: SIBX, anhydrous THF, 0 °C to 60 
°C, 20 h; (d) for compounds 1-4, Method D: pyridinium hydrochloride, 220 °C, 4 h, for compounds 5, 6iiiii and 7, 
Method E: BBr3, CH2Cl2, -78 °C to rt, 20 h; (e) benzyl bromide, K2CO3, acetone, 100 °C, 20 h, for compounds 7ii 
and 6, TBAF, THF, rt, 2 h; (f) TBDMSiCl, imidazole, DMF, rt, 20 h; (g) benzeneboronic acid, Cu(AcO)2, Et3N, 
anhydrous CH2Cl2, rt, 18 h. 
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3 was synthesized in three steps starting with the nucleophilic addition of 1,3-benzothiazole 
(3iii) to 4-fluoro-3-methoxy-benzaldehyde. For compound 6, 6-benzyloxy-1,3-benzothiazole 
(6iiii) and 3-(tert-butyl-dimethyl-silanyloxy)-4-methyl-benzaldehyde (6iii) were synthesized 
and coupled via nucleophilic addition. Oxidation of the resulting alcohol and ether cleavage of 
the silanyl ether using tetra-n-butylammonium fluoride (TBAF) gave the final compound. 7 
was synthesized coupling 1iii and 4-(tert-butyl-silanyloxy)-3-methoxy-benzaldehyde (7iiiii), 
followed by oxidation, cleavage with TBAF, boronic acid-phenol cross-coupling reaction 
mediated by copper(II) acetate and cleavage of the two methoxy groups with boron tribromide 
(BBr3). 8-16 were prepared via two steps as described 10 (a-b in Scheme 2): (a) amide coupling 
between 6-methoxy-benzothiazol-2-yl amine and the corresponding benzoyl chloride and (b) 
ether cleavage. 17 was synthesized by N-methylation of 9i with methyl iodide and sodium 
hydride in DMF and subsequent ether cleavage. 
 
 
 
Scheme 2. Synthesis of Compounds 8-17.  Reagents and conditions: (a) Method B: pyridine, 100°C, 4 h; 
(b) Method E: BBr3, CH2Cl2, -78 °C to rt, 20. 
 
Inhibition of human 17-HSD1 and 17-HSD2: For the determination of 17β-HSD1 and 
17-HSD2 inhibition, tritiated substrates E1 or E2 were incubated with placental enzymes 17β-
HSD1 or 17β-HSD2, respectively, cofactor, and inhibitor. The labeled products formed were 
quantified by HPLC using radiodetection. The inhibition values (IC50) and the selectivity 
factors (SF = IC50 (HSD2)/IC50 (HSD1)) are shown in Table 1. Compounds A and B were used 
as references. In the series of the ketone compounds, 1-5 strongly inhibited 17β-HSD1. Also, 
in the series of the amide derivatives stronger 17β-HSD1 inhibition than the one shown by B 
was observed, with 8 and 15 exhibiting IC50 values in the low nanomolar range. Furthermore, 4 
and 15 displayed strong selectivity for 17β-HSD1 over 17β-HSD2, exhibiting the highest 
selectivity factors (>130) reported in the literature. 
factors (>130) reported in the literature. 
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Table 1: 17-HSD1 inhibitory activities and selectivities of compounds 1-17. 
 
 
 
Cpd X R1 R2 R3 HSD1a HSD2b SFd 
     IC50 (nM)c  
A CO H H OH 44 1035 23 
1 
 
4-F H OH 13 121 9 
2 4-F H OCH3 38 59 2 
3 4-F H H 136 104 1 
4 4-CH3 H OH 27 4003 148 
5 6-OH H OH 78 1538 20 
6 4-CH3 H OBn ni ni nd 
7 4-OPh H OH 863 1457 2 
B CONH H H OH 243 9264 38 
8 
 
2-F H OH 29 1000f <40 
9 4-F H OH 171 1480 9 
10 6-F H OH 112 3804 34 
11 4-CH3 H OH ni nd nd 
12 5-OH H OH 3000e nd nd 
13 6-OH H OH ni nd nd 
14 2-Cl 6-F OH 221 469 2 
15 2-F 6-F OH 13 1774 136 
16 2-F 4-F OH 99 541 5 
17 CONCH3 4-F H OH 670e 2700e 4 
 
aHuman placenta, cytosolic fraction, substrate [3H]E1 + E1 [500 nM], cofactor NADH [500 μM]; bHuman 
placenta, microsomal fraction, substrate [3H]E2 + E2 [500 nM], cofactor NAD+ [1500 μM]; cMean values of three 
determinations, standard deviation less than 10%; dSelectivity factor: IC50 17-HSD2/ IC50 17-HSD1; 
eCalculated with LOGIT transformation; fstandard deviation less than 25 %; nd: not determined,  ni: no inhibition 
(less than 10 % inhibition at 1μM). 
 
Affinities to ER  and : The relative binding affinities (RBA) of the most selective 
compounds of this study were determined using recombinant human ER  and ER  in a 
competition assay 12 with [3H]E2 (E2 was used as reference and its RBA value was set to 100 
%). Only 1 showed a marked affinity to the ERs, while all other compounds were more than 
1000-fold less potent compared to E2. 
 
Further biological evaluation: Additionally, the inhibition of intracellular E2 formation for 
compounds 1 (IC50 = 11 nM), 4 (258 nM), 5 (365 nM), 8 (73 nM) and 15 (37 nM) in T47-D 
cells was determined (Table 2). 
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Table 2: Binding affinities for the ERs  and , 17-HSD1 inhibitory activity in T47-D cells 
and inhibition of Callithrix jacchus 17-HSD1 and 17-HSD2 by selected compounds. 
 
 
 
Cpd X R1 R2 ERa ERa T47-D mHSD1d mHSD2e
    RBA (%)b IC50 (nM)c % inhibition 
       5 nM 50 nM 50 nM 
A CO H H < 10 < 1     
1  4-F H < 1 < 1 11 80  34 
4  4-CH3 H < 0.1 < 0.1 258  83 40 
5  6-OH H < 0.1 < 0.1 365f    
B CONH H H < 0.1 < 0.001 245    
8  2-F H < 0.1 < 0.1 73g 67  48 
10  6-F H < 0.1 < 0.1 152g    
15  2-F 6-F < 0.1 < 0.1 37g 87  51 
 
aHuman recombinant protein, incubation with 10 nM [3H]E2 and inhibitor for 1 h. bRBA: relative binding affinity 
in percent (E2=100%), mean value of three determinations, standard deviation less than 10%. cMean value of 
three determinations, standard deviation less than 10%; dMarmoset placenta, cytosolic fraction, substrate [3H]E1 + 
E1 [500 nM], cofactor NADH [500 μM]; eMarmoset placenta, microsomal fraction, substrate [3H]E2 + E2 [500 
nM], cofactor NAD+ [1500 μM]; fStandard deviation less than 15 %; gCalculated with LOGIT transformation at 50 
nM inhibitor concentration. 
 
The high cellular activities of compounds 1, 8, and 15 indicate that they easily permeate the 
cell membrane and are not metabolized quickly. Furthermore, compounds 1, 4, 8 and 15 were 
tested for inhibitory activity towards Callithrix jacchus 17-HSD1 and 17-HSD2 (Table 2). 
The compounds showed stronger inhibition of marmoset 17-HSD1 compared to the human 
enzyme and a fair selectivity toward 17-HSD2. Compounds 1 and 4 were further investigated 
for inhibition of the most important human hepatic CYP enzymes: 3A4, 2D6, 2C9, 2C19, 1A2 
and 2B6. Both compounds showed very little inhibition (54 μM > IC50 > 3 μM) except for 1A2 
which was inhibited by 1 and 4 moderately (IC50 = 1.8 and 0.57 μM) indicating that there 
should be no major problems regarding CYP inhibition in this compound class. 
 
Discussion and conclusion 
Recently we discovered two new 17-HSD1 inhibitors, compounds A and B (Chart 1). 10 A had 
shown high inhibitory activity, medium selectivity toward 17-HSD2 and very weak selectivity 
toward the ERs. On the contrary, B had shown only medium inhibitory activity and good 
selectivity toward 17-HSD2 and the ERs. In the present study A and B should be optimised 
regarding activity and selectivity in order to obtain compounds suitable for in vivo use. 
Introduction of various substituents with different electronic, lipophilic, steric and H-bonding 
properties into the benzoyl moiety of A and B led to the discovery of two new lead structures, 
compounds 4 and 15. As suggested in our previous study 10 where A and B were hypothesised 
to interact differently with the binding site, the introduction of a wide variety of substituents 
into the benzoyl moiety of A and B had different influence on inhibitory activity: comparing 1 
with 9, 4 with 11 and 5 with 13 shows that only the fluorine in 4-position increased inhibitory 
activity in both classes. The introduction of OH in 2-position and methyl in 4-position turned 
out to be beneficial in case of the ketones  (IC50 = 27 nM for 4 and 78 nM for 5) but was 
deleterious for the amides (11, 13: no inhibition at 1 µM). The introduction of a bulky 
RESULTS  53 
 
substituent like the phenoxy group in 4-position (7), benzylation of the hydroxy group of 4 (6) 
and methylation of the amide function (17) decreased inhibitory activity. Interestingly, 
methylation of the OH group of 1 (2) or replacement by hydrogen (3) on the benzothiazole 
moiety resulted only in a slight decrease of 17-HSD1 inhibition but in a complete loss of 
selectivity toward 17-HSD2. Changing the F position as well as adding a second fluorine in 
the amide series increased 17-HSD1 inhibitory activity: 15 showed the same IC50 value of 13 
nM as the best ketone compound 1. This may be due to favourable electronic effects exerted by 
the fluorines on the H-bonding property of the OH, to the increased lipophilicity or to the 
change in -interacting properties of the aromatic ring as suggested by SAR studies. 10 
Regarding selectivity, in the ketone series introduction of the methyl group in 4-position (4) not 
only increased activity but also decreased inhibition of 17β-HSD2 and affinity to the ERs. 
Thus, compound 4 shows the highest selectivity toward 17-HSD2 described so far (SF 148) 
and only little ER affinity. It has been known for a long time that a substituent in o-position to 
the 3-OH group of E2 or its nonsteroidal analog hexestrol 13 reduces ERα affinity of the parent 
compound. Therefore it can be assumed that the ketone A binds to the ERα like the natural 
substrate. In the amide series  introduction of fluorine in 4-position (9) led to a decrease in 
selectivity towards 17-HSD2, like it has been observed for 1 in the ketone series, while 
introducing a fluorine in 2-position (8) and 6-position (10) did not alter selectivity. The 
difluoro-substituted compound 15 showed the best selectivity in this series toward 17-HSD2 
and the ERs with values similar to 4. Summarising, we have discovered two highly potent 17-
HSD1 inhibitors, which are the most selective compounds described so far. Compounds 4 and 
15 also show very good intracellular activity and a high potency and selectivity towards the 
marmoset enzymes.  Accordingly, they should be suitable candidates for being further 
evaluated in a marmoset model of endometriosis. 
 
Experimental section 
 
The following compounds were prepared according to previously described procedures: 6-methoxy-1,3-
benzothiazole (1iii), 14 6-hydroxy-1,3-benzothiazole (6iiiii), 14 [3-(tert-butyl-dimethyl-silanyloxy)-4-
methyl]benzaldehyde (6iii), 15 3-methoxy-4-(tert-butyl-dimethyl-silanyloxy) benzaldehyde (7iiiii). 16 
Synthetic details and characterization of compounds can be found in supporting information. Method A: 
Formation of methanols; Method B: Amide formation; Method C: Oxidation with SIBX; Method D: 
Ether cleavage with PyHCl; Method E: Ether cleavage with BBr3; Compounds 4ii, 15i, 4i, 4 and 15 are 
presented as examples: 
 
(6-Methoxy-1,3-benzothiazol-2-yl)(4-methyl-3-methoxyphenyl)methanol (4ii). The title compound 
was prepared by reaction of 6-methoxy-benzothiazole (1iii) (0.25 g, 1.5 mmol), nBuLi (0.61 ml, 1.5 
mmol) and 4-methyl-3-methoxybenzaldehyde (0.18 g, 1.2 mmol) according to method A. The product 
was purified by CC (hexane/ethyl acetate 60:40); yield: 89 % (0.42 g); 1H NMR (CDCl3): 2.2 (s, 3H), 
3.79 (s, 3H), 3.84 (s, 3H), 6.07 (s, 1H), 6.98-7.05 (m, 2H), 7.03 (dd, J = 9.1 Hz and J = 2.7 Hz, 1H), 
7.11 (d, J = 7.6 Hz, 1H), 7.24 (d, J= 2.4 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H); 13C NMR (CDCl3): 16.0, 
55.3, 55.7, 74.2, 104.2, 115.4, 118.1, 118.4, 123.4, 127.1, 130.7, 136.5, 139.8, 146.8, 157.6, 158.0, 172. 
 
2,6-Difluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (15i). The title compound 
was prepared by reaction of 6-methoxybenzothiazol-2ylamine (0.3 g, 1.79 mmol) and 2,6-difluoro-3-
methoxy-benzoyl chloride (0.4 g, 1.79 mmol) according to method B. The product was purified by CC 
(dichloromethane/methanol 95:05); yield: 29 % (0.18 g); 1H NMR (CDCl3): 3.83 (s, 3H), 3.89 (s, 3H), 
7.07 (dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 7.21 (dt, J = 1.9 Hz, J = 8.8 Hz, J = 9.1, Hz 1H), 7.36-7.40 (m, 
1H), 7.63 (d, J = 2.5 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 13.07 (s, 1H); 13C NMR (CDCl3): 55,6; 56,8; 
104,8; 111,4; 115,3; 116,1; 116,2; 117,6; 130,6; 143,9; 144,0; 150.7; 150.8; 150,8; 156,5; 164,6. 
 
(4-Methyl-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanone (4i). The title compound 
was prepared by reaction of (4-methyl-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)-methanol 
(4ii) (0.33 g, 1.03 mmol) and 2-iodoxybenzoic acid (0.58 g, 2.06 mmol) according to method C. The 
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product was purified by CC (hexane/ethyl acetate 85:15); yield: quantitative (0.33 g); 1H NMR 
(CDCl3): 2.2 (s, 3H), 3.79 (s, 3H), 3.82 (s, 3H), 7.04 (dd, J = 9.1 Hz and J = 2.5 Hz, 1H), 7.13-7.15 (m, 
1H), 7.27 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 1.3 Hz, 1H), 7.96 (d, J = 9.1 Hz, 1H), 8.12 (dd, J = 7.8 Hz 
and J = 1.6 Hz, 1H); 13C NMR (CDCl3): 16.6, 55.3, 55.7, 103.3, 111.3, 117.4, 124.4, 126.3, 130.3, 
133.9, 138.9, 148.4, 159.6, 165.0, 184.3. 
(4-Methyl-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone (4). The title compound 
was prepared by reaction of (4-methyl-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)-methanone 
(4i) (0.33 g, 1.05 mmol) and pyridinium hydrochloride (12.13 g, 105 mmol) according to method D. 
The product was purified by preparative HPLC; yield: 42 % (0.12 g); 1H NMR (CD3COCD3): 2.32 (s, 
3H), 7.21 (dd, J = 8.8 Hz and J = 2.4 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 2.1 Hz, 1H), 8.02 
(d, J = 1.5 Hz, 1H), 8.06 (d, J = 8.8 Hz, 1H), 8.10 (dd, J = 7.6 Hz and J = 1.5 Hz, 1H), 8.70 (s, 1H), 9.22 
(s, 1H); 13C NMR (CD3COCD3): 17.1, 107.9, 113.75, 117.7, 117.7, 119.0, 124.3, 127.8, 132.1, 135.5, 
140.3, 142.7, 156.7, 159.3, 185.2; MS (ESI): 287.0 (M+H)+. 
 
2,6-Difluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (15). The title compound 
was prepared by reaction of 2,6-difluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)-benzamide 
(15i) (0.18 g, 0.51 mmol) and boron tribromide (5.1 mmol) according to method E. The product was 
purified by CC (dichloromethane/methanol 90:10); yield: 30 % (0.05 g); 1H NMR (CD3SOCD3): 6.97-
7.01 (m, 2H), 7.17-7.22 (m, 1H); 7.41 (d, J = 2.5 Hz, 1H), 7.59 (d, J = 8.2 Hz, 1H); 13C NMR 
(CD3SOCD3): 107,2; 112,2; 112,3; 116,4; 120,6; 120,7; 122,7; 134,4; 142,6; 142,7; 142,7; 142,8; 
143,3; 147,9; 147,9; 151,9; 151,9; 155,3; 155,6; 159,8; 167,1; MS (ESI): 323.1 (M+H)+. 
 
Supporting information 
 
Contents: 
 
a) Chemical synthesis and spectroscopic data for compounds 1-17. 
 
b) Purity (HPLC determination) 
 
c) Biological Methods 
 
 
a) Chemical synthesis and spectroscopic data for compounds 1-17. 
 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Acros, Aldrich, 
Alfa Aesar, Maybridge, Merck or Fluka and were used without purification.  
Column chromatography (CC) was performed on silica gel (70-200 m) coated with silica, preparative 
thin layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and 
reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in  (parts per million: ppm), by reference to the hydrogenated residues of 
deuteriated solvent as internal standard CDCl3:  = 7.24 ppm (1H-NMR) and  = 77 ppm (13C-NMR), 
CD3OD:  = 3.32 ppm (1H-NMR) and  = 49.05 ppm (13C-NMR), CD3COCD3:  = 2.05 ppm (1H-
NMR) and  = 29.9 ppm (13C-NMR) and CD3SOCD3:  = 2.50 ppm (1H-NMR) and  = 39.43 ppm 
(13C-NMR). Signals are described as s, d, t, dd, ddd, m, dt, q for singlet, doublet, triplet, doublet of 
doublets, doublet of doublets of doublets, multiplet, doublet of triplets and quadruplet respectively. All 
coupling constants (J) are given in hertz (Hz). 
Mass spectra (ESI) were recorded on an MSQ® electro spray mass spectrometer (ThermoFisher, 
Dreieich, Germany).  
Tested compounds are ≥ 95 % chemical purity as measured by HPLC. The methods for HPLC analysis 
and a table of data for all tested compounds are provided (see section b). 
 
Method A, general procedure for formation of methanols: 
To a solution of thiazole derivative unsubstituted in position 2 (1 eq) in anhydrous THF a 2.5 M 
solution of nBuLi (1 eq) in hexane was added dropwise at -78 °C (dry ice/acetone bath) under 
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anhydrous conditions. The reaction mixture was stirred for 1 h at –78 °C to form the formyl anion in 
situ. Subsequently, a solution of electrophile (0.8 eq) in anhydrous THF was added dropwise at –78 °C 
(dry ice/acetone bath) and stirring was continued for 30 min. The temperature was then raised to –20 °C 
(NaCl/ice/dry ice/acetone bath) and the reaction mixture was stirred for 90 min. A mixture of water and 
saturated aqueous NH4Cl solution (1:2) was added to quench the reaction at – 20 ° C, and the aqueous 
layer was extracted (3x) with ethyl acetate. The combined organic layers were washed with brine, dried 
over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC or 
recrystallisation. 
 
Method B, general procedure for amide formation: 
To a solution of 2-amino-6-methoxy-1,3-benzothiazole (1 eq) in dry pyridine methoxy-benzoyl chloride 
(1 eq.) was added dropwise at room temperature. The reaction mixture was refluxed for 4 h. Water was 
added to quench the reaction, and the aqueous layer was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated to dryness. 
The product was purified by CC or recrystallisation. 
 
Method C, general procedure for oxidation: 
A mixture of aliphatic alcohol-derivative (1 eq) and stabilized 2-iodoxybenzoic acid (SIBX; 2 eq) in 
anhydrous THF was stirred at 0 °C. After 10 min, the reaction mixture was heated to 60 °C for 18 h. 
After cooling to room temperature, saturated sodium thiosulfate solution was added to quench the 
reaction and the aqueous layer was extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over magnesium sulfate, filtered and concentrated to dryness. The product was 
purified by CC or recrystallisation. 
 
Method D, general procedure for ether cleavage: 
A mixture of methoxybenzene derivative (1 eq) and pyridinium hydrochloride (50 eq per methoxy 
function) was heated to 220 °C for 18 h. After cooling to room temperature, water, 1 M HCl and ethyl 
acetate were added. The aqueous layer was extracted with ethyl acetate. The combined organic layers 
were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The product 
was purified by CC followed by preparative TLC or preparative HPLC, respectively. 
 
Method E, general procedure for ether cleavage: 
To a solution of methoxybenzene derivative (1 eq) in anhydrous dichloromethane at -78 °C (dry 
ice/acetone bath), boron tribromide in dichloromethane (1 M; 5 eq per methoxy function) was added 
dropwise. The reaction mixture was stirred for 20 h at room temperature under nitrogen atmosphere. 
Water was added to quench the reaction, and the aqueous layer was extracted with ethyl acetate. The 
combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated 
to dryness. The product was purified by CC followed by preparative TLC or preparative HPLC, 
respectively. 
General procedure for purification using preparative HPLC. 
All declared final compounds were purified via an Agilent Technologies Series 1200–preparative 
HPLC using a linear gradient run (solvents: acetonitrile, water) starting from 20% acetonitrile up to 
100% in 36 min. 
(4-Fluoro-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)-methanol (1ii). The title compound 
was prepared by reaction of 6-methoxy-1,3-benzothiazole (1iii) (0.30 g, 1.51 mmol), 2.5 M solution of 
nBuLi (0.6 mL, 1.51 mmol) in hexane and 4-fluoro-3-methoxy-benzaldehyde (0.2 g, 1.16 mmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 80:20); yield: 24 % (0.09 
g); 1H NMR (CDCl3): 3.85 (s, 3H), 3.86 (s, 3H), 6.07 (s, 1H), 7.02-7.07 (m, 3H), 7.15 (dd, J = 8.2 Hz 
and J = 1.9 Hz, 1H), 7.24-7.26 (m, 1H), 7.83 (d, J = 8.8 Hz, 1H); 13C NMR (CDCl3): 55.8, 56.2, 73.6, 
104.2, 111.7, 115.6, 116.0, 116.1, 119.1, 123.4, 136.5, 137.2, 146.7, 147.9, 148.0, 151.3, 151.4, 153.4, 
157.8, 172.1. 
(4-Fluoro-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanone (1i). The title compound 
was prepared by reaction of (4-fluoro-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanol 
(1ii) (0.09 g, 0.28 mmol) and 2-iodoxybenzoic acid (0.16 g, 0.56 mmol) according to method C. The 
product was purified by CC (chloroform); yield: quantitative (0.09 g); 1H NMR (CDCl3): 3.93 (s, 3H), 
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4.02 (s, 3H), 7.30-7.32 (m, 1H), 7.35-7.39 (m, 1H), 8.00-8.04 (m, 1H), 8.06-8.09 (m, 1H), 8.12-8.16 (m, 
1H); 13C NMR (CDCl3): 56.0, 56.2, 104.4, 115.8, 115.9, 118.4, 120.6, 125.2, 125.5, 125.9, 126.5, 
132.1, 139.1, 142.4, 149.2, 160.9, 184.4. 
(4-Fluoro-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone (1). The title compound 
was prepared by reaction of (4-fluoro-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanone 
(1i) (0.10 g, 0.32 mmol) and pyridinium hydrochloride (3.64 g, 31.5 mmol) according to method D. The 
product was directly purified by preparative HPLC; yield: 22 % (0.02 g); 1H NMR (CD3COCD3) 7.11 
(dd, J = 8.8 Hz and J = 2.2 Hz, 1H), 7.23 (dd, J = 8.5 Hz and J = 2.2 Hz, 1H), 7.38 (d, J = 2.2 Hz, 1H), 
8.02 (d, J = 8.8 Hz, 1H), 7.97-8.00 (m, 1H), 8.15 (dd, J = 8.5 Hz and J = 2.2 Hz, 1H); 13C NMR 
(CD3COCD3): 107.2, 116.9, 117.1, 118.8, 121.6, 124.8, 124.9, 127.5, 133.2, 146.4, 146.5, 149.0, 155.8, 
157.8, 159.7, 164.9, 184.7; MS (ESI): 290.1 (M+H)+. 
(4-Fluoro-3-hydroxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanone (2). The title compound 
was prepared by reaction of (4-fluoro-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanone 
(1i) (0.10 g, 0.32 mmol) and pyridinium hydrochloride (3.64 g, 31.5 mmol) according to method D. The 
product was directly purified by preparative HPLC; yield: 21 % (0.02 g); 1H NMR (CDCl3): 3.93 (s, 
3H), 7.16-7.24 (m, 2H), 7.31 (d, J = 2.7 Hz, 1H), 8.10 (d, J = 9.1 Hz, 1H), 8.15-8.18 (m, 1H), 8.29 (dd, 
J = 8.5 Hz and J = 2.1 Hz, 1H); 13C NMR (CDCl3): 55.9, 103.4, 115.6, 115.8, 117.8, 120.5, 124.9, 
125.0, 125.6, 126.5, 132.1, 139.1, 143.4, 148.4, 159.9, 184.4; MS (ESI): 304.0 (M+H)+. 
1,3-Benzothiazol-2-yl-(4-fluoro-3-methoxyphenyl)-methanol (3ii). The title compound was prepared 
by reaction of 1,3-benzothiazole (0.20 ml, 1.85 mmol), 2.5 M solution of nBuLi (0.74 ml, 1.85 mmol) 
in hexane and 4-fluoro-3-methoxybenzaldehyde (0.22 g, 1.42 mmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 70:30); yield: 61 % (0.25 g); 1H NMR (CDCl3): 4.04 
(s, 3H), 6.33 (s, 1H), 7.20-7.26 (m, 2H), 7.35-7.41 (m, 1H), 7.53-7.58 (m, 1H), 7.61-7.65 (m, 1H), 7.99-
8.04 (m, 1H), 8.08-8.13 (m, 1H); 13C NMR (CDCl3): 56.1, 73.5, 111.7, 115.9, 116.0, 119.0, 121.7, 
122.8, 125.2, 126.1, 134.9, 137.1, 137.2, 147.7, 147.8, 151.3, 152.3, 153.2, 175.5. 
1,3-Benzothiazol-2-yl-(4-fluoro-3-methoxyphenyl)methanone (3i). The title compound was prepared 
by reaction of 1,3-benzothiazol-2-yl-(4-fluoro-3-methoxyphenyl)methanol (3ii) (0.25 g, 0.86 mmol) and 
2-iodoxybenzoic acid (0.48 g, 1.72 mmol) according to method C. The product was purified by CC 
(hexane/ethyl acetate 90:10); yield: 73 % (0.18 g); 1H NMR (CDCl3): 4.01 (s, 3H), 7.23-7.27 (m, 2H), 
7.55-7.62 (m, 2H), 8.02-8.04 (m, 1H), 8.20 (dd, J = 8.2 Hz and J = 2.2 Hz, 1H), 8.23-8.25 (m, 1H); 13C 
NMR (CDCl3): 56.4, 115.7, 115.8, 116.0, 116.1, 122.2, 125.7, 126.0, 126.1, 126.6, 127.0, 127.7, 131.4, 
136.9, 137.0, 147.8, 166.4, 167.1, 183.4. 
1,3-Benzothiazol-2-yl-(4-fluoro-3-hydroxyphenyl)methanone (3). The title compound was prepared 
by reaction of 1,3-benzothiazol-2-yl-(4-fluoro-3-methoxyphenyl)-methanone (3i). (0.25 g, 0.87 mmol) 
and pyridinium hydrochloride (5.03 g, 43.5 mmol) according to method D. The product was directly 
purified by preparative HPLC; yield: 78 % (0.18 g); 1H NMR (CD3COCD3): 7.36 (dd, J = 8.5 Hz and J 
= 2.2 Hz, 1H), 7.64-7.70 (m, 2H), 8.22-8.30 (m, 4H), 9.19 (s, 1H); 13C NMR (CD3COCD3): 118.0, 
118.1, 122.5, 124.4, 126.1, 126.2, 127.3, 129.1, 129.8, 133.6, 138.7, 147.0, 155.7, 158.3, 169.1, 184.9. 
MS (ESI): 273.9 (M+H)+. 
(6-Methoxy-1,3-benzothiazol-2-yl)(4-methyl-3-methoxyphenyl)methanol (4ii). The title compound 
was prepared by reaction of 6-methoxy-1,3-benzothiazole (1iii) (0.25 g, 1.5 mmol), nBuLi (0.61 ml, 1.5 
mmol) and 4-methyl-3-methoxybenzaldehyde (0.18 g, 1.2 mmol) according to method A. The product 
was purified by CC (hexane/ethyl acetate 60:40); yield: 89 % (0.42 g); 1H NMR (CDCl3): 2.2 (s, 3H), 
3.79 (s, 3H), 3.84 (s, 3H), 6.07 (s, 1H), 6.98-7.05 (m, 2H), 7.03 (dd, J = 9.1 Hz and J = 2.7 Hz, 1H), 
7.11 (d, J = 7.6 Hz, 1H), 7.24 (d, J= 2.4 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H); 13C NMR (CDCl3): 16.0, 
55.3, 55.7, 74.2, 104.2, 115.4, 118.1, 118.4, 123.4, 127.1, 130.7, 136.5, 139.8, 146.8, 157.6, 158.0, 
172.7. 
(4-Methyl-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanone (4i). The title compound 
was prepared by reaction of (4-methyl-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanol 
(4ii) (0.33 g, 1.03 mmol) and 2-iodoxybenzoic acid (0.58 g, 2.06 mmol) according to method C. The 
product was purified by CC (hexane/ethyl acetate 85:15); yield: quantitative (0.33 g); 1H NMR 
(CDCl3): 2.2 (s, 3H), 3.79 (s, 3H), 3.82 (s, 3H), 7.04 (dd, J = 9.1 Hz and J = 2.5 Hz, 1H), 7.13-7.15 (m, 
1H), 7.27 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 1.3 Hz, 1H), 7.96 (d, J = 9.1 Hz, 1H), 8.12 (dd, J = 7.8 Hz 
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and J = 1.6 Hz, 1H); 13C NMR (CDCl3): 16.6, 55.3, 55.7, 103.3, 111.3, 117.4, 124.4, 126.3, 130.3, 
133.9, 138.9, 148.4, 159.6, 165.0, 184.3. 
(4-Methyl-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone (4). The title compound 
was prepared by reaction of (4-methyl-3-methoxyphenyl)(6-methoxy-1,3-benzothiazol-2-yl)methanone 
(4i) (0.33 g, 1.05 mmol) and pyridinium hydrochloride (12.13 g, 105 mmol) according to method D. 
The product was purified by preparative HPLC; yield: 42 % (0.12 g); 1H NMR (CD3COCD3): 2.32 (s, 
3H), 7.21 (dd, J = 8.8 Hz and J = 2.4 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 2.1 Hz, 1H), 8.02 
(d, J = 1.5 Hz, 1H), 8.06 (d, J = 8.8 Hz, 1H), 8.10 (dd, J = 7.6 Hz and J = 1.5 Hz, 1H), 8.70 (s, 1H), 9.22 
(s, 1H); 13C NMR (CD3COCD3): 17.1, 107.9, 113.75, 117.7, 117.7, 119.0, 124.3, 127.8, 132.1, 135.5, 
140.3, 142.7, 156.7, 159.3, 185.2; MS (ESI): 287.0 (M+H)+. 
(2,5-Dimethoxyphenyl)-(6-methoxy-1,3-benzothiazol-2-yl)-methanol (5ii). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazole (1iii) (3.00 g, 18.2 mmol), nBuLi (7.26 ml, 18.2 
mmol) and 2,5-dimethoxybenzaldehyde (2.32 g, 14.0 mmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 80:20); yield: 87 % (5.2 g); 1H NMR (CD3COCD3): 3.76 (s, 3H), 
3.80 (s, 3H), 3.87 (s, 3H), 6.50 (s, 1H), 6.89 (dd, J = 8.8 Hz and J = 3.1 Hz, 1H), 6.96 (d, J = 8.8 Hz, 
1H), 7.09 (dd, J = 8.8 Hz and J = 2.5 Hz, 1H), 7.25 (d, J= 3.1 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.83 (d, 
J = 9.1 Hz, 1H); 13C NMR (CD3COCD3): 56.8, 57.0, 57.5, 69.9, 106.1, 114.0, 115.2, 115.5, 117.0, 
125.0, 133.3, 138.3, 149.4, 152.6, 155.7, 159.4, 175.2. 
(2,5-dimethoxyphenyl)-(6-methoxy-1,3-benzothiazol-2-yl)methanone (5i). The title compound was 
prepared by reaction of (2,5-dimethoxy-phenyl)-(6-methoxy-1,3-benzothiazol-2-yl)-methanol (5ii) 
(5.20 g, 15.7 mmol) and 2-iodoxybenzoic acid (8.79 g, 31.4 mmol) according to method C. The product 
was purified by CC (hexane/ethyl acetate 80:20); yield: 63 % (3.2 g); the compound was used in the 
next step without characterization. 
(2,5-dihydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone (5). The title compound was 
prepared by reaction of (2,5-dimethoxyphenyl)-(6-methoxy-1,3-benzothiazol-2-yl)methanone (5i) (5.2 
g, 15.8 mmol) and boron tribromide (78.9 mmol) according to method E. The product was purified by 
CC (hexane/ethyl acetate 80:20); yield: 59 % (4.5 g); 1H NMR (CD3COCD3): 3.03 (s, 2H), 6.92 (d, J = 
9.1 Hz, 1H), 7.21-7.25 (m, 2H), 7.57 (d, J = 2.5 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 8.82 (d, J = 3.2 Hz, 
1H), 11.67 (s, 1H); 13C NMR (CD3COCD3): 108.2, 119.5, 119.8, 119.9, 120.6, 128.1, 128.4, 140.8, 
149.5, 151.5, 159.4, 160.3, 165.8, 188.7; MS (ESI): 287.6 (M+H)+. 
6-(Benzyloxy)-1,3-benzothiazole (6iiii). To a solution of 6-hydroxy-1,3-benzothiazole (6iiiii) (0.82 g, 
5.42 mmol) and benzyl bromide (0.71 ml, 5.97 mmol) in acetone, potassium carbonate (3.25 g, 38.0 
mmol) was added. The reaction mixture was refluxed overnight. A mixture of water and saturated 
ammonium chloride solution (1:2) was added to quench the reaction, and the aqueous solution was then 
extracted (3x) with ethyl acetate. The combined organic layers were washed with brine, dried over 
magnesium sulfate, filtered, and concentrated to dryness. The product was purified by CC (hexane/ethyl 
acetate 80:20); yield: quantitative (1.31 g); 1H NMR (CDCl3): 5.15 (s, 2H), 7.21 (dd, J = 8.8 Hz and J = 
2.4 Hz, 1H), 7.33-7.36 (m, 1H), 7.39-7.42 (m, 2H), 7.45-7.47 (m, 3H), 8.03 (d, J = 9.1 Hz, 1H), 8.84 (s, 
1H); 13C NMR (CDCl3): 70.7, 105.4, 116.5, 124.0, 127.5, 128.2, 128.7, 136.5, 138.1, 139.1, 151.6, 
157.2, 176.3, 180.0. 
[6-(Benzyloxy)-1,3-benzothiazol-2-yl][3-(tert-butyldimethylsilanyloxy)-4-methylphenyl]methanol 
(6ii). The title compound was prepared by reaction of 6-benzyloxy-1,3-benzothiazole (6iiii) (0.3 g, 1.24 
mmol), nBuLi (0.5 ml, 1.24 mmol) and [3-(tert-butyldimethylsilanyloxy)-4-methyl]benzaldehyde (6iii) 
(0.23 g, 0.96 mmol) according to method A. The product was purified by CC (hexane/ethyl acetate 
80:20); yield: 74 % (0.35 g); 1H NMR (CDCl3): 0.15 (s, 6H), 0.96 (s, 9H), 2.35 (s, 3H), 5.42 (s, 2H), 
6.04 (s, 1H), 7.38-7.40 (m, 3H), 7.40-7.44 (m, 2H), 7.50-7.53 (m, 1H), 7.8 (d, J = 2.5 Hz, 1H), 8.11 (d, 
J = 1.6 Hz, 1H), 8.12 (dd, J = 7.5 Hz and J = 1.6 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H), 8.75 (s, 1H); 13C 
NMR (CDCl3): -4.6, 17.5, 18.2, 25.6, 72.2, 74.4, 106.3, 117.5, 119.3, 124.0, 128.0, 128.1, 128.3, 129.0, 
130.9, 131.0, 132.2, 133.5, 136.0, 138.7, 141.3, 150.5, 158.0, 161.0, 167.5. 
[6-(Benzyloxy)-1,3-benzothiazol-2-yl][3-(tert-butyl-dimethyl-silanyloxy)-4-
methylphenyl]methanone (6i). The title compound was prepared by reaction of [6-(benzyloxy)-1,3-
benzothiazol-2-yl][3-(tert-butyldimethylsilanyloxy)-4-methylphenyl]methanol (6ii) (0.35 g, 0.71 mmol) 
and 2-iodoxybenzoic acid (0.4 g, 1.42 mmol) according to method C. The product was purified by CC 
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(hexane/ethyl acetate 85:15); yield: 72 % (0.25 g); the compound was used in the next step without 
characterization. 
[6-(Benzyloxy)-1,3-benzothiazol-2-yl](3-hydroxy-4-methylphenyl)methanone (6). To a solution of 
[6-(benzyloxy)-1,3-benzothiazol-2-yl][3-(tert-butyldimethylsilanyloxy)-4-methylphenyl]methanone (6i) 
(0.26 g, 0.53 mmol) in THF at 0 °C tetra-n-butylammonium fluoride (TBAF) (0.68 ml, 0.68 mmol) was 
added dropwise. The reaction mixture was stirred for 2 h at rt under nitrogen atmosphere. Water was 
added to quench the reaction, and the aqueous layer was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to 
dryness. The product was purified by CC (hexane/ethyl acetate 80:20) followed by preparative HPLC; 
yield: 50 % (0.10 g); 1H NMR (CD3COCD3) 2.32 (s, 3H), 5.28 (s, 2H), 7.32-7.37 (m, 3H), 7.41-7.44 
(m, 2H), 7.53-7.54 (m, 2H), 7.81 (d, J = 2.5 Hz, 1H), 8.03 (d, J = 1.6 Hz, 1H), 8.10 (dd, J = 7.5 Hz and 
J = 1.6 Hz, 1H), 8.12 (d, J = 8.8 Hz, 1H), 8.76 (s, 1H); 13C NMR (CD3COCD3): 17.5, 72.2, 107.0, 
118.2, 120.0, 124.8, 127.7, 128.1, 129.6, 129.9, 130.4, 130.6, 132.6, 133.6, 135.9, 138.7, 140.7, 150.4, 
157.3, 160.9, 167.0, 185.6; MS (ESI): 376.1 (M+H)+. 
(6-Methoxy-1,3-benzothiazol-2-yl)[3-methoxy-4-(tert-butyldimethylsilanyloxy)phenyl]methanol 
(7iiii). The title compound was prepared by reaction of 6-methoxy-1,3-benzothiazole (1iii) (0.20 g, 1.21 
mmol), nBuLi (0.5 ml, 1.21 mmol) and 3-methoxy-4-(tert-butyldimethylsilanyloxy)benzaldehyde 
(7iiiii) (0.25 g, 0.93 mmol) according to method A. The product was purified by CC (hexane/ ethyl 
acetate 90:10); yield: 65 % (0.34 g); 1H NMR (CDCl3): 0.14 (s, 6H), 0.99 (s, 9H), 3.77 (s, 3H), 3.84 (s, 
3H), 6.03 (s, 1H), 6.83 (d, J = 7.9 Hz, 1H), 6.94 (dd, J = 7.9 Hz and J = 1.8 Hz, 1H), 7.02-7.04 (m, 2H), 
7.26 (t, J = 1.8 Hz, 1H), 7.83 (d, J = 9.2 Hz, 1H); 13C NMR (CDCl3): -4.7, 18.4, 25.6, 55.4, 55.7, 74.0, 
104.2, 110.4, 115.4, 119.3, 120.8, 123.4, 134.4, 136.6, 145.3, 146.8, 151.2, 157.6, 172.9. 
(6-Methoxy-1,3-benzothiazol-2-yl)[3-methoxy-4-(tert-butyl-dimethyl-silanyloxy) 
phenyl]methanone (7iii). The title compound was prepared by reaction of (6-methoxy-1,3-
benzothiazol-2-yl)[3-methoxy-4-(tert-butyl-dimethyl-silanyloxy) phenyl]methanol (7iiii) (0.34 g, 0.78 
mmol) and 2-iodoxybenzoic acid (0.44 g, 1.56 mmol) according to method C. The product was purified 
by CC (hexane/ ethyl acetate 95:05); yield: quantitative (0.34 g); 1H NMR (CDCl3): 0.22 (s, 6H), 1.00 
(s, 9H), 3.92 (s, 6H), 6.98 (d, J = 8.5 Hz, 1H), 7.17 (dd, J = 8.8 Hz and J = 2.5 Hz, 1H), 7.40 (d, J = 2.5 
Hz, 1H), 8.06 (d, J = 2.2 Hz, 1H), 8.08 (d, J = 8.8 Hz, 1H), 8.38 (dd, J = 8.2 Hz and J = 1.9 Hz, 1H); 
13C NMR (CDCl3): -4.5, 18.5, 25.6, 55.5, 55.8, 103.4, 114.0, 117.3, 120.4, 126.2, 126.5, 128.8, 130.2, 
148.5, 150.9, 151.1, 159.6, 165.4, 183.2. 
(6-Methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-hydroxyphenyl)methanone (7ii). To a solution of 
(6-methoxy-1,3-benzothiazol-2-yl)[3-methoxy-4-(tert-butyl-dimethyl-silanyloxy)phenyl] methanone 
(7iii) (0.34 g, 0.78 mmol) in THF at 0 °C tetra-n-butylammonium fluoride (TBAF) (0.82 g, 3.14 mmol) 
was added dropwise. The reaction mixture was stirred for 2 h at rt under nitrogen atmosphere. Water 
was added to quench the reaction, and the aqueous layer was extracted with ethyl acetate. The 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
concentrated to dryness. The product was purified by CC (hexane/ethyl acetate 80:20); yield: 81 % (0.2 
g); the compound was used for the next step without characterisation. 
(6-Methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-phenoxyphenyl)methanone (7i). A mixture of (6-
methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-hydroxyphenyl)methanone (7ii) (0.2 g, 0.63 mmol), 
molecular sives (4 Å), benzeneboronic acid (0.23 g, 1.9 mmol) and copper(II) acetate (0.12 g, 0.63 
mmol) in anhydrous dichloromethane was stirred for 5 min. Triethylamine (0.22 ml, 1.58 mmol) was 
added dropwise and the reaction mixture was stirred for 18 h at room temperature under nitrogen 
atmosphere. Water was added to quench the reaction and the aqueous layer was extracted with ethyl 
acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered 
and concentrated to dryness. The product was purified by preparative CC (hexane/ethyl acetate 80:20); 
yield: quantitative (0.25 g); 1H NMR (CDCl3): 3.92 (s, 3H), 4.00 (s, 3H), 6.95 (d, J = 8.5 Hz, 1H), 7.08-
7.10 (m, 2H), 7.16-7.19 (m, 2H), 7.36-7.41 (m, 3H), 8.06 (d, J = 9.1 Hz, 1H), 8.17 (d, J = 1.9 Hz, 1H), 
8.36 (dd, J = 8.5 Hz and J = 1.9 Hz, 1H); 13C NMR (CDCl3): 55.8, 56.2, 103.4, 114.5, 117.5, 117.6, 
118.2, 119.3, 119.4, 124.1, 126.0, 126.3, 129.8, 130.0, 139.0, 148.5, 150.3, 151.6, 156.0, 159.7, 165.0, 
183.2.
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(6-Hydroxy-1,3-benzothiazol-2-yl)(3-hydroxy-4-phenoxyphenyl)methanone (7). The title compound 
was prepared by reaction of (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-
phenoxyphenyl)methanone (7i) (0.1 g, 0.26 mmol) and boron tribromide (1.56 mmol) according to 
method E. The product was directly purified by preparative HPLC; yield: 84 % (0.08 g); 1H NMR 
(CD3COCD3): 7.02 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 7.17-7.22 (m, 2H), 7.42 (t, J = 7.5 Hz, 
2H), 7.55 (d, J = 2.5 Hz, 1H), 8.08 (d, J = 9.1 Hz, 1H), 8.19 (dd, J = 8.5 Hz and J = 2.2 Hz, 1H), 8.28 
(d, J = 1.9 Hz, 1H), 8.71 (s, 1H), 9.21 (s, 1H); 13C NMR (CD3COCD3): 108.3, 119.5, 119.7, 119.8, 
119.9, 120.4, 121.3, 125.7, 125.9, 128.4, 131.8, 133.1, 140.8, 149.8, 150.1, 151.4, 158.4, 159.9, 184.7; 
MS (ESI): 363.9 (M+H)+. 
2-Fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (8i). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.4 g, 1.96 mmol) and 2-fluoro-3-
methoxy-benzoyl chloride (0.4 g, 1.96 mmol) according to method B. The product was recrystallized in 
ethyl acetate; yield: 30 % (0.18 g); 1H NMR (CDCl3): 3.83 (s, 3H), 3.89 (s, 3H), 7.07 (dd, J = 2.5 Hz, J 
= 8.8 Hz, 1H), 7.31 (dt, J = 1.9 Hz, J = 8.8 Hz, J = 9.1, Hz 1H), 7.50-7.55 (m, 2H), 7.62 (d, J = 2.5 Hz, 
1H), 7.68 (d, J = 8.8 Hz, 1H), 12.69 (s, 1H). 
2-Fluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (8). The title compound was 
prepared by reaction of 2-fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (8i) (0.13 
g, 0.40 mmol) and boron tribromide (4.0 mmol) according to method E. The product was purified by 
CC (dichloromethane/methanol 90:10); yield: 33 % (0.04 g); 1H NMR (CD3SOCD3): 6.91 (dd, J = 2.5 
Hz, J = 8.8 Hz, 1H), 7.09-7.18 (m, 3H); 7.32 (d, J = 2.5 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 9.58 (s, 1H), 
10.21 (s, 1H), 12.51 (s, 1H); 13C NMR (CD3SOCD3): 106,5; 110,1; 115,4; 119,2; 120,7; 120,7; 121,2; 
123,2; 123,3; 124,4; 124,4; 132,8; 145,4; 145,4; 147,5; 149,5; 154,3; 163,3; MS (ESI): 305.2 (M+H)+. 
4-Fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (9i). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.3 g, 1.66 mmol) and 4-fluoro-3-
methoxy-benzoyl chloride (0.3 g, 1.66 mmol) according to method B. The product was recrystalized in 
ethyl acetate; yield: 100 % (0.55 g); 1H NMR (CD3COCD3): 3.88 (s, 3H), 4.03 (s, 3H), 7.05 (dd, J = 8.8 
Hz, J = 2.5 Hz, 1H), 7.33-7.37 (m, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.83-7.86 (m, 
1H), 8.00 (dd, J = 8.2 Hz, J = 1.9 Hz, 1H); 13C NMR (CD3COCD3): 56,2; 56,8; 105,1; 109,0; 114,3; 
116.0; 116,9; 117,1; 117,4; 117,7; 117,9; 122,2; 122,4; 127,3; 157,9; 165,2. 
4-Fluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (9). The title compound was 
prepared by reaction of 4-fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (9i) (0.25 
g, 0.75 mmol) and boron tribromide (7.5 mmol) according to method E. The product was directly 
purified by preparative HPLC; yield: 22 % (0.05 g); 1H NMR (CD3SOCD3): 6.92 (dd, J = 2.5 Hz, J = 
8.5 Hz, 1H), 7.28-7.32 (m, 2H); 7.58 (d, J = 8.8 Hz, 1H), 7.61-7.64 (m, 1H), 7.67 (dd, J = 2.2 Hz, J = 
8.5 Hz, 1H), 9.55 (s, 1H), 10.31 (s, 1H), 12.56 (s, 1H); 13C NMR (CD3SOCD3): 106,3; 115,3; 116,2; 
118,1; 119,8; 119,9; 122,3; 125,8; 132,7; 137,2; 144,5; 144,9, 145,0; 145,0; 145,2; 145,3; 152,1; 154,3; 
164,3; MS (ESI): 305.1 (M+H)+. 
2-Fluoro-5-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (10i). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.4 g, 1.96 mmol) and 2-fluoro-5-
methoxy-benzoyl chloride (0.4 g, 1.96 mmol) according to method B. The product was purified by CC 
(dichloromethane/methanol 95:05); yield: 35 % (0.23 g); 1H NMR (CDCl3): 3.36 (s, 3H), 3.38 (s, 3H), 
6.62 (dd, J = 2.7 Hz, J = 8.8 Hz, 1H), 6.71-6.74 (m, 2H), 6.85-6.87 (m, 2H), 7.25 (d, J = 8.8 Hz, 1H). 
2-Fluoro-5-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (10). The title compound was 
prepared by reaction of 2-fluoro-5-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (10i) (0.23 
g, 0.68 mmol) and boron tribromide (6.8 mmol) according to method E. The product was purified by 
CC (dichloromethane/methanol 90:10); yield: 30 % (0.06 g); 1H NMR (CD3SOCD3): 6.92 (dd, J = 2.5 
Hz, J = 8.5 Hz, 1H), 6.95-6.99 (m, 1H); 7.06-7.07 (m, 1H), 7.17 (t, J = 8.5 Hz, 1H), 7.33 (d, J = 2.5 Hz, 
1H), 7.58 (d, J = 8.8 Hz, 1H), 9.62 (s, 1H), 9.83 (s, 1H), 12.44 (s, 1H); 13C NMR (CD3SOCD3): 106,5; 
115,4; 115,5; 116,7; 117,2; 119,8; 119,9; 121,2; 122,3; 122,3; 122,5; 132,8; 132,8; 151,6; 153,5; 153,5; 
154,4; 154,8; 166,1; MS (ESI): 305.1 (M+H)+. 
3-Methoxy-4-methyl-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (11i). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.3 g, 1.66 mmol) and 3-methoxy-4-
methylbenzoyl chloride (0.3 g, 1.66 mmol) according to method B. The product was recrystallized in 
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ethyl acetate; yield: 100 % (0.55 g); 1H NMR (CDCl3): 2.27 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 7.00 (dd, 
J = 8.8 Hz, J = 2.5 Hz, 1H), 7.22 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 2.2 Hz, 1H), 7.49 (dd, J = 7.6 Hz, J = 
1.6 Hz, 1H), 7.52-7.54 (m, 2H); 13C NMR (CDCl3): 16,5; 55,5; 55,9; 104,2; 109,2; 110,7; 113,6; 115,4; 
119,4; 121,2; 130,5; 130,9; 132,9; 133,0; 157,0; 158,2; 165,2. 
3-Hydroxy-4-methyl-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (11). The title compound was 
prepared by reaction of 3-methoxy-4-methyl-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (11i) 
(0.25 g, 0.76 mmol) and boron tribromide (7.6 mmol) according to method E. The product was purified 
by CC (dichloromethane/methanol 90:10); yield: 13 % (0.03 g); 1H NMR (CD3SOCD3): 2.20 (s, 3H), 
6.91 (dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 7.22 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 2.5 Hz, 1H), 7.46 (d, J = 1.6 
Hz, 1H), 7.53 (dd, J = 1.6 Hz, J = 7.6 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 9.73 (s, 1H); 13C NMR 
(CD3SOCD3): 15,9; 106,3; 114,2; 115,2; 118,5; 120,7; 120,8; 129,5; 130,4; 132,7; 138,3; 141,4; 146,3; 
154,1; 165,5; MS (ESI): 301.1 (M+H)+. 
3,5-Dimethoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (12i). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.3 g, 1.66 mmol) and 3,5-dimethoxy-
benzoyl chloride (0.3 g, 1.66 mmol) according to method B. The product was recrystalized in ethyl 
acetate; yield: 100 % (0.57 g); 1H NMR (CD3OD): 3.88 (s, 3H), 3.90 (s, 6H), 6.75 (t, J = 2.5 Hz, J = 2.2 
Hz, 1H), 7.05 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 7.18 (d, J = 2.2 Hz, 1H), 7.38 (d, J = 2.2 Hz, 1H), 7.53 
(d, J = 2.5 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H); 13C NMR (CD3OD): 56,8; 57,1; 57,1; 106,1; 107,0; 107,6; 
109,1; 117,0; 123,3; 133,4; 135,4; 136,2; 144,5; 158,2; 158,9; 163,1; 166,9. 
3,5-Dihydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (12). The title compound was 
prepared by reaction of 3,5-dimethoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (12i) (0.57 g, 
1.66 mmol) and boron tribromide (16.6 mmol) according to method E. The product was recrystalized in 
methanol/water; yield: 80 % (0.40 g); 1H NMR (CD3SOCD3): 6.47-6.49 (m, 2H), 6.90-6.92 (m, 2H), 
7.30 (d, J = 1.9 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 9.55 (s, 1H); 9.64 (s, 2H), 12.4 (s, 1H); 13C NMR 
(CD3SOCD3): 106,3; 115,3; 116.0; 116,6; 117,1; 117,2; 121,0; 130,1; 130,4; 133,9; 135,9; 154,2; 
158,4; 165,7; MS (ESI): 303.1 (M+H)+. 
2,5-Dimethoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (13i). The title compound was 
prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.3 g, 1.66 mmol) and 2,5-dimethoxy-
benzoyl chloride (0.3 g, 1.66 mmol) according to method B. The product was recrystalized in ethyl 
acetate; yield: 100 % (0.55 g); The product was purified by CC (dichloromethane/methanol 95:05); 
yield: 100 % (0.57 g); the compound was used in the next step without characterisation. 
2,5-Dihydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (13). The title compound was 
prepared by reaction of 2,5-dimethoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (13i) (0.48 g, 
1.39 mmol) and boron tribromide (13.9 mmol) according to method E. The product was purified by CC 
(dichloromethane/methanol 90:10); yield: 25 % (0.15 g); 1H NMR (CD3SOCD3): 6.74 (dd, J = 2.5 Hz, J 
= 8.8 Hz, 1H), 7.07 (s, 1H), 7.12 (d, J = 2.2 Hz, 1H), 9.22 (s, 1H), 9.61 (s, 1H), 11.29 (s, 1H), 11.91 (s, 
1H); 13C NMR (CD3SOCD3): 107,7; 114,3; 115,2; 116,6; 117,1; 117,6; 118,1, 122,2; 137,8; 141,0; 
145,7; 154,4; 155,3; 164,5; MS (ESI): 303.1 (M+H)+. 
2-Chloro-6-fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (14i). The title 
compound was prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.3 g, 1.66 mmol) and 
2-chloro-6-fluoro-3-methoxy-benzoyl chloride (0.4 g, 1.66 mmol) according to method B. The product 
was purified by CC (hexan/ethyl acetate 60:40); yield: 83 % (0.51 g); 1H NMR (CDCl3): 3.72 (s, 3H), 
3.85 (s, 3H), 6.73 (dd, J = 4.4 Hz, J = 9.1 Hz, 1H), 6.79 (dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 6.84 (t, J = 8.5 
Hz, 1H), 7.06 (d, J = 8.8 Hz, 1H), 7.25 (d, J = 2.5 Hz, 1H); 13C NMR (CDCl3): 55,8; 56,6; 108,4; 103,8; 
112,0; 114,0; 114,1; 114,4; 114,6; 115,4; 120,7; 133,1; 141.8; 143.4; 156,8; 160,5. 
2-Chloro-6-fluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (14). The title 
compound was prepared by reaction of 2-chloro-6-fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-
yl)benzamide (14i) (0.25 g, 0.68 mmol) and boron tribromide (6.8 mmol) according to method E. The 
product was purified by CC (dichloromethane/methanol 90:10); yield: 43 % (0.10 g); 1H NMR 
(CD3SOCD3): 6.14 (dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 6.22-6.28 (m, 2H); 6.46 (d, J = 2.5 Hz, 1H), 6.78 
(d, J = 8.8 Hz, 1H); 13C NMR (CD3SOCD3): 104,6; 110,1; 113,2; 113,3; 114,0; 116,6; 116,6; 119,9; 
122,7; 122,9; 132,0; 140,5; 149,0; 149,0; 150,0; 151,9; 153,4; 153,4; 153,4; 153,9;160,6; MS (ESI): 
339.2 (M+H)+. 
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2,6-Difluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (15i). The title compound 
was prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.3 g, 1.79 mmol) and 2,6-difluoro-
3-methoxy-benzoyl chloride (0.4 g, 1.79 mmol) according to method B. The product was purified by 
CC (dichloromethane/methanol 95:05); yield: 29 % (0.18 g); 1H NMR (CDCl3): 3.83 (s, 3H), 3.89 (s, 
3H), 7.07 (dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 7.21 (dt, J = 1.9 Hz, J = 8.8 Hz, J = 9.1, Hz 1H), 7.36-7.40 
(m, 1H), 7.63 (d, J = 2.5 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 13.07 (s, 1H); 13C NMR (CDCl3): 55,6; 
56,8; 104,8; 111,4; 115,3; 116,1; 116,2; 117,6; 130,6; 143,9; 144,0; 150.7; 150.8; 150,8; 156,5; 164,6. 
2,6-Difluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (15). The title compound 
was prepared by reaction of 2,6-difluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide 
(15i) (0.18 g, 0.51 mmol) and boron tribromide (5.1 mmol) according to method E. The product was 
purified by CC (dichloromethane/methanol 90:10); yield: 30 % (0.05 g); 1H NMR (CD3SOCD3): 6.97-
7.01 (m, 2H), 7.17-7.22 (m, 1H); 7.41 (d, J = 2.5 Hz, 1H), 7.59 (d, J = 8.2 Hz, 1H); 13C NMR 
(CD3SOCD3): 107,2; 112,2; 112,3; 116,4; 120,6; 120,7; 122,7; 134,4; 142,6; 142,7; 142,7; 142,8; 
143,3; 147,9; 147,9; 151,9; 151,9; 155,3; 155,6; 159,8; 167,1; MS (ESI): 323.1 (M+H)+. 
2,4-Difluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (16i). The title compound 
was prepared by reaction of 6-methoxy-1,3-benzothiazol-2ylamine (0.3 g, 1.79 mmol) and 2,4-difluoro-
3-methoxy-benzoyl chloride (0.4 g, 1.79 mmol) according to method B. The product was purified by 
CC (dichloromethane/methanol 95:05); yield: 20 % (0.13 g); the compound was used in the next step 
without characterisation. 
2,4-Difluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide (16). The title compound 
was prepared by reaction of 2,4-difluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide 
(16i) (0.13 g, 0.36 mmol) and boron tribromide (3.6 mmol) according to method E. The product was 
purified by CC (dichloromethane/methanol 90:10); yield: 30 % (0.04 g); 1H NMR (CD3SOCD3): 6.92 
(dd, J = 2.5 Hz, J = 8.8 Hz, 1H), 7.15-7.23 (m, 2H); 7.32 (d, J = 2.5 Hz, 1H), 7.59 (d, J = 8.8 Hz, 1H), 
9.61 (s, 1H), 10.61 (s, 1H), 12.54 (s, 1H); 13C NMR (CD3SOCD3): 106,5; 111,7; 111,8; 115,4; 118,8; 
118,9; 121,2; 132,7; 134,2; 134,4; 135,2; 138,6; 139,0; 141,0; 149,4; 154,4; 166,5; MS (ESI): 323.1 
(M+H)+. 
4-Fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)-N-methyl-benzamide (17i). To a solution 
of 4-fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)benzamide (9i) (0.28 g, 0.83 mmol) in 
DMF, NaH (0.02 g, 0.91 mmol) was added and the mixture cooled to 0 ° C for 30 min. Methyl iodide 
(0.1 mL, 1.66 mmol) was added and the reaction mixture was stirred for 3 h at room temperature. Water 
was added to quench the reaction and the aqueous solution was then extracted (3x) with ethyl acetate. 
The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
concentrated to dryness. The product was purified by CC (hexane/ethyl acetate 50:50); yield: 70 % 
(0.20 g); 1H NMR (CD3COCD3): 3.88 (s, 3H), 3.99 (s, 3H), 4.00 (s, 3H), 7.11-7.13 (m, 1H), 7.20-7.23 
(m, 1H), 7.45-7.54 (m, 2H), 8.00-8.04 (m, 2H); 13C NMR (CD3COCD3): 32,8; 56,3; 56,5; 107,5; 113,6; 
115,2; 115,7; 116,1; 116,2; 123,4; 123,5; 128,6; 132,3; 134,8; 154,5; 156,5; 158,0; 167,8. 
4-Fluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)-N-methyl-benzamide (17). The title 
compound was prepared by reaction of 4-fluoro-3-methoxy-N-(6-methoxy-1,3-benzothiazol-2-yl)-N-
methyl-benzamide (17i) (0.20 g, 0.58 mmol) and boron tribromide (5.8 mmol) according to method E. 
The product was purified by CC (dichloromethane/methanol 90:10); yield: 22 % (0.04 g); 1H NMR 
(CD3SOCD3): 3.91 (s, 3H), 6.92 (dd, J = 2.4 Hz, J = 8.8 Hz, 1H), 7.19-7.28 (m, 2H); 7.49 (d, J = 8.8 
Hz, 1H), 7.71-7.74 (m, 1H), 7.89 (dd, J = 2.1 Hz, J = 9.1 Hz, 1H), 9.81 (s, 1H), 10.14 (s, 1H); 13C NMR 
(CD3SOCD3): 32.3; 108,5; 113,1; 115,4; 115,7; 115,8; 118,4; 118,4; 120,7; 120,8; 126,7; 129,8; 133,2; 
144,5; 144,6; 152,4; 154,4; 154,6; 165,8; MS (ESI): 319.1 (M+H)+. 
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b) Purity data of compounds 1 to 17 were determined using LC/MS as follows and are indicated in 
Table 1: 
 
A SpectraSystems® LC system consisting of a pump, an autosampler, and a PDA detector was 
employed. 
Mass spectrometry was performed on an MSQ® electro spray mass spectrometer (ThermoFisher, 
Dreieich, Germany). 
The system was operated by the standard software Xcalibur®. 
An RP-C18 NUCLEODUR® 100-5 (125x3 mm) column (Macherey-Nagel GmbH, Düren, Germany) 
was used as stationary phase. All solvents were HPLC grade. 
In a gradient run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) in 0.1 % 
trifluoroacetic acid was increased from an initial concentration of 0 % at 0 min to 100 % at 15 min and 
kept at 100 % for 5 min. The injection volume was 15 µL and flow rate was set to 800 µL/min. MS 
analysis was carried out at a spray voltage of 3800 V, a capillary temperature of 350 °C, and a source 
CID of 10 V. Spectra were acquired in positive mode from 100 to 1000 m/z at 254 nm for the UV trace. 
 
Table S1: Purity 
 
Cmpd Rt (min) 
HPLC purity 
(≥ %) MS (ESI) m/z 
1 12.15 95 290.1 (M+H)+ 
2 12.66 95 304.0 (M+H)+ 
3 12.30 96 273.9 (M+H)+ 
4 9.64 95 287.0 (M+H)+ 
5 11.37 97 287.6 (M+H)+ 
6 16.59 95 376.1 (M+H)+ 
7 11.20 98 363.9 (M+H)+ 
8 8.10 97 305.2 (M+H)+ 
9 8.39 99 305.1 (M+H)+ 
10 8.38 96 305.1 (M+H)+ 
11 9.24 99 301.1 (M+H)+ 
12 7.36 95 303.1 (M+H)+ 
13 7.81 99 303.1 (M+H)+ 
14 8.32 95 339.2 (M+H)+ 
15 8.04 98 323.1 (M+H)+ 
16 8.46 98 323.1 (M+H)+ 
17 9.09 99 319.1 (M+H)+ 
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c) Biological methods 
 
[2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. Quickszint Flow 302 
scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17-HSD1 and 17-HSD2 were obtained from human placenta according to previously described 
procedures. Fresh human placenta was homogenized and cytosolic fraction and microsomes were 
separated by centrifugation. For the partial purification of 17-HSD1, the cytosolic fraction was 
precipitated with ammonium sulfate. 17-HSD2 was obtained from the microsomal fraction. 
 
Inhibition of human 17-HSD1 
 
Inhibitory activities were evaluated by an established method with minor modifications. Briefly, the 
enzyme preparation was incubated with NADH [500 µM] in the presence of potential inhibitors at 37 
°C in a phosphate buffer (50 mM) supplemented with 20 % of glycerol and EDTA (1mM). Inhibitor 
stock solutions were prepared in DMSO. The final concentration of DMSO was adjusted to 1 % in all 
samples. The enzymatic reaction was started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]-
E1 (final concentration: 500 nM, 0.15 Ci). After 10 min, the incubation was stopped with HgCl2 and 
the mixture was extracted with diethylether. After evaporation, the steroids were dissolved in 
acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 reverse 
phase chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a 
HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of 
the steroids were performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The 
conversion rate was calculated after analysis of the resulting chromatograms according to the following 
equation:  100
1%2%
2%%  EE
Econversion . Each value was calculated from at least three 
independent experiments. 
 
Inhibition of human 17-HSD2 
 
The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 procedure. The microsomal 
fraction was incubated with NAD+ [1500 µM], test compound and a mixture of unlabelled- and [2, 4, 6, 
7-3H]-E2 (final concentration: 500 nM, 0.11 Ci) for 20 min at 37 °C. Further treatment of the samples 
and HPLC separation was carried out as mentioned above. 
The conversion rate was calculated after analysis of the resulting chromatograms according to the 
following equation: 100
2%1%
1%%  EE
Econversion . 
 
ER affinity 
 
The binding affinity of selected compounds to the ER and ER was determined according to 
Zimmermann et al. Briefly, 0.25 pmol of ER or ER, respectively, were incubated with [2, 4, 6, 7-3H]-
E2 (10 nM) and test compound for 1 h at room temperature. The potential inhibitors were dissolved in 
DMSO (5 % final concentration). Evaluation of non-specific-binding was performed with 
diethylstilbestrol (10 µM). After incubation, ligand-receptor complexes were selectively bound to 
hydroxyapatite (5 g/ 60 mL TE-buffer). The complex formed was separated, washed and resuspended in 
ethanol. For radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was 
added and samples were measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, 
Turku). For determination of the relative binding affinity (RBA), inhibitor and E2 concentrations 
required to displace 50 % of the receptor bound labelled E2 were determined. RBA values were 
calculated according to the following equation: 100
)(
)2([%]
50
50 
compoundIC
EICRBA . The RBA value 
for E2 was arbitrarily set at 100 %. 
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Inhibition of 17-HSD1 in T47-D cells 
 
T47-D cells were obtained from ECACC, Salisbury. Stripped FCS and cell culture media were 
purchased from CCpro, Oberdorla. A stock culture of T47-D cells was grown in RPMI 1640 medium 
supplemented with 10 % FCS, L-glutamine (2 mM), penicillin (100 IU/mL), streptomycin (100 
µg/mL), insulin-zinc-salt (10 µg/mL) and sodium pyruvate (1 mM) at 37 °C under 5 % CO2 humidified 
atmosphere. 
The cells were seeded into a 24-well plate at 1x106 cells/well in DMEM medium with FCS, L-
glutamine and the antibiotics added in the same concentrations as mentioned above. After 24 h the 
medium was changed for fresh serum free DMEM and a solution of test compound in DMSO was 
added. Final concentration of DMSO was adjusted to 1 % in all samples. After a pre-incubation of 30 
min at 37°C with 5 % CO2, the incubation was started by addition of a mixture of unlabelled- and [2, 4, 
6, 7-3H]- E1 (final concentration : 50 nM, 0.15 Ci). After 0.5 h incubation, the enzymatic reaction was 
stopped by removing of the supernatant medium. The steroids were extracted into diethylether. Further 
treatment of the samples was carried out as mentioned for the 17-HSD1 assay. 
 
Inhibition of Human Hepatic CYPs 
 
The commercially available P450 inhibition kits from BD Gentest (Heidelberg, Germany) were used 
according to the instructions of the manufacturer. Compounds 1 and 4 were tested for inhibition of the 
following enzymes: CYP3A4, 2D6, 2C9, 2C19, 1A2 and 2B6. Inhibitory potencies were determined as 
IC50 values. 
 
Inhibition of marmoset (Callithrix jacchus) 17-HSD1 and 17-HSD2 
 
17-HSD1 and 17-HSD2 were obtained from marmoset placenta. The inhibition assays were 
performed similarly to the ones carried out using human enzymes. 
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3.III New Insights into the SAR and Binding Modes of 
Bis(hydroxyphenyl)thiophenes and Benzenes: Influence of 
Additional Substituents on 17-Hydroxysteroid 
Dehydrogenase Type 1 (17-HSD1) Inhibitory Activity and 
Selectivity. 
 
Major part of this chapter has been published as an article in 
Journal of Medicinal Chemistry, (2009), 52, 6724–6743. 
 
 
Abstract: 17-hydroxysteroid dehydrogenase type 1 (17-HSD1) is responsible for the 
catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of 
hormone-dependent diseases via activation of the estrogen receptor  (ER). Due to the 
overexpression of 17-HSD1 in mammary tumors, this enzyme should be an attractive target 
for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of 
potent 17-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes and benzenes. In this 
paper, different substituents were introduced into the core structure and the biological 
properties of the corresponding inhibitors were evaluated. Computational methods and analysis 
of different X-rays of 17β-HSD1 lead to identification of two different binding modes for these 
inhibitors. The fluorine compound 23 exhibits an IC50 values of 8 nM and is the most potent 
non-steroidal inhibitor described so far. It also shows a high selectivity (17-HSD2, ER) and 
excellent pharmacokinetic properties after peroral application to rats. 
 
Introduction 
 
Estrogens are involved in the regulation of the female reproduction system. However, it is also 
well known that 17-estradiol (E2), the natural ligand of the estrogen receptors (ERs)  and , 
plays a critical role in the development of several estrogen-dependent pathologies like breast 
cancer1 and endometriosis.2 
Until now, hormone-dependent breast cancers are treated using three different endocrine 
therapies:3,4 aromatase inhibitors and GnRH analogues disrupt the estrogen biosynthesis while 
selective estrogen receptor modulators (SERMs) or pure antiestrogens5 prevent E2 to unfold its 
action at the receptor level. Besides specific disadvantages of each therapeutic approach, all of 
these strategies have in common a rather radical reduction of estrogen levels in the whole body 
leading to significant side effects. 
A softer approach could be the inhibition of an enzyme of the 17-hydroxysteroid 
dehydrogenase (17-HSD) family, especially one which is responsible for the E2 formation 
from estrone (E1). Until now, three subtypes (1, 7 and 12) are able to catalyze this reaction, the 
most important being 17-HSD1. The primary physiological role of 17-HSD7 and 17-
HSD12 is supposed to be in the cholesterol synthesis6,7 and in the regulation of the lipid 
biosynthesis,8 respectively. In addition, Day et al.9 recently, showed that 17-HSD12, although 
highly expressed in breast cancer cell lines, is inefficient in E2 formation. 
17-HSD1, which is responsible for the intracellular NAD(P)H-dependent conversion of the 
weak E1 into the highly potent estrogen E2, is often overexpressed in breast cancer cells10-13 
and endometriosis.14 Inhibition of this enzyme is therefore regarded as a promising novel target 
for the treatment of estrogen-dependent diseases. 
Recently, two groups9, 15, 16 reported about the in-vivo efficacy of 17-HSD1 inhibitors to 
reduce E1 induced tumour growth using two different mouse models and indicating that the 
17-HSD1 enzyme is a suitable target for the treatment of breast cancer. 
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In order to not counteract the therapeutic efficacy of 17-HSD1 inhibitors, it is very important 
that the compounds are selective toward 17-HSD2, the enzyme which catalyzes the 
deactivation of E2 into E1. Additionally, to avoid intrinsic estrogenic effects, the inhibitors 
should not show affinity to the estrogen receptors  and .  
During the last decade, several groups reported on 17-HSD1 inhibitors, most of them having 
steroidal structures.17-19 Recently non-steroidal cores have been published too. Until today four 
classes of compounds are described: thienopyrimidinones,20-21 biphenyl ethanones22 and from 
our group (hydroxyphenyl)naphthalenes23-25 and bis(hydroxyphenyl)azoles, thiophenes, 
benzenes and aza-benzenes.26-30 The most promising compounds of the latest series are 
thiophenes 1, 7 and 33, thiazole 36 and phenylene 40 exhibiting IC50 values toward 17-HSD1 
in the nanomolar range and high selectivity toward 17-HSD2 and the ERs (Chart 1).  
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Chart 1: described bis(hydrophenyl)azoles, thiophenes, benzenes and aza-benzenes 
 
In the following, we will report on structural optimizations which led to the discovery of new 
highly potent and selective 17-HSD1 inhibitors.  
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Chart 2: title compounds 
 
Design 
 
Up to now, several crystal structures of human 17-HSD1 were resolved: as apoenzyme (i.e. 
PDB code: 1BHS31), as binary complex (enzyme-E2, i.e. PDB code: 1IOL32) or as ternary 
complex (enzyme-E2-NADP+: i.e. PDB code 1FDT;33 1A27;34 enzyme-HYC (hybride 
inhibitor): PDB code: 1I5R35).  
The analysis of the ternary complexes available from 17-HSD1 provides useful knowledge 
about the architecture of the enzyme and important hints for structure based drug design: a 
substrate binding site (SUB) and a cofactor binding pocket (COF) can be identified as well as 
the most important amino acids responsible for substrate and cofactor anchoring. The SUB is a 
narrow hydrophobic tunnel containing two polar regions at each end: His221/Glu282 on the 
one side and Ser142/Tyr155 on the other side, corresponding to the binding oxygens in 3- and 
17-hydroxy group of E2. Additionally a flexible loop can be identified which is not well 
resolved in almost all the structures. 
From previous results obtained in the class of bis(hydroxyphenyl)azoles, thiophenes, benzenes 
and aza-benzenes,26, 27 a SAR study highlighted four structural features which are important for 
high 17-HSD1 inhibitory activity: 1. one hydroxyphenyl moiety on the core structure is not 
sufficient for a high potency, 2. only the meta-para and meta-meta dihydroxy substitution 
pattern (O-O distance in the same range as observed for the steroid, d = 11 Å) are active, 3. the 
presence of the meta-hydroxy group is more important for inhibitory activity than the para-, 4. 
only central aromatic rings without hydrogen bond donor function like thiophene, thiazole, 
benzene exhibit inhibitory activity. It was also shown that a correlation seems to exist between 
the activity of the compounds and the electrostatic potential distribution of the molecules:27 to 
be active the ESP values of the different regions of the inhibitor has to be in an appropriate 
range. 
In the present report, we will present the structure optimization of this class of compounds 
leading to an increase in activity and in selectivity of these inhibitors. First, the influence of the 
bioisosteric exchange of one OH group on the enzyme activity will be determined. Secondly, 
the space availability around the inhibitors and the nature of the most appropriate substituent 
will be investigated by substitutions, either on the heterocycle, or on the hydroxyphenyl 
moieties. The nature of the substituent will be varied in order to investigate the possible 
interactions between the inhibitor and the enzyme. Thirdly, computational studies (docking 
studies and ESP calculations) will be performed in order to identify the most plausible binding 
mode for this class of compounds. Furthermore the selectivity toward 17-HSD2 and the ERs 
 and  will be determined as well as the potency of the compounds in T-47D cells and 
inhibition of the two most important hepatic CYP enzymes. Finally, the pharmacokinetic 
profile of the two most promising candidates will be evaluated in rats after oral administration. 
 
Chemistry 
 
The synthesis of compounds 1 to 11, 21 to 25 and 32 is presented in Scheme 1. Starting from 
the mono-brominated key intermediate 1b and the appropriate commercially available boronic 
acids, the preparation of compounds 1a to 11a, 21a to 25a and 32a was accomplished via 
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Suzuki cross coupling reaction36 under microwave assisted conditions (Method A: Cs2CO3, 
DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min). The resulting 
disubstituted thiophenes were subsequently submitted to ether cleavage with borontribromide27 
(Method C: BBr3, CH2Cl2, -78 °C to rt, 18 h) leading to compounds 1 to 11, 21 to 25 and 32 
(Scheme 1). In case of intermediate 25a, the boronic acid 25b was prepared in a three step 
synthesis pathway: first, an iodine substituent was selectively introduced in position 2 of the 
para-bromoanisole (compound 25d) using (diacetoxyiodo) benzene.37 Then, a selective Suzuki 
reaction on the iodo-position of 25d under Method B (Na2CO3, toluene/water (1:1), Pd(PPh3)4, 
reflux, 20 h) led to the intermediate 25c and the corresponding boronic acid 25b was prepared 
using n-butyl lithium and triethyl borate followed by hydrolysis with diluted hydrochloric acid. 
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Scheme 1a: synthesis of compounds 1 to 11, 21 to 25 and 32. Reagents and conditions: (a) Method 
A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min; (b) BBr3, CH2Cl2, -78 
°C to rt, 18 h; (c) PhI(OAc)2, I2, AcOEt, 60 °C, 5 h; (d) Ph-B(OH)2, Method B: Na2CO3, toluene/water (1:1), 
Pd(PPh3)4, reflux, 20 h; (e) 1. n-BuLi, dry THF, 5 min, -78 °C, 2. B(OEt)3, 2 h -78°C to rt, 3. HCl 1N, rt; (f) 
Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h. 
 
The preparation of compounds 31 and 33 to 42 is similar to the synthetic pathway presented in 
Scheme 1 for compounds 1 to 11. The first Suzuki coupling was carried out according to 
Method B with the corresponding dibrominated heterocycle and the methoxylated benzene 
boronic acid. The resulting mono substituted compounds 31b and 33b to 42b were submitted 
to a second cross coupling reaction under microwave assisted conditions following Method A. 
The compounds were subsequently demethylated with boron tribromide to yield compounds 31 
and 33 to 42. 
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The synthesis of compounds 12, 14 and 15 is depicted in Scheme 2. The key intermediate 
mono methoxylated dibromothiophene 12b was prepared following two successive Suzuki 
coupling reactions according to Method B (Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 4 
h) from 2,3,5-tribromothiophene and methoxybenzene boronic acid. The reaction time of both 
cross couplings was carefully controlled (restricted to 4 h) in order to get a selective bromine 
replacement each time. Intermediates 12a, 14a, and 15a were obtained via a third Suzuki 
coupling using Method B. The methoxy substituents were cleaved in a last step, using boron 
tribromide (Method C: BBr3, CH2Cl2, -78 °C to rt, 18 h).  
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Scheme 2a: synthesis of compounds 12, 14 and 15. Reagents and conditions: (a) Method B: Na2CO3, 
toluene/water (1:1), Pd(PPh3)4, reflux, 4 h; (h) boronic acid, Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, 
reflux, 20 h; (d) BBr3, CH2Cl2, -78 °C to rt, 18 h. 
 
Compound 13 was synthesized under microwave assisted conditions in a one pot reaction using 
2,5-dibromo-3-methylthiophene and 3-hydroxyphenyl boronic acid following Method A 
(Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars)) for 15 min. 
The synthesis of the molecules bearing an additional substituent on the meta-hydroxyphenyl 
moiety of thiophene 1 (compounds 16 to 20) is shown in Scheme 3. Intermediate 16c was 
prepared via Suzuki reaction from the para-methoxylated benzene boronic acid and the 2,5-
dibromothiophene following Method B heating the reaction 4 h instead of 20 h in order to 
avoid any dicoupling reaction. Treatment of 16c with n-butyl lithium and triethyl borate 
afforded after hydrolysis with diluted hydrochloric acid the corresponding boronic acid 16b. 
The resulting compound was subjected to an additional cross coupling reaction which was 
carried out with the appropriate bromine derivative following Method A for compounds 17a to 
20a and Method B for compound 16a. The hydrolysis of the methoxy groups with boron 
tribromide (Method C) led to compounds 16 to 20. 
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Scheme 3: synthesis of compounds 16 to 20. Reagents and conditions: (a) Method B: Na2CO3, 
toluene/water (1:1), Pd(PPh3)4, reflux, 4 h; (b) 1.n-BuLi, anhydrous THF, -78 °C, 15 min, 2. B(OEt)3, THF, -78 °C 
to rt, 2 h, 3. HCl 1N; (c) Method A for 17a-20a (Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 
°C, 15 bars), 15 min); Method B for 16a (Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h); (d) BBr3, CH2Cl2, 
-78 °C to rt, 18 h. 
 
The synthesis of compounds 26 to 28 substituted in ortho-position of the para-OH group is 
depicted in Scheme 4. The preparation of the key intermediate 26b started from the 
commercially available 3-formyl-4-methoxyphenyl boronic acid. Reduction of the aldehyde 
function using sodium borohydride followed by a cross coupling reaction with 1b under 
microwave irradiation according to Method A (Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, 
MW (150 W, 150 °C, 15 bars), 15 min) afforded the disubstituted thiophene 26c. The alcohol 
function of 26c was subsequently oxidized with pyridinium chlorochromate to yield to the key 
aldehyde 26b. It was subjected to the Horner-Wadworths-Emmons conditions38 to introduce 
the acrylic ester moiety (intermediate 26a). Hydrolysis of the ester function using lithium 
hydroxide,24 amide bond formation with aniline, EDCI and HOBt39 afforded compound 27a 
The catalytic double bond hydrogenation of 27a was performed using Perlman’s catalyst.40 The 
ether functions of 26a, 27a and 28a were deprotected using boron tribromide (Method C) to 
give the desired compounds 26 to 28. 
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Scheme 4: synthesis of compounds 26 to 28. Reagents and conditions: (a) NaBH4, THF/EtOH (1:1), 0 
°C to rt, 2 h; (b) Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min; 
(c) PCC, CH2Cl2, rt, 30 min; (d) NaH, THF dry, rt, 4 h; (e) BBr3, CH2Cl2, -78 °C to rt, 18 h; (f) 1. LiOH, 
THF/H2O (2:1), reflux, 20 h, 2. aniline, EDCI, HOBt, CH2Cl2, reflux, 20 h; (g) Pd(OH)2, THF/EtOH (1:1), H2, rt, 
20 h. 
 
The synthesis of the difluorinated thiophenes 29 and 30 is presented in Scheme 5. These 
compounds were obtained after two successive cross coupling reactions: in a first step 2,5-
dibromothiophene reacted with 3-fluoro-4-methoxyphenyl boronic acid following Method B 
(Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h). In a second step, the resulting mono 
substituted thiophene 29b was subsequently submitted to a second cross coupling reaction 
under microwave irradiation (Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW 
(150 W, 150 °C, 15 bars), 15 min) to yield the intermediates 29a and 30a. Ether cleavage with 
boron tribromide led to the final compounds 29 and 30. 
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Scheme 5: synthesis of compounds 29 to 30. Reagents and conditions: (a) Method B: Na2CO3, 
toluene/water (1:1), Pd(PPh3)4, reflux, 20 h ; (b) Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW 
(150 W, 150 °C, 15 bars), 15 min; (c) BBr3, CH2Cl2, -78 °C to rt, 18 h. 
 
Biological Results 
 
Activity: inhibition of human 17-HSD1 
 
Placental enzyme was partially purified following a described procedure.26, 27 Tritiated E1 was 
incubated with 17-HSD1, cofactor and inhibitor. After HPLC separation of substrate and 
product, the amount of labelled E2 formed was quantified. The inhibition values of the test 
compounds are shown in Tables 1 to 5. Thiophenes 1, 2, 7 and 29, thiazole 33 and phenylenes 
35 and 37, identified in our previous article,27 were used as reference compounds. 
It was first investigated whether one of the two hydrophenyl moieties could be exchanged by 
another functional group having similar properties. Previous results27 showed that the meta-
hydroxy group is highly important for activity and was therefore maintained in the core 
structure. The exchange of the para-hydroxy group on the meta-para disubstituted thiophene 
(1, IC50= 69 nM) by a bioisosteric function (F, NH2, SH) resulted in moderate (3, IC50= 717 
nM) or weak inhibitors (4 and 5, IC50> 5000 nM) of 17-HSD1 (Table 1). Moving the F atom 
from the para- (compound 3) to the meta-position (compound 8) led to a small increase in 
activity (8, IC50= 535 nM vs. 3, IC50= 717 nM). Replacement of the meta-fluorine for a 
methylsulfonamide moiety (9) did not improve the activity (9, IC50= 523 nM vs. 8, IC50= 535 
nM), while a compound bearing a bulky substituent like tolylsulfonamide (11, IC50= 350 nM) 
showed comparable activity to the mono hydroxylated thiophene (2, IC50= 342 nM) indicating 
that there is some space in this region of the enzyme for substitution but it is unlikely that 
specific interactions between the tolylsulfonamide moiety and amino acids of the active site 
take place. The insertion of a C1-linker between the phenyl moiety and the methylsulfonamide 
group was detrimental for the activity (9, IC50= 523 nM vs. 10, IC50> 1000 nM). It can be 
therefore concluded that the two hydroxy functions are necessary for high activity and the 
para-hydroxy group can not be replaced by a bioisoteric group. 
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Table 1: effect of the exchange of one OH substituent for other functional groups on human 
17-HSD1 and 17-HSD2 inhibitory activities. 
 
S
OH R
S
OH
R
1-6 2
7-11  
cmpd R 
IC50 (nM)a selectivity
factord cmpd R 
IC50 (nM)a selectivity 
factord 17- HSD1b 
17- 
HSD2c 
17- 
HSD1b 
17- 
HSD2c 
1 OH 69 1950 28 7 OH 173 745 4 
2 H 342 2337 7 2 H 342 2337 7 
3 F 717 3655 5 8 F 535 1824 3 
4 NH2 >5000 nt  9 N
H
SO2  523 1575 3 
5 SH >5000 nt  10 NH
SO2 >1000 nt  
6 CN >1000 nt  11 NH
SO2
350 276 1 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 M], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
In order to improve the activity and the selectivity of our inhibitors, substituents capable to 
establish further interactions with the enzyme were added either on the heterocycle or on the 
hydroxyphenyl moieties. Additional functional groups were introduced in both of the meta-
para 2,5-bis(hydroxyphenyl)thiophene 1 (IC50 = 69 nM) and the meta-meta 2,5-disubstituted 
derivative 7 (IC50 = 216 nM). 
Concerning substitution on the heterocycle, two kinds of hydrophobic substituents (Me, Ph) 
were introduced in position 3 on the thiophene ring to investigate the space availability around 
the core (Table 2). The meta-meta thiophenes bearing a methyl (compound 13) or phenyl 
(compound 14) as well as the meta-para thiophene bearing a hydroxyphenyl substituent 
(compound 12) showed a drop of activity compared to the reference compound 7 (IC50= 216 
nM vs. IC50> 1000 nM, 567 nM and 493 nM for 12, 13 and 14, respectively). It is striking that 
only in case of the meta-meta disubstituted series the insertion of a polar meta-hydroxyphenyl 
substituents leads to an increase in activity (15, IC50= 119 nM vs. 12, IC50> 1000 nM). This 
exemplifies that there is space available for further substitution around the heterocycle only in 
case of the meta-meta bis(hydroxyphenyl) substitution pattern and that the third meta-OH 
group is certainly at an appropriate distance to establish supplementary hydrogen bond 
interactions with the active site. 
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Table 2: inhibition of human 17-HSD1 and 17-HSD2 by compounds bearing a 
supplementary substituent on the thiophene core structure 
 
S
R
OH OH
S
R
OH
OH
7
13-15
1
12  
cmpd R 
IC50 (nM)a selectivity
factord cmpd R 
IC50 (nM)a selectivity
factord 17- 
HSD1b
17- 
HSD2c 
17- 
HSD1b
17- 
HSD2c 
1 H 69 1950 28 7 H 173 745 4 
     13 CH3 567 856 1 
     14 493e nt  
12 
OH
 
>1000 nt  15 
OH
119 188 2 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction,  
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 M], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ecalculated value, obtained 
with the LOGIT transformed; ni: no inhibition, nt: not tested 
 
Concerning the substitution of the hydroxyphenyl rings, different groups were introduced 
either on the meta-hydroxyphenyl ring (compounds 16 to 20) or on the para-hydroxyphenyl 
moiety (compounds 21 to 28, Table 3). The ortho-position was not considered, as these 
compounds would not be planar any more. 
Introduction of a substituent in position 5 on the meta-hydroxyphenyl moiety resulted in case 
of a methyl group in a drop of activity (16, IC50= 629 nM vs. 1, IC50= 69 nM). The introduction 
of a fluorine atom led to slight increase in activity in comparison to the unsubstituted 
compound 1 (17, IC50= 42 nM vs. 1, IC50= 69 nM). Moving these functional groups to position 
4 gave a highly active fluorinated compound 19 (IC50= 113 nM) and a very weak methylated 
inhibitor 18 (IC50> 5000 nM). Substituents have also been introduced in position 5 on the para-
hydroxyphenyl ring: a polar group like a hydroxy (compound 22) or a bulky substituent like a 
phenyl (compound 25) in ortho- of the para-OH induced a decrease in activity compared to 
thiophene 1 (IC50= 69 nM vs. IC50= 402 nM and >5000 nM for 22 and 25, respectively). The 
introduction of a fluorine substituent into the same position led to the highly potent compound 
23 (IC50= 8 nM) while substituents like methyl or trifluoromethyl showed equal or slightly 
better activities compared to the reference compound 1 (IC50= 69 nM vs. IC50= 46 nM and 38 
nM for 21 and 24, respectively). Other functional groups showing a higher flexibility like 
ethylacrylate (compound 26), phenylacrylamide (compound 27) or phenylpropaneamide 
(compound 28) were also synthesized and the resulting compounds 26, 27 and 28 turned out to 
have weaker inhibitory activity compared to the unsubstituted thiophene 1 (IC50= 69 nM vs. 
130, 427 and 620 nM for 26, 27 and 28, respectively). The low activity of the unconjugated 
compound 28 indicates that an overall distributed electronic density is an important parameter 
for activity. These results indicate that there is space available in this area for substituents but 
the nature of the substituents are probably not yet optimal (Table 3). 
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Table 3: effect of a supplementary substituent on the hydroxyphenyl moieties on the inhibition 
of the human 17-HSD1 and 17-HSD2 
 
S
OH
OH
S
OH
OH
R
1
16-20
R
21-28
4
5
 
cmpd R 
IC50 (nM)a selectivity 
factord 17- HSD1b 
17- 
HSD2c 
1 H 69 1950 28 
16 5-CH3 629 2584 4 
17 5-F 42 463 11 
18 4-CH3 >5000 nt  
19 4-F 113 183 2 
20 4-OH >5000 nt  
21 CH3 46 1971 49 
22 OH 402 1636 4 
23 F 8 940 118 
24 CF3 38 97 3 
25 Ph >5000 nt  
26 
O
OEt
130 502 4 
27 
O
N
H
427 468 1 
28 
O
N
H
620 982 2 
 
aMean values of three determinations, standard deviation less than 15 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 M], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
The influence of the introduction of a second fluorine on the highly active thiophene 23 (IC50= 
8 nM), either one F on each hydroxyphenyl ring or two F on the same hydroxyphenyl moiety, 
was also examined (Table 4). When the two F were located on each hydroxyphenyl moieties, 
the 4-substituted fluoro derivative (compound 30) is slightly more potent that the one with the 
fluorine in 5-position (29, IC50= 29 nM, vs. 30, IC50= 17 nM). A slight decrease in activity was 
observed when the two fluorine substituents were present at the same hydroxyphenyl ring 
(compound 31, IC50= 56 nM). The exchange of the para-OH function of 23 by a fluorine atom 
(compound 32) confirmed the essential role of this para-hydroxy moiety as previously 
observed. 
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Table 4: effect of two additional fluorine atoms on the 17-HSD1 and 17-HSD2 inhibitory 
activity 
 
S
OH
OH
F
S
OH
OH
F
F
S
OH
F
F
23
29-30
R1
31 32
4
5
 
cmpd R1 
IC50 (nM)a selectivity 
factord 17- HSD1b 
17- 
HSD2c 
23 H 8 940 118 
29 5-F 29 227 8 
30 4-F 17 218 13 
31  56 312 6 
32  780 2640 3 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 M], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); nt: not tested. 
 
Methyl and fluorine substituents have been identified as functional groups able to increase the 
inhibitory activity of the 2,5-bis(hydroxyphenyl) thiophene 1. Previously27 we reported that 
other central core structures like 2,4-thiophene, 2,5-thiazole and 1,4-benzene lead to highly 
active compounds. The influence of an additional methyl or fluorine substituent at these 
structures was therefore also investigated (Table 5). Introduction of CH3 or F into the para-
hydroxyphenyl ring of 33, 36, 38 and 40 resulting in compounds 34, 35, 37, 39 and 42 led to 
equally active derivatives in case of 34 and 35 (IC50= 64 nM vs. 21, IC50= 46 nM). A decrease 
in inhibitory activity in the thiazole and in the benzene classes of compounds was observed 
compared to the thiophene family (37, IC50= 143 nM vs. 21, IC50= 46 nM; 39 and 42, IC50= 
123 nM and 51 nM, respectively vs. 23, IC50= 8 nM). Amongst the investigated molecules, 
introduction of a methyl or fluorine substituent led only in the class of the bis(hydroxyphenyl) 
thiophenes to an increase in activity. 
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Table 5: influence of the core and a supplementary substituent on the inhibition of the human 
17-HSD1 and 17-HSD2 
OH
cycle
R2
R1
21-23
33-42  
cmpd cycle R1 R2 
IC50 (nM)a selectivity 
factord 17- HSD1b
17- 
HSD2c
21 
S  
CH3 OH 46 1971 49 
23 F OH 8 940 118 
       
33 
S  
H OH 77 1270 16 
34 CH3 OH 64 869 14 
35 F OH 64 510 8 
       
36 
S
N
 
H OH 50 4000 80 
37 CH3 OH 143 2023 14 
       
38 
 
H OH 471 4509 10 
39 F OH 123 872 7 
40 OH H 173 2259 21 
41 OH CH3 171 1248 7 
42 OH F 51 239 5 
 
aMean values of three determinations, standard deviation less than 13 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 M], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
Selectivity: inhibition of 17-HSD2 and affinities to the estrogen receptors  and 
 
In order to gain insight into the selectivity of the most active compounds, inhibition of 17-
HSD2 and the relative binding affinities to the estrogen receptors  and  were determined. 
Since 17-HSD2 catalyzes the inactivation of E2 into E1, inhibitory activity toward this 
enzyme must be avoided. The 17-HSD2 inhibition was determined using an assay similar to 
the 17-HSD1 test. Placental microsomes were incubated with tritiated E2 in the presence of 
NAD+ and inhibitor. Separation and quantification of labelled product (E1) was performed by 
HPLC using radio detection. A selection of the most potent 17β-HSD1 inhibitors was tested for 
inhibition of 17β-HSD2. IC50 values and selectivity factors (IC50 HSD2 / IC50 HSD1) are 
presented in Tables 1 to 5. 
Mono-hydroxylated compounds (Table 1) exhibited a poor selectivity regarding 17-HSD2, 
the most selective one being compound 5 with a selectivity factor of 5. This finding suggests 
that the para-OH is important for activity as well as for selectivity (selectivity of the para-meta 
derivative 1: 28). Introduction of further substituents (Tables 2 to 5) into the highly active 
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bis(hydroxyphenyl) scaffold induced a loss of selectivity against 17-HSD2 except in case of 
compounds 21 and 23, which exhibit excellent selectivity factors of 49 and 118, respectively 
toward 17-HSD2. 
A further prerequisite for 17-HSD1 inhibitors to be used as potential drugs is that they do not 
show affinity for ERand ER, since binding to these receptors could counteract the 
therapeutic concept of selective 17-HSD1 inhibition. The binding affinities of the most 
selective compounds of this study were determined using recombinant human protein in a 
competition assay applying [3H]-E2 and hydroxyapatite (Table 6)All tested compounds show 
very marginal to marginal affinity to the ERs except compound 23, which binds weakly to ER 
(RBA= 1 %). Compound 21 was evaluated for estrogenic effects on the ER-positive, mammary 
tumor T-47D cell line. No agonistic, i.e. stimulatory effect was observed after application of 
compound 21 even at a concentration 1000 fold higher compared to E2.  
 
Table 6: binding affinities for the human estrogen receptors  and  of selected compounds 
 
cmpd RBA
a (%) 
ERαb ERβb 
1 0.1< RBA <1 1.5 
17 0.1< RBA <1 0.1< RBA <1 
21 < 0.01 < 0.01 
23 0.01< RBA <0.1 1 
30 0.1 0.01< RBA <0.1 
34 0.01< RBA <0.1 0.01< RBA <0.1 
37 0.01< RBA <0.1 < 0.01 
 
aRBA (relative binding affinity), E2: 100 %, mean values of three determinations, standard deviations less than 10 
%; bHuman recombinant protein, incubation with 10 nM 3H-E2 and inhibitor for 1 h. 
 
Further biological evaluations 
 
Additionally, the intracellular potency of compounds 21 and 23 on E2 formation was evaluated 
using a cell line which expresses both 17-HSD1 and 17-HSD2 (T47D cells). Compound 21 
and 23 inhibited the formation of E2 after incubation with labelled E1 showing IC50 values of 
426 nM and 282 nM, respectively. These results indicate that both compounds are able to 
permeate the cell membrane and inhibit the transformation of E1 into E2. 
Compounds 21 and 23 were further investigated for inhibition of the two most important 
human hepatic enzymes: CYP3A4 and CYP2D6, which are responsible for 75 % of drug 
metabolism. At a concentration of 2 M, both compounds turned out to be equally active 
inhibiting the CYP3A4 by 80 (21) and 71 % (23), respectively and CYP2D6 by 55 (21) and 56 
% (23), respectively. The relatively high inhibition of these enzymes has to be taken into 
consideration in the process of further developing these compounds but should not have an 
impact on the proof of concept in-vitro. 
The pharmacokinetic profiles of compound 21 and 23 were determined in rats after oral 
administration in a cassette dosing approach. Each group consisted of 4 male rats and the 
compounds were administered in doses of 10 mg/kg. Plasma samples were collected over 24 h 
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and plasma concentrations were determined by HPLC-MS/MS. The pharmacokinetic 
parameters are presented in Table 7. The maximal concentration (Cmax obs) as well as the AUC-
value is higher for compound 23 (Cmax= 1388.2 ng/mL, AUC= 19407 ng/mL) than for 
compound 21 (Cmax= 905.0 ng/mL, AUC= 12275 ng/mL). The maximal plasma concentration 
(tmax obs) for compounds 21 and 23 was reached after 4.0 and 8.0 h, respectively, after oral 
administration. These data show that both compounds exhibit excellent pharmacokinetic 
properties in the rat and might therefore be good candidates for further experiments in disease-
oriented rat models. 
 
Table 7: pharmacokinetic parameters of compounds 21 and 23 in male rats after oral 
application (10 mg/kg) 
 
parametersa cmpd 21 23 
Cmax obs (ng/mL) 905.0 1388.2 
Cz (ng/mL) 43.3 24.9 
tmax obs (h) 4.0 8.0 
tz (h) 24.0 24.0 
t1/2z (h) 3.8 2.7 
AUC0-∞ (ng/mL) 12275 19407 
 
a Cmax obs, maximal measured concentration; Cz, last analytical quantifiable concentration; 
tmax obs, time to reach the maximum measured concentration; tz, time of the last sample which has an analytical 
quantifiable concentration; t1/2z, half-life of the terminal slope of a concentration time curve; AUC0-∞, area under 
the concentration- time curve extrapolated to infinity. 
 
Computational chemistry 
 
Molecular modelling 
 
From the biological results it became apparent that introduction of a fluorine atom in ortho-
position to the para-OH phenyl thiophene structure (compound 23) led to a significant increase 
in the 17-HSD1 inhibitory activity. To get an insight into the binding mode of this compound 
and to better understand the favourable interactions achieved by this inhibitor in the active site, 
computational studies were performed by means of the docking software GOLDv3.2 and 
Autodock 4.1. 
The choice of the 3D-structure of the enzyme, i.e. crystal structure, used for the docking 
studies is crucial for obtaining reliable results. It was decided to focus on X-ray structures of 
17-HSD1 having a high resolution and showing a ternary complex (to get closer to the in vivo 
3D-enzyme structure). Three structures appeared to fulfil the criteria: 1FDT and 1A27 both 
describing the ternary complex: enzyme-E2-NADP+ and 1I5R, describing the binary complex: 
enzyme-steroidal hybride inhibitor (HYC), the latter being an adenosine moiety linked to an E2 
core via a C9-linker. These three crystal structures differ mainly in the location of the amino 
acids belonging to the flexible loop G’F (Pro187-Pro200). Since this loop borders both the 
SUB and the COF, its conformational variations strongly influence the size of both binding 
cavities. It is therefore important to take care of the position of this loop in the structures used 
for the docking studies.  
In the X-ray structure 1FDT, the residues 187-200 are not well resolved, but two plausible 
conformations for the loop (noted 1FDT-A and 1FDT-B) have been described33 The backbones 
of these two loops are similar (RMSD of ~ 1 Å), while the main difference is given by the 
orientation of the sidechains, mainly concerning the four amino acids Phe192, Met193, Glu194 
and Lys195. In 1FDT-A, Phe192 and Met193 are turned toward the outer part of the enzyme 
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while Glu194 and Lys195 are oriented toward the substrate and the cofactor (extending the 
substrate binding site = open conformation). On the other hand, in 1FDT-B these two couples 
of residues show a reversed orientation limiting length and volume of the steroid binding site 
compared to 1FDT-A (= closed conformation). Although others21 have only considered 1FDT-
B, we decided to investigate both conformations of this loop.  
Interestingly, the flexible loop in 1A27 shows a comparable geometry as observed in 1FDT-B, 
with Phe192 and Met193 oriented toward the nicotinamide moiety, also restricting the space in 
the substrate binding site. In case of 1I5R, the loop is shifted in direction of the cofactor, 
resulting in a different conformation compared to both 1FDT-A and 1FDT-B. Although, like 
for 1FDT-A, it extends the SUB.  
Compound 23 was docked with NADPH into four different X-ray structures: 1FDT-A, 1FDT-
B, 1A27 and 1I5R. Two different binding modes were observed for compound 23: in case of 
1FDT-B and 1A27, the inhibitor is located exclusively in the steroid binding site (Figure 1) 
adopting a similar orientation as previously described for the bis(hydroxyphenyl) oxazole B26 
(chart 1) while for 1FDT-A and 1I5R, the inhibitor is located in between the steroid and the 
cofactor binding sites, interacting with the nicotinamide moiety. In the following, this binding 
mode will be named as alternative binding mode (Figure 2). 
 
 
 
Figure 1. docking complex between 17-HSD1 (X-ray 1FDT-B) and compound 23 (blue; 
SUB binding mode). NADPH, interacting residues and ribbon rendered tertiary structure of the 
active site are shown. Residues of the flexible loop are rendered in sticks and colored in 
yellow. Hydrogen bonds and - stackings (and hydrophobic interactions) are drawn in yellow 
and blue dashed lines, respectively. For comparison, E2 is depicted in magenta lines. Figures 
were generated with Pymol (http://www.pymol.org). 
 
In case of the steroidal binding mode (1FDT-B and 1A27, Figure 1) the following specific 
interactions can be observed: hydrogen bond interactions between the meta-hydroxy group of 
23 and Ser142/Tyr155 (dO-O= 2.6 Å for both amino acids) and between the para-OH group and 
His221/Glu282 (dO-N= 2.8 Å and dO-O= 3.8 Å, Figure 1). Additionally, hydrophobic 
interactions and - stackings (Phe226, Phe259) are also involved. 
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Figure 2. docking complex between 17-HSD1 (X-ray 1FDT-A) and compound 23 (green; 
alternative binding mode). NADPH, interacting residues and ribbon rendered tertiary structure 
of the active site are shown. Residues of the flexible loop are rendered in sticks and colored in 
blue. Hydrogen bonds and - stackings (and hydrophobic interactions) are drawn in yellow 
and blue dashed lines, respectively. For comparison, E2 is depicted in magenta lines. 
 
In the alternative binding mode obtained using 1FDT-A and 1I5R (Figure 2), compound 23 is 
also stabilized by hydrogen bond interactions: the meta-OH group forms a strong H-bond with 
the phosphate group of the cofactor (dO-O= 2.9 Å). The fluorine atom could establish halogen 
bonds with the backbone -NH- of Val143 and Gly144 (dF-N= 3.2 Å and 3.8 Å, respectively), in 
addition to a halogen bond with the OH-group of Ser142 (dF-O= 3.5 Å) which is involved in the 
catalytic process. Further, the para-OH points perpendicular toward Phe259 (dO-centroid= 4.5 Å) 
indicating a possible OH- interaction. This could explain the importance of this group 
observed in the SARs. Moreover, strong -stacking interactions seem to stabilize the 
inhibitor in this binding mode: between the meta-OHphenyl-thiophene moiety and the 
nicotineamide part of the cofactor (parallel-displaced configuration; distance between the two 
ring centers, 4.3 Å) and between the para-OH-phenyl-thiophene moiety and Phe226 (T-shape 
conformation; closest C-C contact distance 3.7 Å). Moreover, electrostatic interactions 
between the sulfur atom of the heterocycle with the surrounding amino acids like Tyr155 and 
Ser142 might also play a role as described.41 
The results presented so far suggest that both binding modes have to be considered as possible 
for this class of inhibitors. They depend mainly on the orientation of the flexible loop. There is 
only one conformation of the loop leading to a steroidal binding mode (1FDT-B/1A27). In case 
of 1FDT-A/1I5R the pose showing the alternative binding mode is obtained using two X-ray 
structures having two different conformations of the loop. Unfortunately, due to the almost 
identical scoring function values observed for both poses with the docking programs (Gold and 
Autodock), it was not possible to determine which model (1FDT-A/1I5R or 1FDT-B/1A27) is 
the most appropriate to describe the interactions between the inhibitor and the enzyme and 
therefore which is the most plausible binding mode.  
Comparing both poses obtained by docking of 23 in 1FDT-A and 1FDT-B shows that there is a 
common area in the neighbourhood of the catalytic tetrade which corresponds to the D-ring of 
the enzyme-substrate complex (Figure in Supporting Information). 
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Molecular Electrostatic Potential (MEP) 
 
Recently we reported on the influence of the electronic density (MEP maps, “semi-QMAR”) 
on the potency of the inhibitors in this class of compounds.27 The 3D-structures of the 
inhibitors were virtually divided into three areas and a given optimal range of ESP values (in 
Hartree) was determined for each region (-1.7 to -1.2 × 10-2 for I, -1.6 to -0.9 × 10-2 for II and -
1.2 to -0.5 × 10-2 for III). The MEPs of compound 23 were calculated as shown in Figure 3. 
The molecular ESP distribution observed (-1.8 to -1.2 × 10-2 for I, -1.6 to -0.8 × 10-2 for II and 
-1.1 to -0.4 × 10-2 for III) fitted well to the optimal ranges identified previously, confirming the 
correlation between the ESP range and the potency of the compounds. The MEP maps of the 
natural substrate E1 and of E2 were also calculated (Figure 3) and compared to the one of 23. 
The finding that the ESP distribution of 23 and E2/E1 is very different might be an indication 
that compound 23 does not bind in the same way as the steroid. 
 
 
 
Figure 3. structures and MEP maps of both ventral (steroidal -side) and dorsal (steroidal -
side) views of truncated NADPH (A), thiophene 23 (B), E1 (C) and E2 (D). MEP surfaces 
were plotted with GaussView 3.09. 
 
According to the alternative binding mode, the meta-hydroxyphenyl thiophene part of 23 
overlaps with the nicotinamide part of the cofactor and forms stabilizing - interactions. The 
ESP distribution of these two entities should therefore show complementarity. To get an 
insight into this, the MEP map of a truncated NADPH –the counterpart of the meta-OHphenyl-
thiophene moiety- was calculated by ab initio methods. As it can be seen in Figure 3 a certain 
complementarity was observed. The NADPH MEP maps give the explanation for the 
observation27 that a strong polarization between the vertex and the base of the central ring of 
the inhibitors is negative for binding. Positive ESP values on the vertex side lead to repulsion 
effects with the nicotinamide and therefore reduce the inhibitory activity. This finding indicates 
that this class of compound might bind according to the alternative binding mode (Figure 2). 
However, this hypothesis needs to be further investigated. 
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Discussion and Conclusion 
 
Structural optimizations of compound 1 led to the discovery of new substituted 2,5-
bis(hydroxyphenyl)thiophene derivatives: the fluorinated 23 and the methylated 21 being the 
most active and selective inhibitors identified.  
From a previous work in this class of compounds27 it was demonstrated that removal of one of 
the two hydroxyphenyl moieties is detrimental for the activity. In this paper it was shown that 
replacement of the para-OH function by a bioisoteric group like F, NH2, SH, CN leads to a 
drop of activity. The lack of hydrogen donating properties of the fluoro and cyano substituents 
might not be the only reason for this decrease in activity as the amino and the thiol derivatives 
are also less active than the parent compound 1. Interestingly, the omission of a C1-linker 
between the methylsulfonamide moiety and the phenyl ring (compound 9) resulted in an 
increase of potency. Deprivation of electrons from the phenyl ring, obviously is necessary for a 
good inhibition. The relatively high activity observed for compound 11 (IC50= 350 nM) 
especially compared to compound 9 (IC50= 523 nM) demonstrates that in the protein there is 
some space available in this position for a bulky substituent. Furthermore, the tolyl group 
might also be involved in the stabilization of the inhibitor in the binding site, establishing -
stacking interactions with appropriate amino acid residues present in this region. 
With the aim to increase the activity and the selectivity in this class of compound, substituents 
were introduced on the 2,5-bis(hydroxyphenyl)thiophenes 1 and 7. This was successful for 
compound 15 (IC50= 119 nM vs. 7, IC50= 216 nM). Apparently, the formation of an additional 
hydrogen bond is responsible for this increase in inhibitory activity, while a pure -stacking 
interaction as supposed for compound 14 is not sufficient. The 2,5-disubstituted thiophenes 12 
and 15 differ only in the position of one hydroxy group (para: compound 12, meta: compound 
15). The fact that compound 15 shows a much higher activity (IC50= 119 nM vs. 12, IC50> 
1000 nM) indicates that only in case of 15 the geometry of the OH groups is acceptable for a 
reasonable interaction. It demonstrates, as observed already,23, 26 a sharp SAR and a reduced 
flexibility in this region of the active site. 
The trisubstituted compound 14 bearing a phenyl substituent at the thiophene differs from the 
triazole A28 (Chart 2) only in the nature of the heterocycle. The following comparisons 
highlight the importance of the heterocycle for the potency of the molecules: inactive 
compound A vs. thiophene 14 (IC50= 493 nM), thiophene 21 (IC50= 46 nM) vs. thiazole 37 
(IC50= 143 nM) and thiophene 23 (IC50= 8 nM) vs. benzene 39 (IC50= 123 nM). It becomes 
apparent that the thiophene ring is the most appropriate heterocycle for high inhibitory activity. 
Provided that all compounds bind according to the same binding mode, there are different 
explanations for these results: 1. the presence of one or several nitrogens in this area of the 
enzyme is not well tolerated, 2. the absence of the sulfur leads to an inadequate repartition of 
the electron density in the molecule, 3. a reduced flexibility in the binding site is responsible 
that the enzyme can not adjust its geometry to the different hydroxyphenyl moieties (depending 
on the heterocycle, the angles between the phenyl-OHs are different). 
A high increase in activity and selectivity could be reached by introduction of substituents into 
the hydroxyphenyl moiety, especially when the substituent is located ortho- of the para-
hydroxyphenyl group (compounds 21 to 24). Not all substituents are equally well tolerated: 
there is no space available for a phenyl group (compound 25). An additional OH group 
(compound 22) is obviously not able to establish specific interactions while small lipophilic 
substituents (methyl, compounds 21; fluorine, compound 23 and trifluoromethyl, compound 
24) are enhancing the activity. There is enough space in this region of the enzyme to introduce 
a flexible chain (26) but conjugation seems to be necessary to achieve a higher activity as 
already observed with the tolylsulfonamide substituent (compound 11).  
The positive influence of the fluorine atom has often been demonstrated in medicinal 
chemistry42-44 and was also proven in this study with compound 23 (IC50 = 8 nM). The position 
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of the fluorine is decisive for an increase in activity: it has to be in meta-position (17 and 23). 
Highest activity was achieved in ortho- of the hydroxy group (compound 23). This indicates 
that either direct interactions of the fluorine with amino acid residues in this region of the 
active site or the increase of acidity of the neighbouring OH groups might be responsible for 
this effect. 
Introduction of a second fluorine atom into this fluorohydroxyphenyl ring (compound 31) does 
not enhance the activity suggesting that the effects of the fluorine are not additional. A second 
fluorine was also added to the other hydroxyphenyl moiety (in ortho- and meta- of the meta-
OH group) leading to compounds 29 and 30. However, no enhancement of the activity 
compared to the monofluorinated 23 was observed indicating that there are no specific 
interactions of the second fluoro substituent. 
A close look at the X-ray structures of 17-HSD1 crystallized in presence of different steroidal 
ligands showed that the flexible loop (amino acids 187-200) can adopt different geometries 
depending on the nature of the ligand and on the absence or presence of the cofactor in the 
catalytic region. It indicates that some parts of the enzyme can adapt their geometry to the 
molecule present in the active site in order to stabilize it. However, other parts are rigid, 
explaining the sharp SAR observed in this paper and previously.26, 27 
Two plausible conformations of the loop in the ternary complex enzyme-E2-NADP+, PDB 
code: 1FDT, have been described (1FDT-A, 1FDT-B). We have shown that both can be used 
for docking studies. In case of 1FDT-A the substrate binding site is extended, enhancing the 
volume of the active site. It is therefore a good model to evaluate an alternative binding mode 
for inhibitors which are larger than the steroid. A binding mode as observed for steroids in the 
X-ray structures was found when the loop closes the SUB (1FDT-B). Surprisingly, when the 
inhibitors were docked to the protein with the loop in the open conformation, they interact with 
the nicotinamide part of the cofactor. MEP calculations showed a certain complementarity 
between the electronic density of 23 and of the nicotinamide moiety of the cofactor indicating 
that this alternative binding mode is not only plausible, it might be the one which is more 
likely.  
Up to now, designing compounds as potential 17-HSD1 inhibitors, several groups35, 45-47 tried 
to mimic the cofactor. Our finding of the above mentioned alternative binding mode makes 
another strategy very promising: the cofactor, which is likely to be present in the active site 
when the inhibitor is entering, could be used as partner to achieve additional interactions rather 
than trying to displace it.  
The most potent 17-HSD1 inhibitors 21 and 23 exhibit a higher selectivity toward 17-HSD2 
compared to parent compound, (selectivity factors 49 and 118, respectively vs. 28 for 1). This 
indicates that the amino acids close to the CH3 or F substituents must have different properties 
in the two 17-HSD enzymes, which could be further exploited to increase selectivity.  
The most potent inhibitors show only marginal to very little affinity to the ER and no 
stimulation of cell proliferation (agonistic effect) in the ER-positive T-47D cell line could be 
observed. The weak affinity of compound 23 for ER may not be critical as it is reported that 
ER exhibits anti-proliferative effects in breast cancer cells.48 
Compound 23 might be used in an appropriate animal model to prove the concept of 17-
HSD1 inhibition with non-steroidal inhibitors. This compound shows a good pharmacokinetic 
profile in rats. 
In this paper, we described the synthesis of substituted bis(hydroxyphenyl)thiophenes, 
thiazoles and benzenes as inhibitors of 17-HSD1 and the evaluation of their biological 
properties. The most promising compounds of this study, 21 and 23, exhibit high selectivity 
toward 17-HSD2, marginal binding to ER and excellent pharmacokinetic profiles in rats 
after peroral application. These new compounds provide useful tools to validate 17-HSD1 as 
a target for the treatment of estrogen-dependent diseases. 
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Experimental section 
 
Chemical methods 
 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, 
Lancaster, Roth, Merck or Fluka and were used without purification.  
Column chromatography (CC) was performed on silica gel (70-200 m) coated with silica, preparative 
thin layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and 
reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel).  
IR spectra were recorded on a Bruker Vector 33 spectrometer (neat sample). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in  (parts per million: ppm), by reference to the hydrogenated residues of 
deuteriated solvent as internal standard (CDCl3:  = 7.24 ppm (1H NMR) and  = 77 ppm (13C NMR), 
CD3OD:  = 3.35 ppm (1H NMR) and  = 49.3 ppm (13C NMR), CD3COCD3:  = 2.05 ppm (1H NMR) 
and  = 29.9 ppm (13C NMR), CD3SOCD3:  = 2.50 ppm (1H NMR) and  = 39.5 ppm (13C NMR)). 
Signals are described as s, d, t, q, dd, m, dt for singlet, doublet, triplet, quadruplet, doublet of doublets, 
multiplet and doublet of triplets, respectively. All coupling constants (J) are given in hertz (Hz). 
Mass spectra (ESI) were recorded on a TSQ Quantum (Thermofischer) instrument. Elemental analyses 
were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland University. 
 
Compounds 2-bromo-5-(3-methoxyphenyl)thiophene (1b),27 2-(3-methoxyphenyl)-5-(4-
methoxyphenyl)thiophene (1a),27 3-[5-(4-hydroxyphenyl)-2-thienyl]phenol (1),27 2-(3-methoxyphenyl)-
5-phenylthiophene (2a),27 3-(5-phenyl-2-thienyl)phenol (2),27 2,5-bis(3-methoxyphenyl)thiophene 
(7a),27 3,3'-thiene-2,5-diyldiphenol (7),27 2-bromo-5-(4-methoxyphenyl)thiophene (16c),27 4-bromo-2-
iodo-1-methoxy-benzene (25d), 5-bromo-2-methoxybiphenyl (25c),50 [6-methoxy-1,1'-biphenyl-3-
yl]boronic acid (25b),50 [3-(hydroxymethyl)-4-methoxyphenyl]-boronic acid (26d),51 4-bromo-2-(3-
methoxyphenyl)thiophene (33b),27 2-(3-methoxyphenyl)-4-(4-methoxyphenyl)thiophene (33a),27 3-[4-
(4-hydroxyphenyl)-2-thienyl]phenol (29),27 5-bromo-2-(3-methoxyphenyl)-1,3-thiazole (36b),27 2-(3-
methoxyphenyl)-5-(4-methoxyphenyl)-1,3-thiazole (36a),27 3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-
yl]phenol (36),27 4'-bromo-3-methoxybiphenyl (38b),27 3,4''-dimethoxy-1,1':4',1''-terphenyl (38a),27 
1,1':4',1''-terphenyl-3,4''-diol (38),27 3,3''-dimethoxy-1,1':4',1''-terphenyl (40a)27 and 1,1':4',1''-terphenyl-
3,3''-diol (40)27 were prepared following described procedures. 
 
General procedure for Suzuki coupling 
Method A 
A mixture of aryl bromide (1 eq), aryl boronic acid (1.2 eq), caesium carbonate (2.2 eq) and 
tetrakis(triphenylphosphine) palladium (0.01 eq) was suspended in an oxygen free DME/EtOH/water 
(1:1:1) solution. The reaction mixture was exposed to microwave irradiation (15 min, 150 W, 150 °C, 
15 bars). After cooling to rt, water was added and the aqueous layer was extracted with ethyl acetate. 
The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
concentrated to dryness. The product was purified by column chromatography (CC). 
 
Method B: 
A mixture of arylbromide (1 eq), aryl boronic acid (1 eq), sodium carbonate (2 eq) and 
tetrakis(triphenylphosphine) palladium (0.05 eq) in an oxygen free toluene/water (1:1) solution was 
stirred at 100 °C for 20 h under nitrogen atmosphere. The reaction mixture was cooled to rt. The 
aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC. 
 
General procedure for ether cleavage 
Method C:  
To a solution of methoxyphenyl derivative (1 eq) in dry dichloromethane at -78 °C (dry ice/acetone 
bath), boron tribromide in dichloromethane (1 M, 3 eq per methoxy function) was added dropwise. The 
reaction mixture was stirred for 20 h at rt under nitrogen atmosphere. Water was added to quench the 
reaction, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were 
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washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The product was 
purified by preparative thin layer chromatography (TLC). 
 
2-(4-Fluorophenyl)-5-(3-methoxyphenyl)thiophene (3a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 4-fluorophenylboronic 
acid (94 mg, 0.67 mmol), caesium carbonate (383 mg, 1.24 mmol) and tetrakis(triphenylphosphine) 
palladium (6.4 mg, 5.6 mol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 9:1); yield: 75 % (120 mg). 
 
3-[5-(4-Fluorophenyl)-2-thienyl]phenol (3). The title compound was prepared by reaction of 2-(4-
fluorophenyl)-5-(3-methoxyphenyl)thiophene (3a) (80 mg, 0.28 mmol) and boron tribromide (0.84 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); 
yield: 68 % (52 mg); MS (ESI): 270 (M+H)+; Anal. (C16H11FOS) C, H, N. 
 
4-[5-(3-Methoxyphenyl)-2-thienyl]aniline (4a). The title compound was prepared by reaction of 2-
bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 4-aminophenylboronic acid (92 mg, 
0.67 mmol), caesium carbonate (383 mg, 1.24 mmol) and tetrakis(triphenylphosphine) palladium (6.4 
mg, 5.6 mol) according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); 
yield: 63 % (100 mg).  
 
3-[5-(4-Aminophenyl)-2-thienyl]phenol (4). The title compound was prepared by reaction of 4-[5-(3-
methoxyphenyl)-2-thienyl]aniline (4a) (100 mg, 0.37 mmol) and boron tribromide (1.11 mmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 
82 % (82 mg); MS (ESI): 268 (M+H)+; Anal. (C16H13NOS) C, H, N. 
 
4-[5-(3-Methoxyphenyl)-2-thienyl]benzenethiol (5a). The title compound was prepared by reaction of 
2-bromo-5-(3-methoxyphenyl)thiophene (1b) (250 mg, 0.93 mmol), 4-mercaptophenylboronic acid 
(172 mg, 1.12 mmol), caesium carbonate (636 mg, 2.05 mmol) and tetrakis(triphenylphosphine) 
palladium (10.8 mg, 9.3 mol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 7:3); yield: 61 % (160 mg). 
 
3-[5-(4-Sulfanylphenyl)-2-thienyl]phenol (5). The title compound was prepared by reaction of 4-[5-
(3-methoxyphenyl)-2-thienyl]benzenethiol (5a) (150 mg, 0.50 mmol) and boron tribromide (1.50 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); 
yield: 81 % (115 mg); MS (ESI): 285 (M+H)+; Anal. (C16H12OS2) C, H, N. 
 
4-[5-(3-Methoxyphenyl)-2-thienyl]benzonitrile (6a). The title compound was prepared by reaction by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (200 mg, 0.74 mmol), 4-cyanophenylboronic 
acid (131 mg, 0.89 mmol), caesium carbonate (508 mg, 1.64 mmol) and tetrakis(triphenylphosphine) 
palladium (8.5 mg, 7.4 mol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 7:3); yield: 27 % (60 mg).  
 
4-[5-(3-Hydroxyphenyl)-2-thienyl]benzonitrile (6). The title compound was prepared by reaction of 
4-[5-(3-methoxyphenyl)-2-thienyl]benzonitrile (6a) (42 mg, 0.14 mmol) and boron tribromide (0.42 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 6:4); 
yield: 62 % (25 mg); MS (APCI): 277 (M)+; Anal. (C17H11NOS) C, H, N. 
 
2-(3-Fluorophenyl)-5-(3-methoxyphenyl)thiophene (8a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3-fluorophenylboronic 
acid (94 mg, 0.67 mmol), caesium carbonate (381 mg, 1.22 mmol) and tetrakis(triphenylphosphine) 
palladium (6.5 mg, 5.6 mol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 9:1); yield: 82 % (130 mg).  
  
3-[5-(3-Fluorophenyl)-2-thienyl]phenol (8). The title compound was prepared by reaction of 2-(3-
fluorophenyl)-5-(3-methoxyphenyl)thiophene (8a) (130 mg, 0.45 mmol) and boron tribromide (1.35 
mmol) according to method C. The product was purified by preparative TLC 
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(dichloromethane/methanol 99:1); yield: 66 % (82 mg); MS (ESI): 271 (M+H)+; Anal. (C16H11FOS) C, 
H, N.  
 
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (160 mg, 0.60 mmol), 3-
methylsulfonylaminophenylboronic acid (155 mg, 0.72 mmol), caesium carbonate (410 mg, 1.32 mmol) 
and tetrakis(triphenylphosphine) palladium (6.9 mg, 6.0 mol) according to method A. The product was 
purified by CC (petroleum ether/ethyl acetate 6:4); yield: 75 % (150 mg). 
 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9). The title compound was 
prepared by reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9a) (150 
mg, 0.44 mmol) and boron tribromide (1.32 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 61 % (92 mg); MS (ESI): 346 (M+H)+; Anal. 
(C17H15NO3S2) C, H, N 
 
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3-
[(methylsulphonylamino)methyl]benzeneboronic acid (153 mg, 0.67 mmol), caesium carbonate (382 
mg, 1.23 mmol) and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 mol) according to method A. 
The product was purified by CC (petroleum ether/ethyl acetate 8:2); yield: 58 % (122 mg). 
 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10). The title compound was 
prepared by reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10a) (122 
mg, 0.37 mmol) and boron tribromide (1.11 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 33 % (44 mg); MS (ESI): 360 (M+H)+; Anal. 
(C18H17NO3S2) C, H, N. 
 
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]phenyl)-4-methylbenzenesulfonamide (11a). The title 
compound was prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 
mmol), [3-[[(4-methylphenyl)sulfonyl]amino]phenyl]-boronic acid (195 mg, 0.67 mmol), caesium 
carbonate (383 mg, 1.23 mmol) and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 mol) 
according to method A. The product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 88 
% (214 mg). 
 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]phenyl)-4-methylbenzenesulfonamide (11). The title 
compound was prepared by reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]phenyl)-4-
methylbenzenesulfonamide (11a) (214 mg, 0.49 mmol) and boron tribromide (1.47 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 75 % (156 
mg); MS (APCI): 421 (M)+; Anal. (C23H19NO3S2) C, H, N. 
 
3,5-Dibromo-2-(3-methoxyphenyl)thiophene (12c). The title compound was prepared by reaction of 
2,3,5-tribromothiophene (100 mg, 0.31 mmol), 3-methoxybenzeneboronic acid (46 mg, 0.31 mmol), 
sodium carbonate (67 mg, 0.62 mmol) and tetrakis(triphenylphosphine) palladium (17.9 mg, 15.5 mol) 
according to method B heating the reaction 4 h instead of 20 h. The product was purified by CC 
(petroleum ether/ethyl acetate 9:1); yield: 23 % (25 mg). 
 
3-Bromo-2-(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12b). The title compound was 
prepared by reaction of 3,5-dibromo-2-(3-methoxyphenyl)thiophene (12c) (500 mg, 1.43 mmol), 4-
methoxybenzeneboronic acid (268 mg, 1.72 mmol), sodium carbonate (333 mg, 3.15 mmol) and 
tetrakis(triphenylphosphine) palladium (82.6 mg, 71.5 mol) according to method B. The product was 
purified by CC (petroleum ether/ethyl acetate 9:1); yield: 52 % (278 mg). 
 
2,3-Bis(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12a). The title compound was prepared 
by reaction of 3-bromo-2-(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12b) (250 mg, 0.67 
mmol), 3-methoxybenzeneboronic acid (124 mg, 0.80 mmol), sodium carbonate (142 mg, 1.34 mmol) 
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and tetrakis(triphenylphosphine) palladium (38.7 mg, 33.5 mol) according to method B. The product 
was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 72 % (194 mg). 
 
3,3’-[5-(4-Hydroxyphenyl)thiene-2,3-diyl]diphenol (12). The title compound was prepared by 
reaction of 2,3-bis(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12a) (100 mg, 0.24 mmol) and 
boron tribromide (2.16 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 92 % (79 mg); MS (ESI): 359 (M-H)+; Anal. (C22H16O3S) C, H, N. 
 
3,3’-(3-Methylthiene-2,5-diyl]diphenol (13). The title compound was prepared by reaction of 2,5-
dibromo-3-methylthiophene (150 mg, 0.58 mmol), 3-hydroxybenzeneboronic acid (179 mg, 1.27 
mmol), caesium carbonate (868 mg, 2.79 mmol) and tetrakis(triphenylphosphine) palladium (6.7 mg, 
5.8 mol) according to method A. The product was purified by CC (hexane/ethyl acetate 4:6); yield: 45 
% (73 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, N. 
 
3-Bromo-2,5-bis(3-methoxyphenyl)thiophene (14b). The title compound was prepared by reaction of 
3,5-dibromo-2-(3-methoxyphenyl)thiophene (12c) (250 mg, 0.72 mmol), 3-methoxybenzeneboronic 
acid (134 mg, 0.86 mmol), sodium carbonate (148 mg, 1.44 mmol) and tetrakis(triphenylphosphine) 
palladium (41.6 mg, 36.0 mol) according to method B. The product was purified by CC (petroleum 
ether/ethyl acetate 9:1); yield: 72 % (194 mg). 
 
2,5-Bis(3-methoxyphenyl)-3-phenylthiophene (14a). The title compound was prepared by reaction of 
3-bromo-2,5-bis(3-methoxyphenyl)thiophene (14b) (102 mg, 0.27 mmol), benzeneboronic acid (38 mg, 
0.27 mmol), sodium carbonate (58 mg, 0.54 mmol) and tetrakis(triphenylphosphine) palladium (15.6 
mg, 13.5 mol) according to method B. The product was purified by CC (petroleum ether/ethyl acetate 
9:1); yield: 54 % (51 mg). 
 
3,3’-(3-Phenylthiene-2,5-diyl)diphenol (14). The title compound was prepared by reaction of 2,5-
bis(3-methoxyphenyl)-3-phenylthiophene (14a) (50 mg, 0.13 mmol) and boron tribromide (0.78 mmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 
53 % (49 mg); MS (ESI): 345 (M+H)+; Anal. (C22H16O2S) C, H, N. 
 
2,3,5-Tris(3-methoxyphenyl)thiophene (15a). The title compound was prepared by reaction of 3-
bromo-2,5-bis(3-methoxyphenyl)thiophene (14b) (102 mg, 0.27 mmol), 3-methoxybenzene boronic 
acid (42 mg, 0.27 mmol), sodium carbonate (58 mg, 0.54 mmol) and tetrakis(triphenylphosphine) 
palladium (15.6 mg, 13.5 mol) according to method B. The product was purified by CC (petroleum 
ether/ethyl acetate 9:1); yield: 34 % (37 mg). 
 
3,3’,3’’-Thiene-2,3,5-triyltriphenol (15). The title compound was prepared by reaction of 2,3,5-tris(3-
methoxyphenyl)thiophene (15a) (37 mg, 0.09 mmol) and boron tribromide (0.81 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 67 % (21 
mg); MS (ESI): 361 (M+H)+; Anal. (C22H16O3S) C, H, N. 
 
5-(4-Methoxyphenyl)-2-(boronic acid)thiophene (16b). To a solution of 2-bromo-5-(4-
methoxyphenyl)thiophene (16c) (100 mg, 0.37 mmol, 1 eq) in anhydrous THF cooled to -78 °C for 5 
min, n-BuLi (1.6 M in hexane, 0.28 mL, 0.44 mmol, 1.2 eq) was added dropwise and stirred at -78 °C. 
After 15 min, triethyl borate (0.37 mL, 2.22 mmol, 6 eq) was added at -78°C and the mixture was 
stirred for 2 h. After warming to rt, the crude material was acidified with 20 mL of a 1N hydrochloric 
acid solution. The aqueous layer was washed with ethyl acetate. The combined organic layers were 
dried over sodium sulfate, filtered and evaporated under reduced pressure. The title compound was not 
characterized and used without further purification. 
 
2-(3-Methoxyphenyl-5-methylphenyl)-5-(4-methoxyphenyl)thiophene (16a). The title compound 
was prepared by reaction of 1-bromo-3-methoxy-5-methylbenzene (150 mg, 0.74 mmol), [5-(4-
methoxyphenyl)-2-thienyl]-boronic acid (16b) (206 mg, 0.88 mmol), sodium carbonate (181 mg, 1.76 
mmol) and tetrakis(triphenylphosphine) palladium (42.7 mg, 37.0 mol) according to method B. The 
product was purified by CC (hexane/ethyl acetate 7:3); yield: 22 % (50 mg). 
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3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol (16). The title compound was prepared by 
reaction of 2-(3-methoxyphenyl-5-methylphenyl)-5-(4-methoxyphenyl)thiophene (16a) (50 mg, 0.16 
mmol) and boron tribromide (0.96 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 90 % (41 mg); MS (ESI): 281 (M-H)+; Anal. 
(C17H14O2S) C, H, N. 
 
2-(3-Fluoro-5-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (17a). The title compound was 
prepared by reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (200 mg, 0.75 mmol), 3-fluoro-
5-methoxybenzeneboronic acid (152 mg, 0.89 mmol), caesium carbonate (513 mg, 1.65 mmol) and 
tetrakis(triphenylphosphine) palladium (8.7 mg, 7.5 mol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 43 % (122 mg). 
 
3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol (17). The title compound was prepared by 
reaction of 2-(3-fluoro-5-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (17a) (100 mg, 0.32 mmol) 
and boron tribromide (1.92 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 7:3); yield: 88 % (80 mg); MS (APCI): 286 M+; Anal. (C16H11FO2S) C, H, 
N. 
 
5-[5-(4-Methoxyphenyl)-2-thienyl]-2-methylphenol (18a). The title compound was prepared by 
reaction of 5-bromo-2-methylphenol (250 mg, 1.34 mmol), [5-(4-methoxyphenyl)-2-thienyl]-boronic 
acid (16b) (690 mg, 2.95 mmol), caesium carbonate (914 mg, 2.94 mmol) and 
tetrakis(triphenylphosphine) palladium (15.5 mg, 13.4 mol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 47 % (193 mg). 
 
5-[5-(4-Hydroxyphenyl)-2-thienyl]-2-methylphenol (18). The title compound was prepared by 
reaction of 5-[5-(4-methoxyphenyl)-2-thienyl]-2-methylphenol (18a) (161 mg, 0.54 mmol) and boron 
tribromide (3.24 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 7:3); yield: 27 % (42 mg); MS (ESI): 283 (M+H)+; Anal. (C17H14O2S) C, H, N. 
 
2-(4-Fluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (19a). The title compound was 
prepared by reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (200 mg, 0.75 mmol), 4-fluoro-
3-methoxybenzeneboronic acid (152 mg, 0.89 mmol), caesium carbonate (553 mg, 1.78 mmol) and 
tetrakis(triphenylphosphine) palladium (8.7 mg, 7.5 mol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 49 % (149 mg). 
 
2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol (19). The title compound was prepared by 
reaction of 2-(4-fluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (19a) (100 mg, 0.32 mmol) 
and boron tribromide (1.92 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 7:3); yield: 88 % (80 mg); MS (ESI): 287 (M+H)+; Anal. (C16H11FO2S) C, 
H, N. 
 
2-(3,4-Dimethoxyphenyl)-5-(4-methoxyphenyl)thiophene (20a). The title compound was prepared by 
reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (195 mg, 0.73 mmol), 3,4-dimethoxybenzene 
boronic acid (160 mg, 0.88 mmol), caesium carbonate (500 mg, 1.61 mmol) and 
tetrakis(triphenylphosphine) palladium (8.4 mg, 7.3 mol) according to method A. The product was 
purified by CC (dichloromethane/methanol 99:1); yield: 46 % (119 mg). 
 
4-[5-(4-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol (20). The title compound was prepared by 
reaction of 2-(3,4-dimethoxyphenyl)-5-(4-methoxyphenyl)thiophene (20a) (100 mg, 0.31 mmol) and 
boron tribromide (2.79 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 17 % (49 mg); MS (ESI): 285 (M+H)+; Anal. (C16H12O3S) C, H, N. 
 
2-(4-Methoxy-3-methylphenyl)-5-(3-methoxyphenyl)thiophene (21a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (250 mg, 0.92 mmol), 3-methyl-
4-methoxybenzeneboronic acid (152.8 mg, 0.92 mmol), sodium carbonate (243 mg, 2.36 mmol) and 
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tetrakis(triphenylphosphine) palladium (53.1 mg, 46.0 mol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 54 % (154 mg). 
 
4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol (21). The title compound was prepared by 
reaction of 2-(4-methoxy-3-methylphenyl)-5-(3-methoxyphenyl)thiophene (21a) (100 mg, 0.32 mmol) 
and boron tribromide (1.92 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 6:4); yield: 79 % (72 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, 
N. 
 
2-(3,4-Dimethoxyphenyl)-5-(3-methoxyphenyl)thiophene (22a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (206 mg, 1.14 mmol), 3,4-
dimethoxybenzeneboronic acid (247 mg, 1.36 mmol), caesium carbonate (779 mg, 2.51 mmol) and 
tetrakis(triphenylphosphine) palladium (13.2 mg, 11.4 mol) according to method A. The product was 
purified by CC (dichloromethane/methanol 99:1); yield: 34 % (126 mg). 
 
4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol (22). The title compound was prepared by 
reaction of 2-(3,4-dimethoxyphenyl)-5-(3-methoxyphenyl)thiophene (22a) (100 mg, 0.32 mmol) and 
boron tribromide (2.88 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 6:4); yield: 61 % (56 mg); MS (ESI): 283 (M-H)+; Anal. (C16H12O3S) C, H, N. 
 
2-(3-Fluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (23a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (370 mg, 1.37 mmol), 3-fluoro-4-
methoxybenzeneboronic acid (255 mg, 1.50 mmol), caesium carbonate (717 mg, 3.01 mmol) and 
tetrakis(triphenylphosphine) palladium (15.8 mg, 13.7 mol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 98 % (421 mg). 
 
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol (23). The title compound was prepared by 
reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (23a) (240 mg, 0.76 mmol) 
and boron tribromide (4.56 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 1:1); yield: 90 % (195 mg); MS (ESI): 285 (M-H)+; Anal. (C16H11FO2S) C, 
H, N. 
 
2-(3-Methoxyphenyl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]thiophene (24a). The title compound 
was prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (408 mg, 1.51 mmol), 3-
trifluoromethyl-4-methoxybenzeneboronic acid (398 mg, 1.81 mmol), caesium carbonate (1033 mg, 
3.32 mmol) and tetrakis(triphenylphosphine) palladium (17.5 mg, 15.1 mol) according to method A. 
The product was purified by CC (hexane/ethyl acetate 7:3); yield: 75 % (412 mg). 
 
4-[5-(3-Hydroxyphenyl)-2-thienyl]-2-(trifluoromethyl)phenol (24). The title compound was prepared 
by reaction of 2-(3-methoxyphenyl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]thiophene (24a) (300 mg, 
0.82 mmol) and boron tribromide (4.95 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 98 % (272 mg); MS (ESI): 285 (M-H)+; Anal. 
(C17H11F3O2S) C, H, N. 
 
2-(6-Methoxybiphenyl-3-yl)-5-(3-methoxyphenyl)thiophene (25a). The title compound was prepared 
by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (287 mg, 1.07 mmol), [6-methoxy-1,1'-
biphenyl-3-yl]boronic acid (25b) (338 mg, 1.29 mmol), sodium carbonate (250 mg, 2.35 mmol) and 
tetrakis(triphenylphosphine) palladium (61.8 mg, 53.5 mol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 35 % (135 mg). 
 
5-[5-(3-Hydroxyphenyl)-2-thienyl]biphenyl-2-ol (25). The title compound was prepared by reaction 
of 2-(6-methoxybiphenyl-3-yl)-5-(3-methoxyphenyl)thiophene (25a) (100 mg, 0.26 mmol) and boron 
tribromide (1.56 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 88 % (81 mg); MS (ESI): 343 (M-H)+; Anal. (C22H16O2S) C, H, N. 
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[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]methanol (26c). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (408 mg, 1.51 mmol), [3-
(hydroxymethyl)-4-methoxyphenyl]-boronic acid (26d) (329 mg, 1.81 mmol), caesium carbonate (1032 
mg, 3.32 mmol) and tetrakis(triphenylphosphine) palladium (17.5 mg, 15.1 mol) according to method 
A. The product was purified by CC (hexane/ethyl acetate 8:2); yield: 12 % (59 mg).  
 
2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]benzaldehyde (26b). To a solution of [2-methoxy-5-
[5-(3-methoxyphenyl)-2-thienyl]phenyl]methanol (26c) (100 mg, 0.31 mmol, 1 eq) in dichloromethane, 
pyridium chlorochromate (66 mg, 0.31 mmol, 1 eq) was added in small portions over 5 min and stirred 
at rt. After 30 min, the reaction was quenched with water. The resulting organic layer was dried over 
sodium sulfate, filtered and concentrated to dryness. The title compound was not characterized and used 
in the next step without purification.  
 
Ethyl (2E)-3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]acrylate (26a). To a solution of 
sodium hydride (10.4 mg, 0.43 mmol, 1 eq) in anhydrous THF triethyl phosphonate (93 L, 0.46 mmol, 
1.1 eq) was added dropwise and stirred at rt. After 15 min, 2-methoxy-5-[5-(3-methoxyphenyl)-2-
thienyl]benzaldehyde (26b) (100 mg, 0.31 mmol, 0.6 eq) was added and stirred for 4 h at rt. To quench 
the reaction water was added and the resulting organic layer was washed with brine, dried over sodium 
sulfate, filtered, evaporated and purified by CC (hexane/ethyl acetate 7:3); yield: 98 % (120 mg).  
 
Ethyl (2E)-3-[2-hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]acrylate (26). The title 
compound was prepared by reaction of ethyl (2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-
thienyl]phenyl]acrylate (26a) (60 mg, 0.15 mmol) and boron tribromide (0.90 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 17 % (10 
mg); MS (APCI): 366 (M)+; Anal. (C21H18O4S) C, H, N. 
 
(2E)-3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27a). Ethyl 
(2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]acrylate (26a) (720 mg, 2.22 mmol, 1 eq) 
in a solution of THF/water (2:1), was refluxed for 20 h together with lithium hydroxide (320 mg, 13.33 
mmol, 6 eq). After cooling to rt, ether was added, the aqueous layer was acidified with hydrochloric 
acid 1N and washed with dichloromethane. The combined organic layers were dried over sodium 
sulfate, filtered and evaporated under reduced pressure. The resulting carboxylic acid was solubilized in 
dichloromethane (180 mg, 0.53 mmol, 1 eq) and refluxed for 20 h with EDCI (102 mg, 0.53 mmol, 1 
eq) and HOBt (72 mg, 0.53 mmol, 1 eq). After cooling to rt, the organic layer was washed with a 1.5 M 
sodium hydrogenocarbonate solution, brine, dried over sodium sulfate, evaporated under reduced 
pressure and purified by CC (hexane/ethyl acetate 7:3); yield: 51 % (120 mg); MS (ESI): 442 (M+H)+. 
 
(2E)-3-[2-Hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27).  
The title compound was prepared by reaction of (2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-
thienyl]phenyl]-N-phenylacrylamide (27a) (55 mg, 0.13 mmol) and boron tribromide (0.78 mmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 4:6); yield: 
31 % (17 mg); MS (ESI): 414 (M+H)+; Anal. (C25H19NO3S) C, H, N. 
 
3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylpropanamide (28a). (2E)-3-[2-
Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27a) (50 mg, 0.11 mmol, 1 
eq) was solubilized in thr mixture of THF/EtOH (1:1). After addition of palladium hydroxide (1.7 mg, 
0.01 mmol, 0.1 eq) the reaction was stirred at rt under nitrogen atmosphere for 20 h. The crude mixture 
was filtered and the organic layer was evaporated under reduced pressure; yield: quantitative. 
 
3-[2-Hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]-N-phenylpropanamide (28). The title 
compound was prepared by reaction of 3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-
phenylpropanamide (28a) (55 mg, 0.13 mmol) and boron tribromide (0.78 mmol) according to method 
C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 20 % (10 mg); MS 
(ESI): 416 (M+H)+; Anal. (C25H21NO3S) C, H, N. 
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2-Bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b). The title compound was prepared by 
reaction of 2,5-dibromothiophene (500 mg, 2.10 mmol), 3-fluoro-4-methoxybenzeneboronic acid (357 
mg, 2.10 mmol), sodium carbonate (432 mg, 4.20 mmol) and tetrakis(triphenylphosphine) palladium 
(121 mg, 1.05 mmol) according to method B. The product was purified by CC (hexane/ethyl acetate 
95:5); yield: 85 % (427 mg). 
 
2-(3-Fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (29a). The title compound 
was prepared by reaction of 2-bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b) (100 mg, 0.41 
mmol), 3-fluoro-5-methoxybenzeneboronic acid (85 mg, 0.50 mmol), caesium carbonate (280 mg, 0.90 
mmol) and tetrakis(triphenylphosphine) palladium (4.7 mg, 4.1 mol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 82 % (113 mg). 
 
2-Fluoro-4-[5-(3-fluoro-5-hydroxyphenyl)thien-2-yl]phenol (29). The title compound was prepared 
by reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (30a) (100 mg, 
0.30 mmol) and boron tribromide (1.80 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 6:4); yield: 38 % (35 mg); MS (APCI): 304 (M)+; Anal. 
(C16H10F2O2S) C, H, N. 
 
2-(3-Fluoro-4-methoxyphenyl)-5-(4-fluoro-3-methoxyphenyl)thiophene (30a). The title compound 
was prepared by reaction of 2-bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b) (100 mg, 0.41 
mmol), 4-fluoro-3-methoxybenzeneboronic acid (85 mg, 0.50 mmol), caesium carbonate (279 mg, 0.90 
mmol) and tetrakis(triphenylphosphine) palladium (4.7 mg, 4.1 mol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 72 % (100 mg). 
 
2-Fluoro-4-[5-(4-fluoro-3-hydroxyphenyl)thien-2-yl]phenol (30). The title compound was prepared 
by reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (30a) (100 mg, 
0.30 mmol) and boron tribromide (1.80 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 6:4); yield: 75 % (69 mg); MS (APCI): 304 (M)+; Anal. 
(C16H10F2O2S) C, H, N.  
 
2-(3,5-Difluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (31a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (430 mg, 1.60 mmol), 3,5-
difluoro-4-methoxybenzeneboronic acid (357 mg, 1.92 mmol), caesium carbonate (1094 mg, 3.52 
mmol) and tetrakis(triphenylphosphine) palladium (18.5 mg, 16.0 mol) according to method A. The 
product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 42 % (223 mg).  
 
2,6-Difluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol (31). The title compound was prepared by 
reaction of 2-(3,5-difluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (31a) (220 mg, 0.62 
mmol) and boron tribromide (3.72 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 5:5); yield: 10 % (18 mg); MS (ESI): 305 (M+H)+; Anal. 
(C16H10F2O2S) C, H, N. 
 
2-(3,4-Difluorophenyl)-5-(3-methoxyphenyl)thiophene (32a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3,4-
difluorobenzeneboronic acid (105 mg, 0.67 mmol), caesium carbonate (383 mg, 1.23 mmol) and 
tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 mol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 90 % (152 mg). 
 
3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol (32). The title compound was prepared by reaction of 2-
(3,4-difluorophenyl)-5-(3-methoxyphenyl)thiophene (32a) (120 mg, 0.40 mmol) and boron tribromide 
(1.20 mmol) according to method C. The product was purified by CC (dichloromethane/methanol 99:1); 
yield: 85 % (98 mg); MS (ESI): 289 (M+H)+; Anal. (C16H9F2OS) C, H, N. 
 
4-(4-Methoxy-3-methylphenyl)-2-(3-methoxyphenyl)thiophene (34a). The title compound was 
prepared by reaction of 4-bromo-2-(3-methoxyphenyl)thiophene (33b) (400 mg, 1.49 mmol), 3-methyl-
4-methoxybenzeneboronic acid (296 mg, 1.79 mmol), caesium carbonate (1019 mg, 3.27 mmol) and 
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tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 mol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 69 % (320 mg). 
 
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol (34). The title compound was prepared by 
reaction of 4-(4-methoxy-3-methylphenyl)-2-(3-methoxyphenyl)thiophene (34a) (180 mg, 0.58 mmol) 
and boron tribromide (3.48 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 1:1); yield: 54 % (88 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, 
N. 
 
4-(3-Fluoro-4-methoxyphenyl)-2-(3-methoxyphenyl)thiophene (35a). The title compound was 
prepared by reaction of 4-bromo-2-(3-methoxyphenyl)thiophene (33b) (400 mg, 1.49 mmol), 3-fluoro-
4-methoxybenzeneboronic acid (303 mg, 1.78 mmol), caesium carbonate (1019 mg, 3.30 mmol) and 
tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 mol) according to method A. The product was 
purified by CC (petroleum ether/ethyl acetate 9:1); yield: 80 % (403 mg). 
 
2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol (35). The title compound was prepared by 
reaction of 4-(3-fluoro-4-methoxyphenyl)-2-(3-methoxyphenyl)thiophene (35a) (400 mg, 1.27 mmol) 
and boron tribromide (7.63 mmol) according to method C. The product was purified by CC 
(dichloromethane/methanol 98:2); yield: 22 % (88 mg); MS (ESI): 287 (M-H)- 
 
4-(4-Methoxy-3-methylphenyl)-2-(3-methoxyphenyl)-1,3-thiazole (37a). The title compound was 
prepared by reaction of 5-bromo-2-(3-methoxyphenyl)-1,3-thiazole (36b) (402 mg, 1.49 mmol), 3-
methyl-4-methoxybenzeneboronic acid (247 mg, 1.79 mmol), caesium carbonate (1019 mg, 3.27 mmol) 
and tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 mol) according to method A. The product 
was purified by CC (hexane/ethyl acetate 7:3); yield: 69 % (320 mg). 
 
4-[2-(3-Hydroxyphenyl)-1,3-thiazol-5-yl]-2-methylphenol (37). The title compound was prepared by 
reaction of 4-(4-methoxy-3-methylphenyl)-2-(3-methoxyphenyl)-1,3-thiazole (37a) (80 mg, 0.26 mmol) 
and boron tribromide (1.56 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 3:7); yield: 16 % (11 mg), MS (ESI): 274 (M+H)+; Anal. (C16H13NO2S) C, 
H, N. 
 
3-Fluoro-3'',4-dimethoxy-1,1':4',1''-terphenyl (39a). The title compound was prepared by reaction of 
4'-bromo-3-methoxybiphenyl (38b) (175 mg, 0.67 mmol), 3-fluoro-4-methoxybenzeneboronic acid 
(136.7 mg, 0.88 mmol), caesium carbonate (457 mg, 1.47 mmol) and tetrakis(triphenylphosphine) 
palladium (7.7 mg, 6.7 mol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 98:2); yield: 58 % (117 mg). 
 
3''-Fluoro-1,1':4',1''-terphenyl-3,4''-diol (39). The title compound was prepared by reaction of 3-
fluoro-3'',4-dimethoxy-1,1':4',1''-terphenyl (39a) (115 mg, 0.37 mmol) and boron tribromide (2.22 
mmol) according to method C. The product was purified by preparative TLC 
(dichloromethane/methanol 99:1); yield: 62 % (65 mg); MS (ESI): 281 (M+H)+. 
 
3,3''-Dimethoxy-4-methyl-1,1':4',1''-terphenyl (41a). The title compound was prepared by reaction of 
4'-bromo-3-methoxybiphenyl (38b) (230 mg, 0.87 mmol), 4-methoxy-3-methylbenzeneboronic acid 
(172 mg, 1.04 mmol), caesium carbonate (595 mg, 1.91 mmol) and tetrakis(triphenylphosphine) 
palladium (10.1 mg, 8.7 mol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 98:2); yield: 53 % (140 mg). 
 
4-Methyl-1,1':4',1''-terphenyl-3,3''-diol (41). The title compound was prepared by reaction of 3,3''-
dimethoxy-4-methyl-1,1':4',1''-terphenyl (41a) (120 mg, 0.39 mmol) and boron tribromide (2.34 mmol) 
according to method C. The product was purified by preparative TLC (dichloromethane/methanol 
97:3); yield: 38 % (42 mg); MS (ESI): 277 (M+H)+.  
 
4-Fluoro-3,3''-dimethoxy-1,1':4',1''-terphenyl (42a). The title compound was prepared by reaction of 
4'-bromo-3-methoxybiphenyl (38b) (200 mg, 0.76 mmol), 4-fluoro-3-methoxybenzeneboronic acid 
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(154 mg, 0.91 mmol), caesium carbonate (520 mg, 1.67 mmol) and tetrakis(triphenylphosphine) 
palladium (8.8 mg, 7.6 mol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 9:1); yield: 75 % (175 mg). 
 
4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol (42). The title compound was prepared by reaction of 4-
fluoro-3,3''-dimethoxy-1,1':4',1''-terphenyl (42a) (175 mg, 0.57 mmol) and boron tribromide solution 
(3.42 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl 
acetate 1:1); yield: 63 % (100 mg); MS (ESI): 281 (M+H)+. 
 
Biological Methods 
 
[2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. Quickszint Flow 302 
scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17-HSD1 and 17-HSD2 were obtained from human placenta according to previously described 
procedures.35, 52, 53 Fresh human placenta was homogenized and centrifuged. The pellet fraction contains 
the microsomal 17-HSD2, while 17-HSD1 was obtained after precipitation with ammonium sulfate 
from the cytosolic fraction. 
 
1. Inhibition of 17-HSD1  
 
Inhibitory activities were evaluated by a well established method with minor modifications.54-56 Briefly, 
the enzyme preparation was incubated with NADH [500 µM] in the presence of potential inhibitors at 
37 °C in a phosphate buffer (50 mM) supplemented with 20 % of glycerol and EDTA (1mM). Inhibitor 
stock solutions were prepared in DMSO. Final concentration of DMSO was adjusted to 1 % in all 
samples. The enzymatic reaction was started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]- 
E1 (final concentration: 500 nM, 0.15 Ci). After 10 min, the incubation was stopped with HgCl2 and 
the mixture was extracted with ether. After evaporation, the steroids were dissolved in acetonitrile. E1 
and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 rp chromatography 
column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a HPLC-system (Agilent 
1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of the steroids were 
performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The conversion rate was 
calculated according to following equation: 100
1%2%
2%%  EE
Econversion . Each value was 
calculated from at least three independent experiments.  
 
2. Inhibition of 17β-HSD2 
 
The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 procedure. The microsomal 
fraction was incubated with NAD+ [1500 µM], test compound and a mixture of unlabelled- and [2, 4, 6, 
7-3H]-E2 (final concentration: 500 nM, 0.11 Ci) for 20 min at 37 °C. Further treatment of the samples 
and HPLC separation was carried out as mentioned above. 
 
3. ER affinity 
 
The binding affinity of select compounds to the ERα and ERβ was determined according to 
Zimmermann et al.57 Briefly, 0.25 pmol of ERα or ERβ, respectively, were incubated with [2, 4, 6, 7-
3H]-E2 (10 nM) and test compound for 1 h at rt. The potential inhibitors were dissolved in DMSO (5 % 
final concentration). Non-specific-binding was performed with diethylstilbestrol (10 µM). After 
incubation, ligand-receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 mL TE-
buffer). The formed complex was separated, washed and resuspended in ethanol. For radiodetection, 
scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were 
measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku). For determination of 
the relative binding affinity (RBA), inhibitor and E2 concentrations required to displace 50 % of the 
RESULTS  97 
 
receptor bound labelled E2 were determined. RBA values were calculated according to the following 
equation:      100
2%
50
50 
compoundIC
EICRBA . The RBA value for E2 was arbitrarily set at 100 %. 
 
4.Evaluation of the estrogenic activity using T-47D cells 
 
Phenol red-free medium was supplemented with sodium bicarbonate (2 g/L), streptomycin (100 
µg/mL), insuline zinc salt (10 µg/mL), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 
U/mL) and DCC-FCS 5% (v/v). RPMI 1640 (without phenol red) was used for the experiments. Cells 
were grown for 48 h in phenol red-free medium. Compound 21 wasadded at a final concentration of 
100 nM. Inhibitors and E2 were diluted in ethanol (final ethanol concentration was adjusted to 1%). As 
a positive control E2 was added at a final concentration of 0.1 nM. Ethanol was used as negative 
control. Medium was changed every two to three days and supplemented with the respective additive. 
After eight days of incubation, the cell viability was evaluated measuring the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT). The cleavage of MTT to a blue 
formazan by mitochondrial succinat-dehydrogenase was quantified spectrophotometrically at 590 nm as 
described by Denizot and Lang58 with minor modifications. The control proliferation was arbitrarily set 
at 1 and the stimulation induced by the inhibitor was calculated according to following equation:   
   %10012
1% 

inducedEionproliferat
inducedcompoundionproliferatnstimulatio . Each value is calculated as a 
mean value of at least three independent experiments 
 
5. Inhibition of human hepatic CYPs 
 
The commercially available P450 inhibition kits from BD GentestTM (Heidelberg, Germany) were used 
according to the instructions of the manufacturer. Compounds 21 and 23 were tested for inhibition of 
the following enzymes: CYP2D6 and 3A4. Percentage of inhibition at 2 M for compounds 21 and 23 
were determined. 
  
1. In-Vivo Pharmacokinetics 
 
Male Wistar rats weighing 300-330 g (Janvier France) were housed in a temperature- controlled room 
(20-22 °C) and maintained in a 12 h light/12 h dark cycle. Food and water were available ad libitum. 
They were anesthetized with a ketamine (135 mg/kg)/ xylyzine (10 mg/kg) mixture and cannulated with 
silicone tubing via the right jugular vein and attached to the skull with dental cement. Prior to the first 
blood sampling, animals were connected to a counterbalanced system and tubing to perform blood 
sampling in the freely moving rat.  
Compounds 21 and 23 were applied orally in a cassette dosing in 4 rats at the dose of 10 mg/kg body 
weight by using a feeding needle. The compounds were dissolved in a mixture labrasol/water (1:1) and 
given at a volume of 5mL/kg. Blood samples (0.2 mL) were taken at 0, 1, 2, 3, 4, 6, 8, 10 and 24 h 
postdose and collected in heparinised tubes. They were centrifuged at 3000g for 10 min, and plasma 
was harvested and kept at -20 °C until analyzed.  
HPLC-MS/MS analysis and quantification of the samples was carried out on a Surveyor-HPLC-system 
coupled with a TSQ Quantum (Thermo/Fisher) triple quadrupole mass spectrometer equipped with an 
electrospray interface (ESI).  
 
Computational Chemistry 
 
1. Molecular Modelling 
 
All molecular modelling studies were performed on Intel(R) P4 CPU 3.00 GHz running Linux CentOS 
5.2. The X-ray structures of 17-HSD1 (PDB-ID: 1A27, 1FDT and 1I5R) were obtained from the 
Protein Databank59 and further prepared using the BIOPOLYMER module of SYBYL v8.0 (Sybyl, 
Tripos Inc., St. Louis, Missouri, USA). Water molecules, E2 (or HYC for 1I5R) and sulfate ions were 
stripped from the PDB files and missing protein atoms were added and correct atom types set. Finally 
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hydrogen atoms and neutral end groups were added. All basic and acidic residues were considered 
protonated and deprotonated, respectively. Since almost all histidines are oriented toward the outer part 
of the enzyme, accessible for the surface, they were considered as protonated (HIP) after a prediction 
run made by MolProbity.60 For 1I5R the cofactor NADPH was merged into the enzyme after an 
accurate overlay with the hybrid inhibitor HYC and the X-rays 1A27 and 1FDT. Further, every crystal 
structure was minimized for 500 steps with the steepest descent minimizer as implemented in SYBYL 
with the backbone atoms kept at fixed positions in order to fix close contacts, followed by 2000 steps 
conjugate gradient minimization requested for an overall better starting structure. 
Inhibitor 23 was built with SYBYL and energy-minimized in MMFF94s force-field as implemented in 
Sybyl. Subsequently an ab-initio geometry optimizations was performed gas phase at the B3LYP/6-
311**G (d,p) level of density functional theory (DFT) by means of the Gaussian03 software,61, 62 in 
order to obtain the RESP charges of compound 23, thought to better perform in Autodock4. 
Two different softwares were used for docking studies: GOLDv3.263 and Autodock4,64, 65 using the 
graphical user interface AutoDockTools (ADT 1.5.2). Since both allow flexible docking of ligands, no 
conformational search was employed to the ligand structure. For both programs the compound 23 was 
docked in 50 independent genetic algorithm (GA) runs.  
GOLDv3.2: Active-site origin was set at the center of the steroid binding site, while the radius was set 
equal to 13 Å. The automatic active-site detection was switched on. Further, a slightly modified 
GOLDSCORE fitness function (increased scaling for hydrophobic contacts) was used and genetic 
algorithm default parameters were set as suggested by the GOLD authors.  
Autodock4: The docking area has been defined by a box, centered on the mass center of the CD-rings 
of the cocrystallized E2. Grids points of 60 × 70 × 74 with 0.375 Å spacing were calculated around the 
docking area for all the ligand atom types using AutoGrid4. The Lamarckian genetic algorithm local 
search (GALS) method was used. Each docking run was performed with a population size of 200. A 
mutation rate of 0.02 and a crossover rate of 0.8 were used to generate new docking trials for 
subsequent generations. The GALS method evaluates a population of possible docking solutions and 
propagates the most successful individuals from each generation into the next one.  
Both programs performed in a similar way, supporting the herein suggested binding modes. The quality 
of the docked poses was evaluated based mainly on visual inspection of the putative binding modes of 
the ligand, and secondly on the scoring functions, which give a good measure to discriminate between 
the found binding modes for one single X-ray conformation, but do not help us to compare the poses of 
different X-rays.  
 
2. MEP 
 
For selected compounds ab-initio geometry optimisations were performed gas phase at the B3LYP/6-
311**G (d,p) level of density functional theory (DFT) by means of the Gaussian03 software and the 
molecular electrostatics potential map (MEP) was plotted using GaussView3, the 3D molecular 
graphics package of Gaussian.66 These electrostatic potential surfaces were generated by mapping 6-
311G** electrostatic potentials onto surfaces of molecular electron density (isovalue = 0.0002e/Å). The 
MEP maps are color coded, where red stands for negative values (3.1*10-2 Hartree) and blue for 
positive ones (4.5*10-2 Hartree).  
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4. Discussion and Conclusion 
 
The main goal of this thesis was to develop a new class of non-steroidal highly potent and 
selective inhibitors of 17-hydroxysteroid dehydrogenase type 1 (17-HSD1) as suitable tools 
for in vivo application in order to afford new chemical entities able to improve the treatment of 
estrogen-dependent pathologies. 
Chapter 3.I reports about the discovery of compound I.6 and I.21 by optimizing a novel, in 
silico identified, core scaffold (I.5). Pharmacophore model derivation, hit identification, and 
optimization via the synthesis and biological evaluation of 21 benzothiazole derivatives were 
successfully performed. The pharmacophore model was generated by superimposing five 
diverse 17-HSD1 crystal structures (PDB-ID: 1equ, 1i5r, 3hb5, 1a27, 1dht) available in the 
Protein Data Bank and their corresponding cocrystallized steroidal ligands EQI, HYC, E2B, 
E2, and DHT, respectively. This new pharmacophore model enabled us to define 23 features of 
both the ligands and of the constant regions of the protein, involved in ligand-protein 
interaction. A small molecule in house library was screened through a partial match strategy: 
the molecules were left free to be placed into the pharmacophore and only virtual hits that 
cover at least six features were retained. The virtual hits were tested experimentally and [5-(2-
hydroxyethyl)-4-methyl-1,3-thiazol-2-yl](3-hydroxyphenyl)methanone) (I.51‡), which resulted 
to be the most potent one (17-HSD1 inhibition = 34 % at 1 M), was selected as starting point 
for further optimization. Interestingly, based on pharmacophore results, it was observed that 
the ethyl group in 5 position of the thiazole moiety of I.5 is placed where the steroidal B ring is 
located (corresponding to the feature HY2 as depicted in Figure 14A). 
 
 
 
Figure 14: Rigidification. Compound I.5 (A) and compound I.6 (B) mapped to the 
pharmacophore model (figure revised from Figure 5 of Chapter 3.I). 
 
Consequently, the rigidification was successfully applied to compound I.5 and led to the 
discovery of the highly potent benzothiazole I.6 (17-HSD1 IC50 = 44 nM). In addition to the 
fact that the decrease of freedom conformational degrees given by rigidification might be 
sufficient to explain the much higher potency of I.6 compared to I.5, further analysis of the 
surrounding aminoacid residues demonstrated that the phenyl ring of the benzothiazole moiety 
is at optimal distance (d = 4.8 Å) to undergo a cation- interaction with Arg258, which is not 
possible in the case of I.5 (see Figure 14). 
                                                 
‡For the sake of clarity, all compounds that are referred to chapter 3 are presented as a combination of a Roman 
numeral (I-III) and an Arabic numeral. The roman numeral indicates in which result part they are enclosed and 
the Arabic numeral corresponds to the compound number of the chapter. (e.g. I.9 is compound 9 described in 
chapter I) 
DISCUSSION AND CONCLUSION  - 104 - 
In the optimization process the carbonyl bridge of I.6 was varied using several linkers with 
different lengths, geometries and H-bonding properties. The 17-HSD1 inhibitory activity was 
found highly influenced by the nature of the linker: the comparison of inactive tetrahedral 
alcohol (I.7), methoxy (I.8), thiomethyl (I.9), methylene (I.10), and sulphonamide (I.22) with 
the active, planar carbonyl (I.6) and amide derivatives (I.18 and I.21) led us to conclude that a 
flat geometry of the linker is required for the activity (see Table 5). 
 
Table 5. Influence of linker´s geometry on 17-HSD1 inhibitory activity. 
 
 
 
Compound X R1 R2 HSD1a 
    % inhib. (1µM) IC50b (nM) 
I.6 CO m-OH OH 91 44 
I.7 CHOH m-OH OH 28 nd 
I.8 CHOCH3 m-OH OH 13 nd 
I.9 CHSCH3 p-OH OH ni nd 
I.10 CH2 p-OH OCH3 ni nd 
I.18 NHCO m-OH OH 40 nd 
I.21 CONH m-OH OH 83 243 
I.22 SO2NH m-OH OH ni nd 
 
a Human placenta, cytosolic fraction, substrate [3H]E1 + E1 [500 nM], cofactor NADH [500 μM]. b Mean values 
of three determinations, standard deviation less than 10 %. c nd: not determined. d ni: no inhibition. 
 
Based on pharmacophore results it was observed that the hydroxy-phenyl moieties of the 
two most active 17-HSD1 inhibitors described in chapter 3.I (I.6 and I.21) do not interact 
with the same area of the enzyme (see Figure 15). 
 
 
 
Figure 15. I.6 (dark orange) and I.21 (blue) mapped to the pharmacophore. 
 
The difference in activity between I.6 and I.21 is in agreement with the number of features 
covered by each compound (6 versus 5). Furthermore, concerning the binding modes 
similarities were observed between the previously described bicyclic substituted 
hydroxyphenylmethanone [126] 17-HSD1 inhibitors and I.6. These results were taken into 
account in the further optimization process (described in chapter 3.II). In order to evaluate the 
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protein-ligand interaction, the ligands of the different X-ray structures studied were replaced by 
compound I.6 and I.21 according to their pharmacophoric binding modes and the interactions 
between the inhibitors I.6 and I.21 and each of the crystal structures were considered. The 
maximum number of interactions was observed with the crystal structure 1equ, originally 
containing the inhibitor equiline (see Table 6).  
 
Table 6. Interactions found in the complexes between I.6 and 1equ and I.21 and 1equ. 
 
Compound interactions amino acid residues 1equ 
6 
H 
Ser142 (donor)  
Asn152 (acceptor) 2.53a 
Asn152 (donor)  
Tyr155 (donor) 3.90 
His221 (d donor) 3.13 
 Tyr 155 6.71 Arg258 4.89 
21 H 
Tyr155 (acceptor) 2.91 
Tyr218 (donor)  
His221 (donor) 2.47 
Glu282 (acceptor) 2.43 
 Arg258 4.34 
 
a Distance (Å) between the heteroatoms for H-bonds (H) and between centroids or centroid and cation for -
interactions (). 
 
Interestingly 1equ is the unique 17-HSD1 crystal structure where the aminoacid residue 
Arg258 is turned into the active site. Notably, the importance of this amino acid residue was 
already postulated by Alho-Richmond S et al. [137], who proposed to target it in the inhibitor 
design process. 
Concerning the selectivity against 17β-HSD2, it should be achieved to mainly avoid 
systemic effects since the expression of this enzyme is downregulated in EDD tissues but it is 
present in several organs (i.e. liver, small intestine, bones). However, it is difficult to estimate 
how high the SF should be to minimize potential side effects due to the lack of respective in 
vivo data. For our drug development program, an SF of approximately 20 is considered 
sufficient to justify further biological evaluation. In this study the retroamide I.21 is the most 
17HSD2 selective compound identified. It is striking that the amide I.18 shows a complete 
loss in selectivity against 17HSD2 (see Table 7). 
 
Table 7: Inhibition of human 17-HSD1 and 17-HSD2 by the best 17-HSD1 inhibitors 
described in chapter 3.I. 
 
 
Compound X R1 R2 HSD1a [IC50 (nM)c] HSD2b [IC50 (nM)c] SFd 
I.6 CO m-OH OH 44 1035 24 
I.12 CO m-OH H 365 1356 4 
I.14 CO p-OH OH 243 2471 10 
I.18 NHCO m-OH OH 1307 3813 3 
I.21 CONH m-OH OH 243 9264 38 
 
a Human placenta, cytosolic fraction, substrate [3H]E1 + E1 [500 nM], cofactor NADH [500 μM]. b Human 
placenta, microsomal fraction, substrate [3H]E2 + E2 [500 nM], cofactor NAD+ [1500 μM]. c Mean values of three 
determinations, standard deviation less than 10 %. d Selectivity factor = IC50 (HSD2)/IC50(HSD1). 
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As no 3D-structure of 17-HSD2 is known, it is not possible to figure out the structural 
differences between the two enzymes at protein level. These results indicate that the orientation 
of the amide group is an important feature to gain activity for 17HSD1 and selectivity against 
17HSD2. 
In the first part of our search, I.6 resulted as the most active compound in terms of 17-
HSD1 inhibition, showing fair selectivity against 17-HSD2 but pronounced affinity to ERs 
(see table 8). 
 
Table 8. Binding affinities for the human estrogen receptors  and  of I.6 and I.21. 
 RBAa (%) 
Compound ERb ERb 
I.6 1.000 < RBA < 10.000 0.100 < RBA < 1.000 
I.21 0.010 < RBA < 0.100 RBA < 0.001 
 
a RBA (relative binding affinity). E2: 100 %, mean values of three determinations, standard deviations less than 
10 %. b Human recombinant protein, incubation with 10 nM [3H]E2 and inhibitor for 1 h. 
 
Compound I.21 on the other hand showed medium inhibitory activity at the target enzyme as 
well as fair selectivity against 17-HSD2 and ERs. Furthermore, I.21 inhibits the formation of 
E2 intracellularly with an IC50 value in the nanomolar range (245 nM). This shows that it is 
able to enter the cell, and that it can be active at the target enzyme. Further optimizations of 
these first benzothiazole-type lead compounds were necessary in order to develop potential 
candidates for in vivo application. 
Chapter 3.II deals with the optimization of I.6 ( = II.A) and I.21 ( = II.B). 
 
 
Figure 14: Structures´modifications of II.A and II.B. 
 
Introduction of various substituents with different electronic, lipophilic, steric and H-
bonding properties into the benzoyl moiety of these compounds successfully led to the 
discovery of two new lead structures, compounds II.4 and II.15 (see following). 
As suggested in our previous study where II.A and II.B were hypothesised to interact 
differently with the binding site, the introduction of a wide variety of substituents into the 
benzoyl moiety of II.A and II.B had different influence on inhibitory activity: comparing II.1 
with II.9, II.4 with II.11 and II.5 with II.13 shows that only the fluorine in 4-position 
increased inhibitory activity in both classes (IC50 = 13 nM for II.1 and 171 nM for II.9). The 
introduction of OH in 2-position and methyl in 4-position turned out to be beneficial in case of 
the ketones (IC50 = 27 nM for II.4 and 78 nM for II.5) but was deleterious for the amides 
(II.11, II.13: no inhibition at 1 µM). The introduction of a bulky substituent like the phenoxy 
group in 4-position (II.7), benzylation of the hydroxy group of II.4 (II.6) and methylation of 
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the amide function (II.17) decreased inhibitory activity. Interestingly, methylation of the OH 
group of II.1 (II.2) or replacement by hydrogen (II.3) on the benzothiazole moiety resulted 
only in a slight decrease of 17-HSD1 inhibition (IC50 = 38 nM) but in a complete loss of 
selectivity toward 17-HSD2 (SF = 2). Changing the F position as well as adding a second 
fluorine in the amide series increased 17-HSD1 inhibitory activity: II.15 showed the same 
IC50 value of 13 nM as the best ketone compound II.1. This may be due to favourable 
electronic effects exerted by the fluorines on the H-bonding property of the OH, to the 
increased lipophilicity or to the change in -interacting properties of the aromatic ring. 
Regarding selectivity, in the ketone series introduction of the methyl group in 4-position 
(II.4) not only increased activity but also decreased inhibition of 17β-HSD2 and affinity to the 
ERs. Thus, compound II.4 shows the highest selectivity toward 17-HSD2 described so far 
(SF 148) and only little ER affinity. It has been known for a long time that a substituent in o-
position to the 3-OH group of E2 or its nonsteroidal analog hexestrol [138] reduces ERα 
affinity of the parent compound. Therefore it can be assumed that the ketone II.A binds to the 
ERα like the natural substrate. In the amide series  introduction of fluorine in 4-position (II.9) 
led to a decrease in selectivity towards 17-HSD2, like it has been observed for II.1 in the 
ketone series, while introducing a fluorine in 2-position (II.8) and 6-position (II.10) did not 
alter selectivity. The difluoro-substituted compound II.15 showed the best selectivity in this 
series toward 17-HSD2 and the ERs with values similar to II.4 (see Table 9). 
 
Table 9: 17-HSD1 inhibitory activity, selectivity against 17-HSD2, binding affinities for the 
human estrogen receptors  and  and intacellular activity (T47-D) for the best 17-HSD1 
inhibitors compared to II.A and II.B. 
 
 
Cpd X R1 R2 
HSD1a 
[IC50 (nM)c] 
HSD2b 
[IC50 (nM)c] 
SFd ERe RBAf (%) 
ERe 
RBAf (%) 
T47-D  
IC50 (nM)c 
II.Ag 
CO 
H H 44 1035 23 < 10 < 1  
II.1 4-F H 13 121 9 < 1 < 1 11 
II.4 4-CH3 H 27 403 148 < 0.1 < 0.1 258 
II.5 6-OH H 78 1538 20 < 0.1 < 0.1 365i 
II.Bg 
CONH 
H H 243 9264 38 < 0.1 < 0.001 245 
II.8 2-F H 29 1000 h < < 0.1 < 0.1 73l 
II.10 6-F H 112 3804 34 < 0.1 < 0.1 152l 
II.15 2-F 6- 13 1774 136 < 0.1 < 0.1 37l 
 
a Human placental, cytosolic fraction, substrate [3H]E1 + E1 [500 nM], cofactor NADH [500 μM]; b Human 
placental, microsomal fraction, substrate [3H]E2 + E2 [500 nM], cofactor NAD+ [1500 μM]; c Mean values of 
three determinations, standard deviation less than 10%; d Selectivity factor: IC50 17-HSD2/ IC50 17-HSD1; e 
Human recombinant protein, incubation with 10 nM [3H]E2 and inhibitor for 1 h. f RBA (relative binding affinity). 
E2: 100%, mean values of three determinations, standard deviations less than 10%. g Compounds II.A and II.B: 
internal standard; h standard deviation less than 25 %. i standard deviation less than 15 %; l Calculated with 
LOGIT transformation at 50 nM inhibitor concentration. 
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Summarising, we have discovered two highly potent 17-HSD1 inhibitors (II.4 and II.15), 
which are the most selective (against 17-HSD2) compounds described so far. The amide 
derivative II.15 showed better intracellular activity than II.4 in T47-D cell line. The high 
cellular activity of compound II.15 indicates that it easily permeates the cell membrane and is 
not metabolized quickly. 
Furthermore, compounds II.1, II.4, II.8, and II.15 were tested for inhibitory activity 
towards Callithrix jacchus 17-HSD1 and 17-HSD2 (Table 10).  
 
Table 10: Inhibition of Callithrix jacchus 17HSD1 and 17HSD2. 
 
 
 
Cpd X R1 R2 m17-HSD1
a 
% inhibition 
m17-HSD2b 
% inhibition 
    5 nM 50 nM 50 nM 
II.1 
CO 4-F H 80  34 
II.4 4-CH3 H  83 40 
II.8 
CONH 2-F H 67  48 
II.15 2-F 6-F 87  51 
 
a Marmoset placenta, cytosolic fraction, substrate [3H]E1 + E1 [500 nM], cofactor NADH [500 μM]; b Marmoset 
placenta, microsomal fraction, substrate [3H]E2 + E2 [500 nM], cofactor NAD+ [1500 μM]; 
 
The compounds showed stronger inhibition of marmoset 17-HSD1 compared to the 
human enzyme and a fair selectivity against 17-HSD2. Accordingly, they should be suitable 
candidates for being further evaluated in a marmoset model of endometriosis.  
Compounds II.1 and II.4 were further investigated for inhibition of the most important 
human hepatic CYP enzymes: 3A4, 2D6, 2C9, 2C19, 1A2 and 2B6. Both compounds showed 
very little inhibition (54 μM > IC50 > 3 μM) except for 1A2 which was inhibited by 1 and 4 
moderately (IC50 = 1.8 and 0.57 μM) indicating that there should be no major problems 
regarding CYP inhibition in this compound class. 
Furthermore, in vitro metabolic stability for the best inhibitors described here was 
evaluated using human hepatic microsomes (II.4 and II.5), and human hepatic S9-fraction 
(II.1, II.8 and II.15). The hepatic microsomes contain a wide variety of phase I enzymes while 
the hepatic S9 fraction (microsomes and cytosol of hepatocytes) contain a wide variety of both 
phase I and phase II enzymes. The two carbonyl derivatives II.4 and II.5 showed intrinsic 
clearance (Clint) values of 94 and 108 µL/min/mg protein, respectively, and thus, they can be 
arranged in the high clearance category (through phase I metabolism) although the often 
prescribed calcium channel blocker verapamil, used here as reference, revealed similar value 
(Clint = 105 µL/min/mg protein) defining a high but not too high liability to metabolic 
transformation. 
Concerning the metabolic stability which resulted from the S9 assay (see Table 11), two 
compounds were used as controls: Midazolam as marker for phase I metabolism (phase I 
metabolism is prerequisite for phase II metabolism) and 7-hydroxycoumarin as marker for 
phase II metabolism (predominantly metabolised by glucuronidation and sulphatation).  
DISCUSSION AND CONCLUSION  - 109 - 
Table 11: Metabolic stability in human hepatic S9-fraction. 
 
 
 
Cpd X R1 R2 
S9a 
Clint (mL/min/mg/protein) 
II.1 CO 4-F H 279 
II.8 
CONH
2-F H 128 
II.15 2-F 6-F 102 
Midazolamb    35 
7-Hydroxycoumarinc    65 
 
a Human hepatic S9 fraction (1 mg/mL mixture of microsomes and cytosol of hepatocytes) supplemented with 
NADPH, UDPGA and PAPS; b Reference (phase I metabolism); c Reference (phase II metabolism); 
 
Although the amide derivatives II.8 and II.15 showed more than two-fold better overall 
metabolic stability than the keto derivative II.1 , they can be arranged in the high clearance 
category (through phase I and phase II metabolism) and this should be taken into account for in 
vivo evaluation of these newly discovered potent and selective 17-HSD1 inhibitors. 
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